<SEC-DOCUMENT>0001657312-23-000017.txt : 20230803
<SEC-HEADER>0001657312-23-000017.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803083449
ACCESSION NUMBER:		0001657312-23-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		231138250

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vrna-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791,d:b73f682a7eba47bb8475826fed6005cd--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:vrna="http://veronapharma.com/20230630" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001657312</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>vrna:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>vrna:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="loanadvance"><xbrli:measure>vrna:loanAdvance</xbrli:measure></xbrli:unit><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBCDELoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib73f682a7eba47bb8475826fed6005cd_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM __________ TO __________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Verona Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-7">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">London</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">SE1 2RE</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-12">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-13">44</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">203</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">283 4200</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Ordinary shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Nasdaq Stock Market LLC (<ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric>)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric>    No &#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of July 27, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">635,875,302</ix:nonFraction> ordinary shares, nominal value &#163;0.05 per share, outstanding, which if all held in ADS form, would be represented by 79,484,413 American Depositary Shares, each representing eight (8) ordinary shares.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_25">Item 1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_25">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_94">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_94">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_109">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_109">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_112">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_112">23</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II - OTHER INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_118">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_118">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_121">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_121">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_124">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_124">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_127">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_127">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_130">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_130">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_133">Item 5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_133">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_136">Item 6</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_136">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib73f682a7eba47bb8475826fed6005cd_139">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib73f682a7eba47bb8475826fed6005cd_139">27</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_25"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:69.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">270,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">227,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="f-33">894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">10,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">9,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">6,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">287,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">242,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-42">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" scale="3" id="f-43">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" scale="3" id="f-44">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-47">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-48">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">16,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">16,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">303,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-52">259,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">13,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-57">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-58">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-60">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-61">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">10,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">19,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">19,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">9,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-67">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-68">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">19,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">9,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">30,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">29,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-73"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-74"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76">0.05</ix:nonFraction></ix:nonFraction> par value shares; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-77">651,659,630</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-78">631,338,246</ix:nonFraction> issued, and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-79">635,787,302</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-80">606,301,054</ix:nonFraction> outstanding, at June 30, 2023 and December 31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-81">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-82">40,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-83">596,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">529,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares held in treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="f-85">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-86">1,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-87">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-88">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-89">359,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-90">333,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">273,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">230,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">303,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">259,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-95">2,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-96">14,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-97">10,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-98">32,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">12,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">5,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">22,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">12,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">9,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-104">20,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-105">32,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-106">45,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">9,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">20,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">32,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">45,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-111">1,934</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-112">5,409</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" scale="3" id="f-113">379</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-114">6,711</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-115">3,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-116">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-117">6,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-118">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-119">740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-120">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">1,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-122">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" scale="3" id="f-123">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-124">2,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-125">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-126">3,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-131">8,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-132">17,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-133">25,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">42,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-135">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-136">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-137">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-138">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">17,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">25,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">42,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per ordinary share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-143"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-144">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-145"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-146">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-149"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-150">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">634,469,423</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-154">484,777,837</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-156">627,996,124</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-158">483,226,039</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:18.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-159">631,338,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">40,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">529,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-162">1,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-163">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">333,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">230,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">16,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">16,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-168">20,321,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-169">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-170">55,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-171">56,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-172">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-173">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-174">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-175">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-176">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">4,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-178">4,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">651,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">590,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">1,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">350,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">276,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-188">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-189">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-190">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-191">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-192">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-193">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-194">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-195">651,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">596,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-198">975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">359,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">273,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-202">489,177,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">385,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-205">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">263,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">148,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">24,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">24,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-211">80,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-212">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-213">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-214">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-215">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-216">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares to treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-217">4,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-218">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-219">322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-221">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-222">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-223">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-224">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-225">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-226">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">494,058,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">32,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">388,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-230">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">288,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">126,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-234">17,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-235">17,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-236">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-237">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-238">689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-239">689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-240">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-241">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-244">494,058,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">32,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">390,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-247">591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">306,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">110,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-251">25,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-252">42,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (gain)/loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-253">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-254">3,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-255">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-256">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redemption premium on debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-257">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-258">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-259">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-260">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-261">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-262">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-263">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-264">694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" scale="3" id="f-265">380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-266">6,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-267">2,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-268">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-269">417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-270">680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-271">6,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-272">6,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-273">305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-274">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="f-275">939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="f-276">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-277">951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-278">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-279">27,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-280">34,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-282">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-284">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-285">56,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-286">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from draw under the Oxford Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-287">9,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of withholding taxes from share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-290">1,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-291">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-293">68,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-294">1,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-295">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-296">1,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-297">42,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-298">36,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-299">227,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-300">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-301">270,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-302">111,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-303">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-304">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-305">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-306">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 1 - <ix:nonNumeric contextRef="c-1" name="vrna:OrganizationAndBusinessDescriptionTextBlock" id="f-307" continuedAt="i5f4200c2bafe425db7b7aea19be3fb1b" escape="true">Organization and description of business operations </ix:nonNumeric></span></div><ix:continuation id="i5f4200c2bafe425db7b7aea19be3fb1b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the &#8220;Company&#8221;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has <ix:nonFraction unitRef="subsidiary" contextRef="c-1" decimals="INF" name="vrna:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-308">one</ix:nonFraction> wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2023, the Company submitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#8220;COPD&#8221;) and is preparing for a potential commercial launch in 2024, subject to approval of the NDA. In conjunction with the submission, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="vrna:PaymentsForApplicationFees" format="ixt:num-dot-decimal" scale="6" id="f-309">3.2</ix:nonFraction>&#160;million Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) application fee to the FDA. The Company has requested a small business waiver of this application fee and, as such, the amount has been recorded within Other current assets in the Condensed Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-310">359.1</ix:nonFraction>&#160;million as of June 30, 2023. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of June 30, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the six months ended June 30, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-311">20,321,384</ix:nonFraction> ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-312">2,540,173</ix:nonFraction> ADSs) under the at-the-market offering program entered into in March 2021 (the &#8220;2021 ATM Program&#8221;). The shares sold were at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-313">2.88</ix:nonFraction> per share (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-314">23.08</ix:nonFraction> per ADS), raising aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-315">56.9</ix:nonFraction>&#160;million after deducting issuance costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2023, through a registration statement on Form S-3, the Company replaced the 2021 ATM Program, with an open market sale agreement with Jefferies LLC (&#8220;Jefferies&#8221;) to sell its ordinary shares, in the form of ADSs, with aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="vrna:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-316">200.0</ix:nonFraction>&#160;million, from time-to-time, through an &#8220;at the market&#8221; equity offering program under which Jefferies will act as sales agent (the &#8220;2023 ATM Program&#8221;). Jefferies is entitled to a commission at a rate of up to <ix:nonFraction unitRef="number" contextRef="c-66" decimals="3" name="vrna:SaleOfStockCommissionFeePercentage" scale="-2" id="f-317">3.0</ix:nonFraction>% of the gross proceeds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine, if approved. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.</span></div></ix:continuation><div id="ib73f682a7eba47bb8475826fed6005cd_46"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 2 - <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-318" continuedAt="ia8e8a8543455409b98caa3b29ea2f849" escape="true">Basis of presentation and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ia8e8a8543455409b98caa3b29ea2f849"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-319" continuedAt="ifa6f7341c46e49f88202a9fe7c0d3e7a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on March 7, 2023 (the &#8220;2022 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2022, was derived from audited consolidated financial statements included in the 2022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="ifa6f7341c46e49f88202a9fe7c0d3e7a">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-320" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-321"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-322">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, pharmaceutical development.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-323" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-324" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under this model, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. This update became effective for the Company on January 1, 2023 and the adoption of this update did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 3 - <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-325" continuedAt="i94febbdd05d14707b0ac608caee19172" escape="true">Equity interest </ix:nonNumeric></span></div><ix:continuation id="i94febbdd05d14707b0ac608caee19172"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-326">40.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-327">25.0</ix:nonFraction>&#160;million in cash and an equity interest, valued at $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="f-328">15.0</ix:nonFraction>&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the six months ended June 30, 2023.</span></div></ix:continuation><div id="ib73f682a7eba47bb8475826fed6005cd_61"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 4 - <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-329" continuedAt="i47dc8d20d49a4d1a9f1eec3c23768a44" escape="true">Accrued expenses</ix:nonNumeric></span></div><ix:continuation id="i47dc8d20d49a4d1a9f1eec3c23768a44"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-330" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-331">3,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-332">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-333">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-334">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-335">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-336">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-337">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-338">13,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib73f682a7eba47bb8475826fed6005cd_64"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 5 - <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-339" continuedAt="i7d6ca25b076a4c00a55324fc08789653" escape="true">Term loan</ix:nonNumeric></span></div><ix:continuation id="i7d6ca25b076a4c00a55324fc08789653"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On October 14, 2022 (the &#8220;Effective Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;) for an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-340">150.0</ix:nonFraction>&#160;million (the &#8220;Oxford Term Loan&#8221;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-341">10.0</ix:nonFraction>&#160;million, which was funded on the Effective Date (the &#8220;Oxford Term A Loan&#8221;), and up to <ix:nonFraction unitRef="loanadvance" contextRef="c-68" decimals="INF" name="vrna:LineOfCreditFacilityNumberOfLoanAdvances" format="ixt-sec:numwordsen" id="f-342">four</ix:nonFraction> additional term loan advances in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-343">140.0</ix:nonFraction>&#160;million. The Oxford Term Loan has a maturity date of October 1, 2027. On March 24, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-344">10.0</ix:nonFraction>&#160;million under the second term loan advance (the &#8220;Oxford Term B Loan&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Oxford Term A Loan and Oxford Term B Loan (together, the &#8220;Oxford Term Loan Advances&#8221;) bear interest at a variable rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last day of the month that immediately precedes the month in which the interest will accrue and (ii) <ix:nonFraction unitRef="number" contextRef="c-72" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-345">2.38</ix:nonFraction>%, plus (b) <ix:nonFraction unitRef="number" contextRef="c-73" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-346">5.50</ix:nonFraction>% (the &#8220;Basic Rate&#8221;) and shall not increase by more than <ix:nonFraction unitRef="number" contextRef="c-74" decimals="4" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="f-347">2.00</ix:nonFraction>% above the Basic Rate as of the funding date of each such term loan. For the six months ended June 30, 2023, the effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-348">11</ix:nonFraction>% per annum. There was no material difference between the carrying value and the estimated fair value of the Oxford Term Loan Advances outstanding.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 6 - <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-349" continuedAt="i022f37de00f846b28df03fd420eb1576" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="i022f37de00f846b28df03fd420eb1576"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-350" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-351">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-352">1,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-353">2,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-354">2,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-355">3,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-356">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-357">7,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-358">3,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-359">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-360">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-361">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-362">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-363" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-364">19,276,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-365">1,320,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-366">240,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-367">1,050,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-368">19,306,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-369">2,824,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-370">80,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-371">120,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-372">21,930,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-373" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-374">34,542,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-85" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-375">4,305,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-376">30,237,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-377">3,680,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-378">26,557,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 7 - N<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-379" continuedAt="i30ca42c61faf41c3a6f385b092c7b831" escape="true">et loss per share </ix:nonNumeric></span></div><ix:continuation id="i30ca42c61faf41c3a6f385b092c7b831"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on Nasdaq each represent <ix:nonFraction unitRef="number" contextRef="c-3" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="f-380">eight</ix:nonFraction> ordinary shares. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-381" continuedAt="ib9697bb4f04b4e98b8a96004a143f066" escape="true">The following table shows the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022 (in thousands except per share amounts):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="ib9697bb4f04b4e98b8a96004a143f066"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-382">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-383">17,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-384">25,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-385">42,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-386"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-387">634,469</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-388"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-389">484,778</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-390"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-391">627,996</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-392"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-393">483,226</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-394"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-395">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-396"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-397">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-398"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-399">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-400"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-401">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three and six months ended June 30, 2023 and 2022, outstanding share options, RSUs and warrants over <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-402"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-403">48.5</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-404"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-405">46.2</ix:nonFraction></ix:nonFraction>&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div></ix:continuation><div id="ib73f682a7eba47bb8475826fed6005cd_82"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 8 - <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-406" continuedAt="i8e97d13c359241b1b851c917d34c188e" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i8e97d13c359241b1b851c917d34c188e">The Company had previously accrued up to the maximum exposure of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-407">6.9</ix:nonFraction>&#160;million related to a matter with a supplier and also had certain invoices in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-408">1.5</ix:nonFraction>&#160;million in accounts payable to the same supplier. Both items were settled for $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LossContingencyLossInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-409">2.1</ix:nonFraction>&#160;million in the three months ended June 30, 2023 resulting in a reversal of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-410">6.3</ix:nonFraction>&#160;million in Research and development costs in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s discussion and analysis of financial condition and results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 7, 2023 (the &#8220;2022 Form 10-K&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">In addition to historical information, this Quarterly Report on Form 10-Q contains statements that constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, the development of ensifentrine or any other product candidates, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials and potential regulatory approvals and commercialization, research and development costs, timing and likelihood of success, the potential impact and benefits of ensifentrine or any other product candidates, potential collaborations, our estimates regarding expenses, future revenues, capital requirements, debt service obligations and our need for additional financing, the funding we expect to become available from cash receipts from U.K. tax credits and under the $150.0 million debt facility secured in October 2022 and related timing, and the sufficiency of our cash and cash equivalents to fund operations, are forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors including, but not limited to, those set forth under Part II, Item 1A of this Quarterly Report on Form 10-Q under the heading &#8220;Risk Factors&#8221; and Part I, Item 1A of the 2022 Form 10-K under the heading &#8220;Risk Factors&#8221;. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical need. Our product candidate, ensifentrine, is an investigational, first-in-class, inhaled, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (&#8220;PDE3&#8221; and &#8220;PDE4&#8221;), combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Initially, we are developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;), a common, chronic, progressive, and life-threatening respiratory disease without a cure. If successfully developed and approved, ensifentrine would be the first therapeutic with a novel mode of action for COPD in over a decade.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2023, we submitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for approval of ensifentrine for the maintenance treatment of COPD. Based on the results from our successful Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) program, we believe ensifentrine, if approved, has the potential to change the treatment paradigm for COPD.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Also, in June 2023, the ENHANCE results were published in the peer reviewed publication, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">American Journal of Respiratory and Critical Care Medicine (&#8220;AJRCCM&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Ensifentrine met the primary endpoint in both the ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in measures of lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in ENHANCE-1 and ENHANCE-2. Ensifentrine was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In May 2023, we presented 12 abstracts and a symposium on expanded analyses of the ENHANCE trials including subgroup and pooled data covering exacerbations, use of rescue medication and healthcare utilization, at the American Thoracic Society International Conference ("ATS") 2023. The abstracts were published on the ATS website and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">AJRCCM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If approved, we intend to commercialize inhaled ensifentrine for the maintenance treatment of COPD in the United States (&#8220;U.S.&#8221;). Although we believe ensifentrine will not be regulated as a drug device combination, patients use a readily available standard jet nebulizer to take ensifentrine. Outside the U.S., we intend to license ensifentrine to companies with expertise and experience in developing and commercializing products in those regions. To that end, we have entered into a strategic collaboration with Nuance Pharma Limited, a Shanghai-based specialty pharmaceutical company (&#8220;Nuance Pharma&#8221;), to develop and commercialize ensifentrine in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Phase 2 clinical trials, ensifentrine has demonstrated positive results in patients with COPD, asthma and cystic fibrosis (&#8220;CF&#8221;). Two additional formulations of ensifentrine have been evaluated in Phase 2 trials for the treatment of COPD: dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses and negative cash flows from operations since inception, and have an accumulated deficit of $359.1 million as of June 30, 2023. We expect to incur additional losses and negative cash flows from operations until our product candidates potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate significant expenses in connection with our ongoing activities, if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure, ramp up production to commercial scale with our manufacturing and other Chemistry, Manufacturing and Controls activities to potentially commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue the clinical development of our DPI and pMDI formulations of ensifentrine and research and develop other formulations of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct further clinical trials for ensifentrine for the treatment of acute COPD, CF or any other indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and progress pre-clinical studies relating to other potential indications of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our continuing operations as a U.S. public company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of June 30, 2023, together with expected cash receipts from U.K. tax credit program and funding expected to become available under the $150.0 million debt financing facility secured in October 2022 (the &#8220;Oxford Term Loan&#8221;), will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2025, including the planned commercial launch of ensifentrine in the U.S., if approved. The Oxford Term Loan advances are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions. Refer to Note 5 - Term Loan for additional information on the Oxford Term Loan.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Clinical development update</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Phase 3 ENHANCE program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We reported positive top-line results from ENHANCE-2 and ENHANCE-1, in August and December 2022, respectively. Ensifentrine successfully met the primary endpoints in both trials, demonstrating statistically significant and clinically meaningful improvements in measures of lung function in moderate to severe COPD patients. Improvements in symptoms and quality of life measures were shown in both trials, which reached statistical significance in ENHANCE-1. Ensifentrine substantially reduced the rate and risk of moderate to severe COPD exacerbations and was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ENHANCE trials were designed to evaluate ensifentrine as monotherapy and added onto a single bronchodilator. Each trial enrolled approximately 800 subjects, for a total of approximately 1,600 subjects, at sites primarily in the U.S. and Europe. The two trials provided replicate evidence of efficacy and safety data over 24 weeks and ENHANCE-1 also evaluated longer-term safety in approximately 400 subjects over 48 weeks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject demographics and disease characteristics were well balanced between treatment groups in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1 approximately 69% of subjects received background COPD therapy, either a long-acting muscarinic antagonist (&#8220;LAMA&#8221;) or a long-acting beta-antagonist (&#8220;LABA&#8221;). Additionally, approximately 20% of all subjects received inhaled corticosteroids (&#8220;ICS&#8221;) with concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-2 approximately 55% of subjects received background COPD therapy, either a LAMA or a LABA. Additionally, approximately 15% of all subjects received ICS with concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Highlights</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Primary endpoint met (FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AUC 0-12 hr)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, change from baseline in average FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> area under the curve 0-12 hours post dose at week 12 was 87 mL (p&lt;0.0001) for ensifentrine in ENHANCE-1 and 94 mL (p&lt;0.0001) for ensifentrine in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Demonstrated consistent improvements with ensifentrine in all subgroups including gender, age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> reversibility and geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Secondary endpoints evaluating lung function met:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, increase in peak FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> of 147 mL (p&lt;0.0001) 0-4 hours post dose at week 12 in ENHANCE-1 and 146 mL (p&lt;0.0001) in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, increase in morning trough FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> of 35 mL (p=0.0413) at week 12 in ENHANCE-1 and 49 mL (p=0.0016) in ENHANCE-2, supporting twice daily dosing regimen.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exacerbation rate and risk reduced</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Subjects receiving ensifentrine demonstrated a 36% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks (p=0.0503) compared to those receiving placebo in ENHANCE-1 and a 43% reduction (p=0.0090) in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In pooled exacerbation data from ENHANCE-1 and ENHANCE-2, ensifentrine demonstrated a 40% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks (p=0.0012) compared to those receiving placebo. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 38% (p=0.0382) in ENHANCE-1 and by 42% (p=0.0089) in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In pooled exacerbation data from ENHANCE-1 and ENHANCE-2, ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 41% (p=0.0009).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COPD symptoms and Quality of Life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;QOL&#8221;)</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1, daily symptoms as measured by E-RS** Total Score in the ensifentrine group improved from baseline to greater than the minimal clinically important difference (&#8220;MCID&#8221;) of -2 units with a statistically significant improvement compared to placebo at week 24. Improvements in symptoms were early and sustained with statistical significance versus placebo at weeks 6, 12 and 24. Similar improvements were demonstrated in ENHANCE-2 but statistical significance was not achieved due to improvements observed in the placebo group over time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1, QOL as measured by SGRQ** Total Score in the ensifentrine group improved from baseline to greater than the MCID of -4 units with a statistically significant improvement compared to placebo at week 24. Improvements in QOL were early and sustained with statistical significance versus placebo at weeks 6, 12 and 24. In ENHANCE-2, QOL as measured by SGRQ* Total Score in the ensifentrine group also improved from baseline to greater than the MCID of -4 units at weeks 12 and 24, numerically exceeding placebo at each measurement, but statistical significance was not achieved due to improvements observed in the placebo group over time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Favorable safety profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Ensifentrine was well tolerated with very few adverse events occurring in more than 1% of subjects and greater than placebo over 24 and 48 weeks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: Forced Expiratory Volume in one second, a standard measure of lung function</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**E-RS, Evaluating Respiratory Symptoms, and SGRQ, St. George&#8217;s Respiratory Questionnaire, are validated patient reported outcome tools</span></div><div style="text-align:center"><img src="vrna-20230630_g1.jpg" alt="ENHANCE Summary.jpg" style="height:395px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Nuance Pharma</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2021, we entered into an agreement with Nuance Pharma for exclusive rights to develop and commercialize ensifentrine in Greater China, with future potential milestone payments up to $179 million plus royalties. In August 2022, Nuance Pharma received clearance from the Center of Drug Evaluation for its Investigational New Drug application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of COPD in mainland China. Nuance Pharma initiated a Phase 1 trial with ensifentrine in healthy volunteers in March 2023. In </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">April 2023, Nuance Pharma dosed the first subject in its pivotal Phase 3 clinical trial evaluating ensifentrine for the maintenance treatment of COPD in mainland China.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Critical accounting estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There were no material changes to the Company&#8217;s critical accounting estimates described in the Company&#8217;s 2022 Form 10-K during the six months ended June 30, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Components of results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs consist of salary and personnel related costs and third party costs for our research and development activities for ensifentrine. Personnel related costs include a share-based compensation charge relating to our stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Phase 3 ENHANCE program has completed study conduct and analysis, we expect our research and development costs to decrease over the next several quarters until we add new compounds or develop ensifentrine further in other delivery methods or indications. Due to the nature of research and development, the expected costs are inherently uncertain and may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs consist of salary and personnel related costs, including share-based compensation, expenses relating to operating as a public company, including professional fees, insurance and commercial related costs, as well as other operating expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect commercial costs to increase as we continue to develop our commercial operations, prepare for a potential launch and, in the event of successful regulatory approval, incur sales force, marketing and other launch related costs. As we develop our knowledge of the market and refine our commercialization plans, expected costs may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) are driven by interest income and expense, foreign exchange movements on cash and cash equivalents and taxes receivable, and the U.K. research and development tax credits (the &#8220;R&amp;D tax credit&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We participate in the U.K. Small and Medium Enterprises research and development tax relief program. The tax credits are calculated as a percentage of qualifying research and development expenditure and are payable in cash by the U.K. government to us. Credits recorded in the 2022 financial year are expected to be received in the fourth quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to corporate taxation in the U.S. and the U.K. We have generated losses since inception and have therefore not paid U.K. corporation tax. The income taxes presented in our Condensed Consolidated Statements of Operations and Comprehensive Loss represent the tax impact from our operating activities in the U.S., which generates taxable income based on intercompany service arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to various utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the three months ended June 30, 2023 and 2022</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the three months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,543)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,965)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,353)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,497)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,687)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,807)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,766)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were a net reversal of expense of $2.5&#160;million for the three months ended June 30, 2023, compared to costs of $15.0&#160;million for the three months ended June 30, 2022, a decrease of $17.5&#160;million. Research and development costs related to clinical trial and other development costs decreased by $17.8 million period over period primarily related to the Phase 3 ENHANCE program as at the end of Q2 2023, all study analyses were complete, following the completion of study conduct at the end of 2022, whereas in the same period in the prior year significant costs were incurred associated with the then ongoing study conduct. Additionally, we recorded a $6.3 million reversal of costs, accrued primarily in the three months ended March 31, 2023, related to the resolution of a supplier matter and certain invoices, as discussed in Note 8 - Commitments and contingencies, which resulted in net negative research and development expense for the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were $12.4&#160;million for the three months ended June 30, 2023, compared to $5.5&#160;million for the three months ended June 30, 2022, an increase of $6.9&#160;million. This increase was primarily due to a $5.0&#160;million increase in people related costs, inclusive of share-based compensation, as well as an increase of $1.7&#160;million for costs related to the build out of commercial and information technology infrastructure in preparation for a potential commercial launch. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) for the three months ended June 30, 2023 was income of $1.5&#160;million compared to income of $2.8&#160;million for the three months ended June 30, 2022, a decrease of $1.4&#160;million. This decrease was primarily due to a net reversal in the current period related to the R&amp;D tax credit of $1.9&#160;million resulting from the reversal in clinical trial and other development costs. Additionally, the R&amp;D tax credit in the same period in the prior year was higher as it included the full credit for expenditures made in the second quarter of the prior year as well as an increase in the credit for expenditures made in the first quarter of the prior year based upon feedback from HM Revenue &amp; Customs in July 2022 that a cap on the credit which was previously applied was not applicable to us. This was partially offset by increases of $3.2&#160;million in interest income from higher cash balances and higher interest rates and $3.4&#160;million related to the strengthening of the pound sterling in the current period while the pound sterling weakened in the second quarter of the prior year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the six months ended June 30, 2023 and 2022</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,409)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,573)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,585)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,067)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,442)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,550)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,603)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $10.1&#160;million for the six months ended June 30, 2023, compared to $32.6&#160;million for the six months ended June 30, 2022, a decrease of $22.5&#160;million. This decrease was primarily due to a $22.9&#160;million decrease in clinical trial and other development costs as the Phase 3 ENHANCE program which has completed study conduct and analysis as of the end of the current period whereas in the same period in the prior year significant costs were incurred associated with the then ongoing study conduct. Additionally, we recorded a reversal of $1.5 million of costs which were expensed in the year ended December 31, 2022 related to the resolution of the supplier matter, as discussed in Note 8 - Commitments and contingencies. This was partially offset by a $0.6 million increase in third party costs primarily associated with the NDA submission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were $22.0&#160;million for the six months ended June 30, 2023 compared to $13.0&#160;million for the six months ended June 30, 2022, an increase of $9.1&#160;million. This increase was driven primarily by a $7.6&#160;million increase in people related costs, inclusive of share-based compensation, as well as an increase of $2.9 million related to the build out of information technology and commercial infrastructure in preparation for a potential commercial launch. These increases were partially offset by a non-recurring $2.0 million charge related to the modification of the assignment and license agreement with Ligand UK Development Limited, which was incurred in the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) for the six months ended June 30, 2023 was income of $7.1&#160;million compared to $3.1&#160;million for the six months ended June 30, 2022, an increase of $4.0&#160;million. This increase was primarily due to an increase of $5.9&#160;million in interest income from a higher average cash balance and higher interest rates as well as an increase of $5.3&#160;million related to the strengthening of the pound sterling in the first half of the year while the pound sterling weakened in the comparable period in the prior year. This was partially offset by a $6.3&#160;million decrease in the R&amp;D tax credit due to the relative activity of the Phase 3 ENHANCE program in the current period as compared to the same period in the prior year.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our cash flows for the six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,397)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash used in operating activities was $27.1 million in the six months ended June 30, 2023, compared to $34.0 million during the six months ended June 30, 2022, a decrease of $6.9 million. The decrease in cash used in operating activities was primarily due to the decrease in clinical trial and other development costs, partially offset by our payment related to the resolution of the supplier matter as discussed in Note 8 - Commitments and contingencies, as well as a $3.2 million Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) application fee paid to the FDA in connection with our NDA submission. We have requested a small business waiver of this application fee and, as such, the amount has been recorded within Other current assets in the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash provided by financing activities was $68.8 million in the six months ended June 30, 2023, compared to net cash used in financing activities of $1.4 million in the six months ended June 30, 2022, an increase of $70.2 million. The increase in cash provided by financing activities was primarily due to the proceeds from issuance of ordinary shares of $56.9 million and the proceeds from our draw under the Oxford Term Loan of $10.0 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the issuances of our equity securities, including warrants, from borrowings under term loan facilities and from upfront payments from the Nuance Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses since inception, including net losses of $25.6 million for the six months ended June 30, 2023, and $68.7 million for the year ended December 31, 2022. As of June 30, 2023, we had an accumulated deficit of $359.1 million. We expect to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than leases and the Oxford Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">2023 Financing and Capital Transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">six months ended June 30, 2023, we completed the following financing and capital transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">Received $10.0&#160;million under the second term loan advance related to the Oxford Term Loan;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">Sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the at-the-market offering program entered into in March 2021 (the &#8220;2021 ATM Program&#8221;), at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of approximately $56.9&#160;million after deducting issuance costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">Replaced the 2021 ATM Program with an open market sale agreement with Jefferies LLC (&#8220;Jefferies&#8221;) to sell our ordinary shares, in the form of ADSs, with aggregate gross proceeds of up to $200.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Refer also to Note 5 - Term Loan to the condensed consolidated financial statements for additional information on the Oxford Term Loan and to Note 1 - Organization and description of business operations for additional information on 2023 activity under the 2021 ATM Program.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Funding requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of June 30, 2023, together with, expected cash receipts from U.K. tax credits and additional funding expected to become available under the Oxford Term Loan, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2025, including the planned commercial launch of nebulized ensifentrine for COPD maintenance treatment in the U.S. Future advances under the Oxford Term Loan are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions. Our cash and cash equivalents are maintained at financial institutions in amounts that exceed federally insured limits. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may require additional capital to commercialize ensifentrine, to continue the clinical development of our DPI and pMDI formulations of ensifentrine and to research and develop additional formulations of or with ensifentrine. In addition, we may seek to initiate or conduct preclinical or clinical studies with ensifentrine in additional indications or to discover or in-license and develop additional product candidates. We may need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders and ADS holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect such holders&#8217; rights as a shareholder or ADS holder. Any future debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our security holders&#8217; ownership interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements for ensifentrine or any future product candidates will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the progress, timing and completion of pre-clinical testing and clinical trials for ensifentrine or any future product candidates and the potential that we may be required to conduct additional clinical trials for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the time and costs involved in obtaining regulatory approvals for ensifentrine or any future product candidate we develop and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">selling and marketing activities undertaken in connection with the anticipated commercialization of ensifentrine or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty payments from future sales of ensifentrine or any future product candidates, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_112"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of June 30, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_115"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_118"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are not currently subject to any material legal proceedings.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_121"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Except as discussed below, our risk factors have not changed materially from those described in Part I, Item 1A of the 2022 Form 10-K under the heading &#8220;Risk Factors&#8221;. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We will need additional funding to complete development and commercialization of any future product candidates, or development and commercialization of other formulations or target indications of ensifentrine, if approved. If we are unable to raise capital when needed, or if a failure of any financial institution where we maintain our cash and cash equivalents prevents or delays us from accessing uninsured funds, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we conduct further clinical trials of ensifentrine, and develop ensifentrine in other formulations or for other indications. In addition, if we obtain regulatory approval for ensifentrine or any other product candidates, we expect to incur significant commercialization expenses related to activities including product positioning studies, product manufacturing, medical affairs, marketing, sales and distribution. Furthermore, we expect to incur ongoing costs associated with operating as a public company in the United States and maintaining a listing on the Nasdaq Global Market, or Nasdaq. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we obtain regulatory approval for ensifentrine for the treatment of COPD in the US, we estimate that our existing cash resources, expected cash receipts from the UK tax credit program and funding expected to become available under the $150.0 million debt facility will enable the Company to fund planned operating expenses and capital expenditure requirements through at least the end of 2025 including the commercial launch of ensifentrine in the US. Future advances under the Oxford Term Loan are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In addition, our operating plan may change as a result of many factors unknown to us. These factors, among others, may necessitate that we seek additional capital sooner than currently planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs, timing and outcome of the regulatory submission and review of ensifentrine for the treatment of COPD in the US and other regions, including any post-marketing studies that could be required by regulatory authorities, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the cost, progress and results of any other studies required to support the commercial positioning of ensifentrine for the treatment of COPD, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the cost, progress and results of any clinical trials for the treatment of CF, asthma or other indications, or for other formulations of ensifentrine including fixed-dose combination products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the cost of manufacturing clinical and, if approved, commercial supplies of the ensifentrine active ingredient and derived formulated drug products;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for ensifentrine in other indications and of the development of DPI and pMDI formulations of ensifentrine, or fixed-dose combination formulations of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales and distribution, for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the timing and amount of revenue, if any, received from commercial sales of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the sales price and availability of adequate third-party coverage and reimbursement for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for ensifentrine, although we currently have no commitments or agreements to complete any such transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize ensifentrine. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect our business, the holdings or the rights of our shareholders, or the value of our ordinary shares or ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue our research and development programs relating to ensifentrine or any commercialization efforts, be unable to expand our operations, or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_124"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_127"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_130"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div id="ib73f682a7eba47bb8475826fed6005cd_133"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 6. Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference to Filings Indicated </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">Articles of Association, as amended and as currently in effect</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465923054551/tm2314238d1_ex10-1.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465923054551/tm2314238d1_ex10-1.htm">Second Amended and Restated 2017 Incentive Award Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/01/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q223.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q223.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q223.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q223.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q223.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q223.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q223.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q223.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ib73f682a7eba47bb8475826fed6005cd_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VERONA PHARMA PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q223.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8481798a2dd44861a58b4b8fed6982ff_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Zaccardelli, Pharm.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q223.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i11d6ba69ca684eb495aa443bc3b0be31_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Hahn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q223.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1130db3c46ac49438707c29d85bcd997_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322q223.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if1e35e34cf8c44aa89fa6cce8cfd136c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vrna-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20230630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationanddescriptionofbusinessoperations" roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations">
        <link:definition>0000007 - Disclosure - Organization and description of business operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandsummaryofsignificantaccountingpolicies" roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies">
        <link:definition>0000008 - Disclosure - Basis of presentation and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterest" roleURI="http://veronapharma.com/role/EquityInterest">
        <link:definition>0000009 - Disclosure - Equity Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://veronapharma.com/role/Accruedexpenses">
        <link:definition>0000010 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Termloan" roleURI="http://veronapharma.com/role/Termloan">
        <link:definition>0000011 - Disclosure - Term loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://veronapharma.com/role/Sharebasedcompensation">
        <link:definition>0000012 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalizationandnetlosspershare" roleURI="http://veronapharma.com/role/Capitalizationandnetlosspershare">
        <link:definition>0000013 - Disclosure - Capitalization and net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentandcontingencies" roleURI="http://veronapharma.com/role/Commitmentandcontingencies">
        <link:definition>0000014 - Disclosure - Commitment and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>0000015 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://veronapharma.com/role/AccruedexpensesTables">
        <link:definition>0000016 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://veronapharma.com/role/SharebasedcompensationTables">
        <link:definition>0000017 - Disclosure - Share based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandnetlosspershareTables" roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareTables">
        <link:definition>0000018 - Disclosure - Capitalization and net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>0000019 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails">
        <link:definition>0000020 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterestDetails" roleURI="http://veronapharma.com/role/EquityInterestDetails">
        <link:definition>0000021 - Disclosure - Equity Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://veronapharma.com/role/AccruedexpensesDetails">
        <link:definition>0000022 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermloanDetails" roleURI="http://veronapharma.com/role/TermloanDetails">
        <link:definition>0000023 - Disclosure - Term loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareBasedCompensationExpenseDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails">
        <link:definition>0000024 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareOptionActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails">
        <link:definition>0000025 - Disclosure - Share based compensation - Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationRSUActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails">
        <link:definition>0000026 - Disclosure - Share based compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandnetlosspershareComputationDetails" roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails">
        <link:definition>0000027 - Disclosure - Capitalization and net loss per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandcontingenciesDetails" roleURI="http://veronapharma.com/role/CommitmentandcontingenciesDetails">
        <link:definition>0000028 - Disclosure - Commitment and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrna_InterestRatePeriodAxis" abstract="true" name="InterestRatePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AccruedResearchAndDevelopmentFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCredit" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OrganizationAndBusinessDescriptionTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_OxfordTermLoanMember" abstract="true" name="OxfordTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" abstract="false" name="ResearchAndDevelopmentExpenseNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OxfordTermALoanMember" abstract="true" name="OxfordTermALoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_InterestRatePeriodDomain" abstract="true" name="InterestRatePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentInterestRatePeriodOneMember" abstract="true" name="DebtInstrumentInterestRatePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_LineOfCreditFacilityNumberOfLoanAdvances" abstract="false" name="LineOfCreditFacilityNumberOfLoanAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" abstract="false" name="AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_OxfordTermBCDELoanMember" abstract="true" name="OxfordTermBCDELoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_EquityInterestReceivable" abstract="false" name="EquityInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SaleOfStockCommissionFeePercentage" abstract="false" name="SaleOfStockCommissionFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AmericanDepositorySharesMember" abstract="true" name="AmericanDepositorySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_OxfordTermBLoanMember" abstract="true" name="OxfordTermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" abstract="false" name="ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" abstract="false" name="LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" abstract="false" name="IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TaxCreditAndIncomeTaxesReceivableCurrent" abstract="false" name="TaxCreditAndIncomeTaxesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_NuanceShanghaiPharmaCoLtdMember" abstract="true" name="NuanceShanghaiPharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_PaymentsForApplicationFees" abstract="false" name="PaymentsForApplicationFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vrna-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_be91955d-100e-4da7-8d28-ad307a5309e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4cea8390-73f7-47d9-9ff1-b88490dadba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be91955d-100e-4da7-8d28-ad307a5309e4" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4cea8390-73f7-47d9-9ff1-b88490dadba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1d87aeca-d5c6-442f-82bc-9de5c29de9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be91955d-100e-4da7-8d28-ad307a5309e4" xlink:to="loc_us-gaap_LiabilitiesCurrent_1d87aeca-d5c6-442f-82bc-9de5c29de9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3b2ffdaf-d22f-4530-9f94-9334d43361a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3b2ffdaf-d22f-4530-9f94-9334d43361a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_73d127e3-5626-4732-a80c-27862a539145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:to="loc_us-gaap_AdditionalPaidInCapital_73d127e3-5626-4732-a80c-27862a539145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5b88e6c8-41ae-4a40-bd61-f46a0e411643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:to="loc_us-gaap_TreasuryStockValue_5b88e6c8-41ae-4a40-bd61-f46a0e411643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f021e22d-431a-48df-a712-6922ee3be0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:to="loc_us-gaap_CommonStockValue_f021e22d-431a-48df-a712-6922ee3be0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8b1d3afb-ef5c-47ef-b95d-e548622b18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a87fd6c0-948d-40ac-b038-9cb6768dbb76" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8b1d3afb-ef5c-47ef-b95d-e548622b18e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_047aff2f-03df-432c-a292-6ce7ec5525cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_e3455126-a7fd-4dd7-bba0-470c858e04fa" xlink:href="vrna-20230630.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_047aff2f-03df-432c-a292-6ce7ec5525cd" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_e3455126-a7fd-4dd7-bba0-470c858e04fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30dc41e7-4ff5-4ea4-8739-5705f1b53814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_047aff2f-03df-432c-a292-6ce7ec5525cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30dc41e7-4ff5-4ea4-8739-5705f1b53814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ae398e01-c6d6-4f6e-a206-19811e2da584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_047aff2f-03df-432c-a292-6ce7ec5525cd" xlink:to="loc_us-gaap_OtherAssetsCurrent_ae398e01-c6d6-4f6e-a206-19811e2da584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_47ef8646-2efc-4c1c-b730-3b5ce3d5c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_047aff2f-03df-432c-a292-6ce7ec5525cd" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_47ef8646-2efc-4c1c-b730-3b5ce3d5c9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e9def77b-aeed-4938-9f28-08e9a6ab597f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e9def77b-aeed-4938-9f28-08e9a6ab597f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e95f799c-25e3-4a33-8a7a-bd8787edbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:to="loc_us-gaap_AccountsPayableCurrent_e95f799c-25e3-4a33-8a7a-bd8787edbdca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7b86a5cf-9c8b-4922-b1d8-90123bf1ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:to="loc_us-gaap_TaxesPayableCurrent_7b86a5cf-9c8b-4922-b1d8-90123bf1ee9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_80f05008-4713-4e74-bc08-1fffafa37c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_80f05008-4713-4e74-bc08-1fffafa37c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_50e3edcd-61c4-486e-a86d-61317bcf35a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15e92390-e35f-4042-a397-97ff905168c4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_50e3edcd-61c4-486e-a86d-61317bcf35a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88701191-7143-4e1d-8c48-0b914d60f172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_87aa0517-dc7d-4379-9816-1faf0b62d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88701191-7143-4e1d-8c48-0b914d60f172" xlink:to="loc_us-gaap_Liabilities_87aa0517-dc7d-4379-9816-1faf0b62d86c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_291931f8-f6a9-49f3-9930-07d4c9a6cb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88701191-7143-4e1d-8c48-0b914d60f172" xlink:to="loc_us-gaap_CommitmentsAndContingencies_291931f8-f6a9-49f3-9930-07d4c9a6cb55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9f1d0500-ee72-4ba2-b24f-19da5bbb25a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88701191-7143-4e1d-8c48-0b914d60f172" xlink:to="loc_us-gaap_StockholdersEquity_9f1d0500-ee72-4ba2-b24f-19da5bbb25a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_ba3148f9-d886-418e-b2b1-3b510a65f1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbfb97ae-d469-4b42-9841-d1a5ab4168d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ba3148f9-d886-418e-b2b1-3b510a65f1ab" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_fbfb97ae-d469-4b42-9841-d1a5ab4168d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_49939652-7125-4e5f-ba52-ab6c2dc96f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ba3148f9-d886-418e-b2b1-3b510a65f1ab" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_49939652-7125-4e5f-ba52-ab6c2dc96f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2e90b19e-b01b-4e28-af51-cc16a99332f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ba3148f9-d886-418e-b2b1-3b510a65f1ab" xlink:to="loc_us-gaap_Goodwill_2e90b19e-b01b-4e28-af51-cc16a99332f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f07484e-00c1-4233-9344-d6ab14188b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ba3148f9-d886-418e-b2b1-3b510a65f1ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f07484e-00c1-4233-9344-d6ab14188b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8c426cf1-2e1d-4397-8e83-5c61cbe6225d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4416b427-a8d6-42e4-aa2c-ce865c41a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c426cf1-2e1d-4397-8e83-5c61cbe6225d" xlink:to="loc_us-gaap_AssetsNoncurrent_4416b427-a8d6-42e4-aa2c-ce865c41a962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11524f2f-1003-449f-833c-f15ab9c545cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c426cf1-2e1d-4397-8e83-5c61cbe6225d" xlink:to="loc_us-gaap_AssetsCurrent_11524f2f-1003-449f-833c-f15ab9c545cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e53f0e02-2c17-4b9d-9864-5ebaea77b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f9065136-81fb-419e-aac0-53a14e21629c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_e53f0e02-2c17-4b9d-9864-5ebaea77b7d3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f9065136-81fb-419e-aac0-53a14e21629c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_25abe1e9-c1db-46b3-8714-18f2e89323d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_e53f0e02-2c17-4b9d-9864-5ebaea77b7d3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_25abe1e9-c1db-46b3-8714-18f2e89323d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9c7c7aca-0f97-49f0-b7b1-dd434147ac04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f9fd8a2e-fcc9-422e-a41c-4f977d5a78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c7c7aca-0f97-49f0-b7b1-dd434147ac04" xlink:to="loc_us-gaap_InvestmentIncomeNet_f9fd8a2e-fcc9-422e-a41c-4f977d5a78b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_9b6ef613-7cfa-450a-ab92-ef67ea56474a" xlink:href="vrna-20230630.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c7c7aca-0f97-49f0-b7b1-dd434147ac04" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_9b6ef613-7cfa-450a-ab92-ef67ea56474a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_86d79471-2c4c-44e5-ae9f-0f0f882bb2f9" xlink:href="vrna-20230630.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c7c7aca-0f97-49f0-b7b1-dd434147ac04" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_86d79471-2c4c-44e5-ae9f-0f0f882bb2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bb65608c-d86c-413c-89d4-c8dcb642864b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c7c7aca-0f97-49f0-b7b1-dd434147ac04" xlink:to="loc_us-gaap_InterestExpense_bb65608c-d86c-413c-89d4-c8dcb642864b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_962c61f1-cde9-429a-a498-6c979131efb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f7c25d64-6df1-4ed1-81e5-4c4abd6a1522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_962c61f1-cde9-429a-a498-6c979131efb4" xlink:to="loc_us-gaap_OperatingExpenses_f7c25d64-6df1-4ed1-81e5-4c4abd6a1522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ba2459e-abd2-41f3-9738-043852c6cded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_81838e56-6757-4672-a677-64e23bb2a181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7ba2459e-abd2-41f3-9738-043852c6cded" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_81838e56-6757-4672-a677-64e23bb2a181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61f8cbd5-9019-46e2-a492-2bb7750805d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7ba2459e-abd2-41f3-9738-043852c6cded" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61f8cbd5-9019-46e2-a492-2bb7750805d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b78fc9ac-1321-4018-ae3f-313613faaa68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75d9d0cc-2804-43c7-a0ba-53d003f52481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b78fc9ac-1321-4018-ae3f-313613faaa68" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75d9d0cc-2804-43c7-a0ba-53d003f52481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_46a98d5a-b749-477a-ba83-d9e9a046314f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b78fc9ac-1321-4018-ae3f-313613faaa68" xlink:to="loc_us-gaap_OperatingIncomeLoss_46a98d5a-b749-477a-ba83-d9e9a046314f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3b8bfeaf-80e6-491e-912b-9a9e89513ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9b2afeba-53c5-4c2e-87e9-eda42d8b2805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3b8bfeaf-80e6-491e-912b-9a9e89513ae3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9b2afeba-53c5-4c2e-87e9-eda42d8b2805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_654f9b8f-ac6b-46df-9dd0-e946eec85856" xlink:href="vrna-20230630.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3b8bfeaf-80e6-491e-912b-9a9e89513ae3" xlink:to="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_654f9b8f-ac6b-46df-9dd0-e946eec85856" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37726242-5204-4f36-bd14-79b761612ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_86c481f9-6626-443e-b992-2a9aaf9ef979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37726242-5204-4f36-bd14-79b761612ee5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_86c481f9-6626-443e-b992-2a9aaf9ef979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ff6c1b7d-da6d-4c25-809c-31e22a342d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37726242-5204-4f36-bd14-79b761612ee5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ff6c1b7d-da6d-4c25-809c-31e22a342d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e44334d8-7917-49d8-b2cb-15de218f246e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37726242-5204-4f36-bd14-79b761612ee5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e44334d8-7917-49d8-b2cb-15de218f246e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_063c12c3-c2ba-4e9c-830b-edbebeffb426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37726242-5204-4f36-bd14-79b761612ee5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_063c12c3-c2ba-4e9c-830b-edbebeffb426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3509868-f87f-4dac-8c25-d28e19f9b6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ecfcc48-e2cf-4415-9ca4-bdca3dbae3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3509868-f87f-4dac-8c25-d28e19f9b6ab" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ecfcc48-e2cf-4415-9ca4-bdca3dbae3ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_7bbc6a73-6159-45a0-99b0-233975616fa1" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_7bbc6a73-6159-45a0-99b0-233975616fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_5ebed1b3-f300-4c87-aa99-f6edbd68d016" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_5ebed1b3-f300-4c87-aa99-f6edbd68d016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2c9ace79-d828-4423-afb7-dd763448cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2c9ace79-d828-4423-afb7-dd763448cd72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_7ccf24c1-beba-47fa-a673-31e35eec4176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_7ccf24c1-beba-47fa-a673-31e35eec4176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f14b6de-67a1-4d63-81ff-6c35631412b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f14b6de-67a1-4d63-81ff-6c35631412b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4325571b-38e2-445b-a3fb-fc985bd5b772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_ShareBasedCompensation_4325571b-38e2-445b-a3fb-fc985bd5b772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef6ee283-c29a-43db-80f8-185c51cf3dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef6ee283-c29a-43db-80f8-185c51cf3dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2805b33f-3056-4b65-b7f8-4d24ff9ca51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2805b33f-3056-4b65-b7f8-4d24ff9ca51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fa5e2420-93be-426f-b430-91a0f5a614c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fa5e2420-93be-426f-b430-91a0f5a614c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2748843e-c148-4d68-a631-3c349871f238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2748843e-c148-4d68-a631-3c349871f238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_50dca91e-14fe-46de-a613-d364e71dcb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_50dca91e-14fe-46de-a613-d364e71dcb2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a21fa064-d842-4132-8c10-78b20001d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a21fa064-d842-4132-8c10-78b20001d3ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_dd8fecbf-473a-4dd0-a5cb-d6de69c99a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_dd8fecbf-473a-4dd0-a5cb-d6de69c99a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_31039750-945d-40c5-b5ee-d9440204450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc67d237-3e2e-4997-adb7-711e35046083" xlink:to="loc_us-gaap_NetIncomeLoss_31039750-945d-40c5-b5ee-d9440204450e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca76211-19db-4697-8b08-2fa62c70c788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_620c3083-dad6-4fa3-b99e-4facc39469e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca76211-19db-4697-8b08-2fa62c70c788" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_620c3083-dad6-4fa3-b99e-4facc39469e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dc954ea-370b-461b-b4d5-8576ca6a58f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca76211-19db-4697-8b08-2fa62c70c788" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dc954ea-370b-461b-b4d5-8576ca6a58f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_67d61677-5ddd-4b09-be59-f145c062ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca76211-19db-4697-8b08-2fa62c70c788" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_67d61677-5ddd-4b09-be59-f145c062ee5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18626bd8-532e-4b6f-9368-f3342efcc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca76211-19db-4697-8b08-2fa62c70c788" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18626bd8-532e-4b6f-9368-f3342efcc2cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f357a881-5d67-412b-8ffd-edd1993983a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_a13b8900-949e-4133-b6fd-1da32197d22e" xlink:href="vrna-20230630.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f357a881-5d67-412b-8ffd-edd1993983a1" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_a13b8900-949e-4133-b6fd-1da32197d22e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_f79831c1-53f9-4606-870c-4df7732567ed" xlink:href="vrna-20230630.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f357a881-5d67-412b-8ffd-edd1993983a1" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_f79831c1-53f9-4606-870c-4df7732567ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96c1d680-c7cc-48f7-9f19-3b4d393c77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f357a881-5d67-412b-8ffd-edd1993983a1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96c1d680-c7cc-48f7-9f19-3b4d393c77b2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vrna-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="if225c823713341c8a515b597547d3f0c_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_84f3a746-0620-46f1-aa66-aa0ccf67482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_84f3a746-0620-46f1-aa66-aa0ccf67482a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d03d005-252d-4bb8-a6b4-7ecdd9417af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockholdersEquity_0d03d005-252d-4bb8-a6b4-7ecdd9417af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_855a8651-90ec-4246-831d-c1b1616682f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_NetIncomeLoss_855a8651-90ec-4246-831d-c1b1616682f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcbb909-347d-4729-95cb-9b6fcc267d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcbb909-347d-4729-95cb-9b6fcc267d6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_64b1457b-1235-4fc7-ad8e-b0702125e26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_64b1457b-1235-4fc7-ad8e-b0702125e26e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_df714fef-57d2-4fa4-b460-c8267da90a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_df714fef-57d2-4fa4-b460-c8267da90a61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0ca95e61-c2de-474e-aa44-fa4bbcebea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0ca95e61-c2de-474e-aa44-fa4bbcebea3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8ad21b94-2843-418a-8ee3-a55cb4b9d7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8ad21b94-2843-418a-8ee3-a55cb4b9d7bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52fb60fb-2c6e-4c96-93f7-cad4f77920f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52fb60fb-2c6e-4c96-93f7-cad4f77920f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aa78cc55-0768-45ed-aad7-34de976784a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aa78cc55-0768-45ed-aad7-34de976784a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_81216142-851d-43d4-a511-f527b64ea779" xlink:href="vrna-20230630.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_81216142-851d-43d4-a511-f527b64ea779" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7c79d21-6632-42b3-8beb-c468581a3fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7c79d21-6632-42b3-8beb-c468581a3fa1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dbd0450d-3ed3-419b-a7e7-24fa386892a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e0facf7-bf4b-4998-adb0-a071d91685f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:to="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_df378238-a280-4d21-b8bc-78d4d503ccb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:to="loc_us-gaap_EquityComponentDomain_df378238-a280-4d21-b8bc-78d4d503ccb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:to="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_791f14cb-cb41-44a4-92f0-a003f8bb9baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_CommonStockMember_791f14cb-cb41-44a4-92f0-a003f8bb9baa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3985016a-25dc-4358-9bc4-f9b9a1ce0d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3985016a-25dc-4358-9bc4-f9b9a1ce0d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9ff5343f-8dda-4fab-99c9-625383e0a133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_TreasuryStockMember_9ff5343f-8dda-4fab-99c9-625383e0a133" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8d4f062-36c9-4a78-97b4-f8f6140cc2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8d4f062-36c9-4a78-97b4-f8f6140cc2e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32aaf444-c43e-408e-bcd6-c2463252ce6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_RetainedEarningsMember_32aaf444-c43e-408e-bcd6-c2463252ce6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_7407e755-8b20-4539-8d6f-f486c5710347" xlink:href="vrna-20230630.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_7407e755-8b20-4539-8d6f-f486c5710347" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended" id="if2d8adbd234f4093a0f6103530230d9b_OrganizationConsolidationandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_54f9522e-cf86-468b-9bfe-16305628274a" xlink:href="vrna-20230630.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_54f9522e-cf86-468b-9bfe-16305628274a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PaymentsForApplicationFees_0cb8df12-8033-4712-8599-be7518d79140" xlink:href="vrna-20230630.xsd#vrna_PaymentsForApplicationFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_PaymentsForApplicationFees_0cb8df12-8033-4712-8599-be7518d79140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9315dd8-4a1c-4cef-9c5b-5c15f74465c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9315dd8-4a1c-4cef-9c5b-5c15f74465c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_12bc58a3-7cd0-473c-bc6b-8c45b2ff50ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_12bc58a3-7cd0-473c-bc6b-8c45b2ff50ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2df8ad08-21d6-42b4-8bac-6c0531dbb173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2df8ad08-21d6-42b4-8bac-6c0531dbb173" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42e00b5e-f9aa-403e-8bf3-aa9810141e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42e00b5e-f9aa-403e-8bf3-aa9810141e8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_02b14d42-a24e-4ff8-81e0-9baef7a3813a" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_02b14d42-a24e-4ff8-81e0-9baef7a3813a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockCommissionFeePercentage_50613f42-3a39-49f3-a0ab-e4ef4d0c56b5" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockCommissionFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_SaleOfStockCommissionFeePercentage_50613f42-3a39-49f3-a0ab-e4ef4d0c56b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_16422c2b-c915-4971-a2a0-af697e3e55bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:to="loc_us-gaap_ClassOfStockDomain_16422c2b-c915-4971-a2a0-af697e3e55bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:to="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_beb418dc-a57a-4428-86f4-b2750dc2894a" xlink:href="vrna-20230630.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:to="loc_vrna_AmericanDepositorySharesMember_beb418dc-a57a-4428-86f4-b2750dc2894a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7443035-476a-4bdf-8771-a50e5641d9d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7443035-476a-4bdf-8771-a50e5641d9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ATMProgramMember_34565d20-fb13-4938-b270-f86aeaa9c942" xlink:href="vrna-20230630.xsd#vrna_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:to="loc_vrna_ATMProgramMember_34565d20-fb13-4938-b270-f86aeaa9c942" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#EquityInterestDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended" id="id4491cd736ab4eb9a6015357f9ea54f4_EquityInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1147dfa4-c59c-49ff-969d-df5c61bb1df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1147dfa4-c59c-49ff-969d-df5c61bb1df8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a2bd880c-0ba8-4cba-a28e-16e71184d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a2bd880c-0ba8-4cba-a28e-16e71184d01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_f9290973-c86a-47b5-9b3d-f311748c1920" xlink:href="vrna-20230630.xsd#vrna_EquityInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_vrna_EquityInterestReceivable_f9290973-c86a-47b5-9b3d-f311748c1920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:to="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5250df6d-46bd-4e82-9c4c-5871aee27b04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5250df6d-46bd-4e82-9c4c-5871aee27b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_e930407e-7c1f-4994-86ac-024f269ebaf8" xlink:href="vrna-20230630.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_e930407e-7c1f-4994-86ac-024f269ebaf8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#TermloanDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended" id="iaa99b5c4bea64d0e8aa380fd8ca5caca_TermloanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8bdba99-6969-4760-894f-4f591f633949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8bdba99-6969-4760-894f-4f591f633949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_29a66a01-3d98-455c-a5b1-0c30694fe62c" xlink:href="vrna-20230630.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_29a66a01-3d98-455c-a5b1-0c30694fe62c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_5310dd23-e3df-48ec-aa7b-6fa5f3fd66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_5310dd23-e3df-48ec-aa7b-6fa5f3fd66ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8ac0019b-4440-4c34-a4dd-decda3de4c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8ac0019b-4440-4c34-a4dd-decda3de4c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2c6d60de-23cd-4cf7-afa8-f908709ae2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2c6d60de-23cd-4cf7-afa8-f908709ae2fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_08bded2f-7064-4d6d-8d62-6e4db2f00633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_08bded2f-7064-4d6d-8d62-6e4db2f00633" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7cea6696-f234-4c7b-a2cf-2ff4a59485a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:to="loc_us-gaap_CreditFacilityDomain_7cea6696-f234-4c7b-a2cf-2ff4a59485a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:to="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d762e9df-77c2-4d55-b902-86518beb33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:to="loc_us-gaap_LineOfCreditMember_d762e9df-77c2-4d55-b902-86518beb33ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_33847d3c-6951-450d-9acb-3463325a1031_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_33847d3c-6951-450d-9acb-3463325a1031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_8c84d2a1-6ebe-4ee1-a832-ba95745a59fa" xlink:href="vrna-20230630.xsd#vrna_OxfordTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermLoanMember_8c84d2a1-6ebe-4ee1-a832-ba95745a59fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember_70048695-beae-497b-a47f-00b1c1ced7a7" xlink:href="vrna-20230630.xsd#vrna_OxfordTermALoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermALoanMember_70048695-beae-497b-a47f-00b1c1ced7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember_4a64c455-cf58-4100-a63e-5b9e6c907d75" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermBCDELoanMember_4a64c455-cf58-4100-a63e-5b9e6c907d75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember_8533ba33-7c8d-401a-9628-9402b074d08b" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermBLoanMember_8533ba33-7c8d-401a-9628-9402b074d08b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_688bd008-1b38-4a23-8f3a-bad1f871080e_default" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:to="loc_vrna_InterestRatePeriodDomain_688bd008-1b38-4a23-8f3a-bad1f871080e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:to="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_db20e3b0-3bab-4a3d-9a0a-4b1a2779c561" xlink:href="vrna-20230630.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_db20e3b0-3bab-4a3d-9a0a-4b1a2779c561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e921fe4-b2d6-4f96-b262-55c8711d83e4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:to="loc_srt_RangeMember_5e921fe4-b2d6-4f96-b262-55c8711d83e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:to="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cf4e7ef0-8ea8-483f-b78e-a7166cb2c2a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:to="loc_srt_MinimumMember_cf4e7ef0-8ea8-483f-b78e-a7166cb2c2a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_505e3733-f546-4be5-b485-0c5c26d13142_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:to="loc_us-gaap_VariableRateDomain_505e3733-f546-4be5-b485-0c5c26d13142_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:to="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a4d5c999-fe81-40b9-929b-6089855011e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:to="loc_us-gaap_BaseRateMember_a4d5c999-fe81-40b9-929b-6089855011e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i6d6583c2e4254fc9b7b86bec96734976_SharebasedcompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03471402-89df-4364-9987-7366e7c08540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03471402-89df-4364-9987-7366e7c08540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6a512ed-dddf-4938-9754-912b63f80e96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6a512ed-dddf-4938-9754-912b63f80e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_86f321be-2f4c-4785-94d8-34916bea6cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_86f321be-2f4c-4785-94d8-34916bea6cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35a1b78c-3091-4f3b-8552-f3098ef353ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35a1b78c-3091-4f3b-8552-f3098ef353ca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended" id="id09871e2d45d4586a99c1a1cd166f712_SharebasedcompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_248ee8d3-8773-45f7-8c78-6fc2ca064be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_248ee8d3-8773-45f7-8c78-6fc2ca064be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9cfb9c89-8520-4b86-8022-7e7c51c11c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9cfb9c89-8520-4b86-8022-7e7c51c11c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa977eba-368e-4199-b4c3-0e72907935d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:to="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57cb7e87-6ed6-45da-8ff0-2cb74f221a85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57cb7e87-6ed6-45da-8ff0-2cb74f221a85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b7f3a43-cc45-44a8-b282-82ed42019828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b7f3a43-cc45-44a8-b282-82ed42019828" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vrna-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97871af2-53b9-4268-b936-d925a159a6d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e3952cda-edf1-4e28-a808-3e10f64e4f76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_dc97c0f9-8411-43f4-a788-b57331b3658b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0d69083f-fe80-46e0-a02d-1eb2f222f21a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermALoanMember_381c1732-7925-4463-9791-d76dbb13e048_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan</link:label>
    <link:label id="lab_vrna_OxfordTermALoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermALoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember" xlink:href="vrna-20230630.xsd#vrna_OxfordTermALoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermALoanMember" xlink:to="lab_vrna_OxfordTermALoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d3e02e4a-655e-4fcb-8fa6-6e17db92f7c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9f1edaad-fbec-428b-a88b-5f495812c61c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dbb599b4-2230-417e-8982-d5db43de65b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c685916e-9a40-4761-b460-d7f60911a85d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d0bf7c01-1cdb-4d18-b379-990bc99287c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_8c2fdcf8-e06f-4c48-b144-5a40e36bad44_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:to="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f04950c-5f60-4dcf-94c9-318194fb7456_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_24285426-38e4-4702-8f0a-e0adf1aed63b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_aa70c675-00fc-435b-a830-241cdf03e97d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_c4d03f7f-0d1b-4b6d-9903-b3c1f1ea675d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss in period</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod" xlink:to="lab_us-gaap_LossContingencyLossInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_ddb3d1fb-3cd1-478b-9855-9e4ddff4eba3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_ef417fe5-a83b-4678-9377-aeacee0b2d72_terseLabel_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20230630.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_cc92a0c7-d04a-4daf-a24a-2e8814311d31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income/(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9362b166-9b87-4081-bc35-4ce0d36fea88_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary &#163;0.05 par value shares; 651,659,630 and 631,338,246 issued, and 635,787,302 and 606,301,054 outstanding, at June 30, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1da8613f-6c93-4030-be4b-dfc5e3a384b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_bf27342c-9f97-4ad9-bc97-b98af94232b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PaymentsForApplicationFees_bbe7c715-51e8-4d3e-a1df-f819f58dbe56_terseLabel_en-US" xlink:label="lab_vrna_PaymentsForApplicationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription drug user fee</link:label>
    <link:label id="lab_vrna_PaymentsForApplicationFees_label_en-US" xlink:label="lab_vrna_PaymentsForApplicationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Application Fees</link:label>
    <link:label id="lab_vrna_PaymentsForApplicationFees_documentation_en-US" xlink:label="lab_vrna_PaymentsForApplicationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Application Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PaymentsForApplicationFees" xlink:href="vrna-20230630.xsd#vrna_PaymentsForApplicationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PaymentsForApplicationFees" xlink:to="lab_vrna_PaymentsForApplicationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_4b2332b4-531c-4f5d-a0f4-839f11dc6996_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan</link:label>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermBCDELoanMember" xlink:to="lab_vrna_OxfordTermBCDELoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f3f67b11-539c-43dd-82fe-ae684462134d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bc90857e-f0c1-4f08-a150-6bae3390cc78_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4284f89-420a-4e06-817d-34518bf754a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermBLoanMember_129e9eca-f383-4f9e-8cb5-79d97be062b0_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan</link:label>
    <link:label id="lab_vrna_OxfordTermBLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermBLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermBLoanMember" xlink:to="lab_vrna_OxfordTermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_055b1296-9497-4ee2-a5e6-6bdfb9e2584b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a872df4-d130-4bb3-a3cc-c87c0a69d51a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_31d8e1bc-2d88-4062-beee-361089e6dc42_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:href="vrna-20230630.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_214fb9d2-f189-4b68-b881-deeb792d75f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e30f8a76-c3c3-4d9a-831c-650d620f331b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_bd9e03bc-4dc4-41e4-9524-832cc61d117f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b76fd222-ad0a-4f8e-850f-5472818bbd54_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from draw under the Oxford Term Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_d98cfece-1b81-4113-b636-8b76e0d798fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0e40f8b8-fa67-4460-b800-a2269af7bfb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_5050fd49-c059-4e2f-862d-82e28a167127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9f3fe784-15eb-42fa-8419-01888d27a700_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9f32a27e-54e1-4ac8-8cf4-2e7edfae25ef_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e14d24a-f72f-40b1-a86c-06dd1d144231_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d07d6cb6-67b8-481a-83c8-4ded1727f64d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_f4f9bae4-d00e-4671-8c9b-77da4b09d027_terseLabel_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_label_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares [Member]</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_documentation_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember" xlink:href="vrna-20230630.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AmericanDepositorySharesMember" xlink:to="lab_vrna_AmericanDepositorySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f6f6e51d-9753-4717-bbfb-7de15198747e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gain)/loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b07ed87f-7226-4b6a-98d5-135559f3e0a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_3f9d0f0b-fa6b-4994-ae60-b65438435ff5_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_47e4857c-cf17-4dc9-b71a-a8894107635b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2b4810f3-6ac4-43bd-a5d6-3ce0e6010339_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a9b12bee-8c15-4c86-9899-2c1d2209a9c7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_86f06219-0c5f-41c8-bcc4-3732ef716e33_terseLabel_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement [Member]</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember" xlink:href="vrna-20230630.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AtTheMarketSalesAgreementMember" xlink:to="lab_vrna_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2cbc10a5-77bf-469e-a675-809230e6e199_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4eaa5035-328a-4c00-8404-496a59d29e50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_6ee702bb-7f57-490b-bd3c-4ed420f1e68e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_001a2176-939b-493c-b8b1-2081c7a41235_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f37a154a-b50f-4a00-a3da-05a170511a8f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f508d792-063e-4c23-abc5-29767cc95d21_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_119415ab-4868-4a40-8fe7-180ac5306176_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ec85dc3d-2609-4894-8fb9-4063bbc787b3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6411364b-6f9c-4e2c-8388-59d9b3819147_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_541dd04a-eb19-4129-bfb7-c595f6e2ff4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d3cd32a0-4067-4d68-a4c3-7a6d35fface3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_28a2a387-b4f3-43ac-a3be-10f45f50b989_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate increase</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e52df5a5-211e-4535-9cd5-1e074a8af525_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_508241c1-c821-45b3-b0be-45665b5717c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf9efd0f-1931-4175-983a-f0104d81c441_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9e70fccb-0b75-43b7-9722-dc3715b0fea0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d8b665c8-0b09-4a5e-a128-30edae915a65_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7c81c577-ad47-40a4-b7c6-b71a7c7dbb6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5052dbe0-c30e-42ea-84ab-926c0725fd82_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0e4d600-d490-4420-96c3-8cb624ee6223_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_37d1ee6d-2548-4a96-8da5-0b6da6c31775_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fcad42d4-b8de-40b4-a111-6d9582fda282_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7dd13760-e7a0-41e0-ba2f-2094815f664e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c54ff38c-50cc-4cbb-b0a3-01f81c60ef01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_39a0067f-037f-47bc-9887-5ce302a49d82_terseLabel_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and description of business operations</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_label_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description [Text Block]</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_documentation_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:href="vrna-20230630.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:to="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_f3b2c097-65bf-4ded-b7dc-75b49f618b29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fc7c1c25-6ca9-4447-b703-0ffb74765bd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c614ba79-41f5-4163-958e-994ee488fef5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c81d98de-bb64-4f49-a865-5b010eda732f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_58a59b39-6d3d-462c-927b-b973c5623da2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b10ac068-d91c-46ec-86c1-e7e52c717f78_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_f0cdc1f9-2a61-42ad-a984-8a7f7d3475e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5c695ff-fea9-4e82-a17e-3b07e3c998be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2e7dbf37-2881-4c53-89c7-9d9c0fbb3b8c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240e55b5-1b92-4878-a6dc-b9d6907a956a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a309b632-66b5-4773-95ba-488d38c68faa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e13b978a-2ce9-410b-8efe-ed9deda4c425_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_82dcb76a-688c-45d9-ac42-a6147521bbf0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_88675ea9-5138-407a-bb22-0c7f07eca092_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_389dac04-7038-46e2-92c0-3028f74c50b6_terseLabel_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_label_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd [Member]</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_documentation_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:href="vrna-20230630.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:to="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e734f44e-a201-42cf-b02b-e8aec7f10e6c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_aa985069-bf58-493e-b962-977b93e27b8b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_22dc1cf4-d586-4312-8155-cb12945aa882_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cc3c7394-1888-40e7-976e-c91cd429d876_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1043cc7c-adda-4c84-87ff-7d6e0b4b323a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_ec02dd72-65e0-47c7-b3a3-2b22ad4fbe61_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_970d11f8-6a29-4603-aef7-f63dafaffbbc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f7293d26-8104-4bf0-bda0-65062b2f8506_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3d0ccaed-986a-4e47-b0df-21a58b739222_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17336bd7-363e-494e-9d6c-c3f5473ae1c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8e7a26c6-f898-4c5b-aa0b-9e56fca4ed49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_eda2ea77-76c1-47f4-b29e-8b2cbc3b089f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redemption premium on debt</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EquityInterestReceivable_33479d57-781e-4ca6-a0e1-7b9ea2c1c3c3_terseLabel_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_label_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_documentation_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable" xlink:href="vrna-20230630.xsd#vrna_EquityInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EquityInterestReceivable" xlink:to="lab_vrna_EquityInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f625d44e-e413-407d-a93e-10599b477982_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ATMProgramMember_d9b9ee36-3967-4795-815a-042f053f951e_terseLabel_en-US" xlink:label="lab_vrna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_vrna_ATMProgramMember_label_en-US" xlink:label="lab_vrna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_vrna_ATMProgramMember_documentation_en-US" xlink:label="lab_vrna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ATMProgramMember" xlink:href="vrna-20230630.xsd#vrna_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ATMProgramMember" xlink:to="lab_vrna_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_82582216-fe0a-4410-923d-8fab3606478e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c5568158-26c3-45eb-a63f-e727b047a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_69ceeb73-75a2-45a7-bf7a-2e2b69f9181d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_6885ab96-2e64-4b48-b185-b5f5f8639ac5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cc5d5e4c-1f3d-4a7e-901b-945bf6a05e55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodDomain_47df2584-4c37-4b52-a2db-655709509488_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_label_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodDomain" xlink:to="lab_vrna_InterestRatePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_924612ce-be42-4cca-afd1-7170277ad006_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_de5e5090-0b63-4530-889b-949e70e9ca0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_235e9413-b7da-4405-955d-f8f59271bab1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6837d687-2d84-4070-9583-a386848c0f52_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_12c91fec-d7cb-4c5d-b1c5-9dc7f49e06ad_terseLabel_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain/(loss)</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_label_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_documentation_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:href="vrna-20230630.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:to="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a1ca12eb-cfce-42ad-9328-a7c96055c5b7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0664a195-e69b-4d01-9edd-47a7dd20af9e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">People related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_99dc3231-9def-45ba-af9c-1a6bef13440e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d5c84511-a432-493b-8262-439af21831f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef6dd941-abda-4794-8724-d9b32a67c031_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7fdc6a2d-52a0-4848-8f23-d0b52f7e05da_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e3168372-bc7d-4285-80df-a8a25f01ff22_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization and net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_d693e80a-2b45-4984-a504-178e167a1a54_terseLabel_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and general corporate costs</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_label_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:href="vrna-20230630.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:to="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_70d9ae34-ddb2-46f1-b03a-740b1edf8782_terseLabel_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_74afbea7-3b02-45b5-8d6e-04bfb7b57b3a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_215c2f25-828e-4271-9171-08778865488d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae966656-118a-43e3-a482-6c82ff547e3d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a25db929-f010-4127-baee-323831f37f46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_0e96539e-5d4e-4414-9b70-a30afa5441d3_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_label_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One [Member]</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:href="vrna-20230630.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:to="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_3effb4be-9699-4549-949a-2a6b157d969d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_24cdd786-a9ae-4108-b42f-72a85a8a7a57_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a4e30af8-ecab-472b-aaf9-e5ba9cb30e08_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bc9a0b15-68dc-482a-a810-cda01aace498_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a79cc2a9-07ec-4ae3-a856-fb675298b50b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_be9b7cdd-500f-4607-8421-afcaf1fa724b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_273a477a-7d63-45f6-8d89-bd54368714f9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3b6333bf-69e9-4e92-b34f-40cd7824f6c1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_278b8297-3eff-4ace-a597-c4d8610156ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts_c88a2c16-04bc-4d26-8c79-67210d3db7dc_terseLabel_en-US" xlink:label="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Reversal Of Research And Development Costs</link:label>
    <link:label id="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Reversal Of Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:href="vrna-20230630.xsd#vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:to="lab_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SaleOfStockCommissionFeePercentage_fcc148e6-dddf-400d-bc0d-e439adba6db2_terseLabel_en-US" xlink:label="lab_vrna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee percentage</link:label>
    <link:label id="lab_vrna_SaleOfStockCommissionFeePercentage_label_en-US" xlink:label="lab_vrna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Fee Percentage</link:label>
    <link:label id="lab_vrna_SaleOfStockCommissionFeePercentage_documentation_en-US" xlink:label="lab_vrna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockCommissionFeePercentage" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockCommissionFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SaleOfStockCommissionFeePercentage" xlink:to="lab_vrna_SaleOfStockCommissionFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_85e4c10d-db7b-4b7d-bbf0-316f39896c44_terseLabel_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares per ADS</link:label>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_label_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listing, Depository Receipt Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingDepositoryReceiptRatio" xlink:to="lab_dei_EntityListingDepositoryReceiptRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_829ce4c6-0dca-4e35-b3bb-9b28c34b38ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_7355cb71-4c5b-4740-b7c2-ca1ac626dd13_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_76f34d26-41b5-47ae-9602-bb69b64c8546_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_63900eca-b79f-4ff6-882f-fc6b7e67bb13_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_25c97ca9-614b-4353-944c-b7576f0bd9c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermLoanMember_b16382f4-38b0-48a2-85eb-7f2768b6228f_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan</link:label>
    <link:label id="lab_vrna_OxfordTermLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember" xlink:href="vrna-20230630.xsd#vrna_OxfordTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermLoanMember" xlink:to="lab_vrna_OxfordTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_63798615-e759-480f-b6c4-31209319e92e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_63f968ec-d1de-4301-ba40-d1d841f3a2cc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodAxis_b24e47e8-fd77-4b83-84e0-a58953ca925f_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_label_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodAxis" xlink:to="lab_vrna_InterestRatePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_65c149e0-7c5c-4c24-b48d-8717a0e2e9e0_terseLabel_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (Note 8)</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_label_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Net Of Adjustments</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_documentation_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:href="vrna-20230630.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:to="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_96b094ed-b6fb-4db9-906c-a7751fca3faa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c2a8d6e7-1633-4891-bbf9-647a64849c22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in pounds sterling per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_54f9843b-3bab-4cda-8e0c-c96409ce78a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of withholding taxes from share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_607d0af4-ef01-42d2-a59d-c7882f7f7136_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2fe91972-8d18-4058-8fca-46ffcc760c3f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1d6a51b8-0f54-4c90-a19b-28876037da9d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_866c15c5-1752-4076-8a77-962a19b3390f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_776d7f0f-5f50-4c60-bef8-f4d2d3647bcb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_db465e68-e28a-4ab0-bef1-b7b2bbe173b9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_089733c1-3456-4d00-a64c-20274bf12c39_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_1ad6dee1-f566-4908-ac51-5aee61c0e2a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_bd11f500-3b68-413a-905e-703fc8d99070_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_de9fbef6-4507-4582-84af-52d0b1b158da_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit/(loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5588d0ae-2166-4b26-882d-cad3a0ec1ebe_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ceb20fa4-6c0f-4f26-91b1-0a69e5eb2d52_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2830c182-4a26-4543-b67d-3b261ab24930_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e7ce3420-0cd3-42ea-bf98-5796e4d99457_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2f988ce1-a759-4987-a6e9-8163add7e3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2a28505c-8b08-494d-8ed7-66f4624bf3b3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_57a625c6-0fc0-4cc1-93e2-20d86055b8ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1536c0e1-4d4a-4c9d-861a-9a5164f34d0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_4ca9c2d3-6b3d-4cb6-bc72-831f4f1629ad_verboseLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_label_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:href="vrna-20230630.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:to="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6f374bfb-1416-4542-a3e0-83ada8ca0bef_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_72790b97-b790-4655-aced-e5995371f41c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f54afc47-30b2-4392-95a2-79ea5129c391_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1b5bc1f2-33b0-4eac-a159-2371b435ec2b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit/(loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_085c424d-ad5d-4fa6-84d0-6afb6cd705c0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3c2c8a6e-b91e-40cd-a50b-3dfd158b18f5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_afd57da2-3fb0-41f7-8521-80efd7d8557f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1e654157-2267-4ee9-91db-1f66d346bbd2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_09854d29-a03a-4541-ac48-2c040e977d3e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a9b2d496-0da6-4b17-90b1-a1c2e87020de_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_934acb54-54b6-4c22-a41d-11b74d94150f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c77f791f-27c0-4a2a-a2d9-5954de2141f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_274ce117-a985-4244-9814-41880cf5ccee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_fa71f3cf-da94-46f7-bed6-e7b9e2746c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_01d43b56-106d-4264-9be3-c0089323d4fc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_0b53b4bb-9664-4001-9db5-b1732285788c_negatedTerseLabel_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based compensation reclassified as cash-settled</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_label_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_documentation_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:href="vrna-20230630.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:to="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ef096f1f-1fa1-4c31-8e83-61dc73caeff9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_15ef1008-cc5a-44c0-90a0-cf78aaaf17e4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_02f18113-7f49-4fd0-a44d-10fdb63ab000_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in sale (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7d00587e-64dd-41a6-b678-afc3af8c67a5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d1e1b68f-225f-42f6-a021-3b583e9d6fb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3df91ce2-9630-441d-9d6c-4594a9e5adaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1da7a5b3-1857-4b13-90e7-e783545782e4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8185d3ba-3bf0-4081-aea1-a90a824a6bd2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_88a43f03-11a4-48cf-bcdf-a8bba60307c7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_86e35c4f-6ed4-4efc-b20d-e5ba0fd94687_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7d9882a2-eec8-4ef3-a1f7-b99833010a56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8a5450ca-9a53-4fe2-aace-1b70358e065b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_34bcfe23-2339-4145-935e-1a32dfd3785b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_89224f14-11d3-4a3c-bde5-e3ddfc76e0fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4c54130d-d1a6-40b7-a9e2-fedb0b452506_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_87f21b99-71cf-4bfc-97a5-2a7283ac348f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_72aa5b4e-af8c-4461-941b-e4276c363f9a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d5174209-acc9-4f11-a564-fb950b447725_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_64849bf5-c7ad-41e3-adb9-992c5b83e732_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f513b74-d015-4670-9c31-e3a81f41c161_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_52f2ad3a-9bf7-4e7f-bbf4-5e5e295c6ff8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_62e5d4d4-81e0-4dd3-9630-06bbc614d6d1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2d506a40-9da5-46b6-8819-370b4fc8f425_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_a7e298ee-7c28-4b42-97ad-f120f7cd6820_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2472294c-2d98-4a83-a715-b432172c3e22_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d447264-bbf9-4d04-a550-36eec3a15e0f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ddd0556b-6b91-41d5-93f1-4f3fa47fb5b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_10567da1-e679-4842-bbb1-d60296e6ea17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares withheld for taxes on vested stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b134f48-31c9-4dbd-9f25-318e7ff6c8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0f8cf0dc-9a75-43b9-86cc-74ccc886cf7d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c20cf627-30b8-4278-b32b-20b725157e14_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f5da1f18-d630-4202-ae00-7afd22ae0637_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_179350fb-2e5d-4b65-a338-c79c14c1a37b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8c0fcbbd-b7aa-4d3a-b7c8-fb380fb35676_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_09c4c1f5-6422-4383-8069-82f7f3e5cbf6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_dab5ac56-c6d5-4fe5-aa9c-c05f4355cd5e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cab2d43f-8da7-420f-bbe7-be0dab25f8e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_4de110e8-f594-4edf-aa2d-be681b90a552_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03399c86-ce1d-4dcd-83ac-132f0e5c9be7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f2cf04f1-614b-4c55-9f8b-8294cb7b7893_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7d4470ce-d3b3-43d1-b2b1-e444a6ff00e5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9427256f-4ce4-4a55-8f00-dd0425c7cf83_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5f66a527-8916-4a6c-b5f5-b29b257db506_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49a87a27-d9a5-4568-9b2b-89174c9c1231_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_586c0928-9d13-49aa-b895-e96c6732d758_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9388f8f8-0006-450d-a867-23715dfdf64e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_845bbaa6-ce0f-4dcf-847e-ad5b4b7ab0dd_terseLabel_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:href="vrna-20230630.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c1b698d4-24b5-49a8-b7e4-400c4dc20172_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e55fe200-11a0-47d4-b8b0-bba62a0e5ca1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_25b3ba3c-8b77-4e5a-87a7-9d27fbf7db10_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_485c57bd-331f-4f18-a933-67f7f328baac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_b79a1f0c-ca67-4d2e-a51b-ed87a9bcec77_terseLabel_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of loan advances</link:label>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_label_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Loan Advances</link:label>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_documentation_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Loan Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:href="vrna-20230630.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:to="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9eb05415-dcd7-484a-a4e2-b59ae81b4f2e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of furniture and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f77cc5f4-efc2-4b36-9313-fc5e2d9e9705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9b5e85d6-a0ef-4ce3-8fa1-bc44959595ad_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8cbef9d8-3f1d-4dbb-8ce6-f86337bf6468_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_194fbc70-76fa-4a28-bc7a-f81e25aad730_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting standards and recent accounting standards not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c5e27792-6eb4-4eef-aeb6-b52a0234e6c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_77f47c87-3970-49a3-858a-9a8c9deaf4c4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_334f6048-ba58-42dc-be04-eadedb8a3b09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_871aef3e-a2ae-4882-b208-e38dda17370c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_250c2c57-8e96-4df0-af70-a1ca02d972ba_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2e0998df-9c5f-402b-9ad7-33068ec90422_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vrna-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:05366ea1-23fd-40b7-bcaf-82cbf48115f8,g:86c2bc6f-d2f5-4253-97f5-485556f1c791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20230630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_84f810e6-adf8-40d5-a91a-41e1536194e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentType_84f810e6-adf8-40d5-a91a-41e1536194e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_daee0781-ee87-4cb6-a4a0-24c0cb530189" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentQuarterlyReport_daee0781-ee87-4cb6-a4a0-24c0cb530189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_16f376f0-9303-49cd-9f82-ce993cade0cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentPeriodEndDate_16f376f0-9303-49cd-9f82-ce993cade0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_219ac06a-74e2-4cf6-9322-88d428976599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentTransitionReport_219ac06a-74e2-4cf6-9322-88d428976599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ae1d6954-eece-4a63-b37b-414b3e5f4bf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityFileNumber_ae1d6954-eece-4a63-b37b-414b3e5f4bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6059ed25-7586-4072-bb2e-630f794862e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityRegistrantName_6059ed25-7586-4072-bb2e-630f794862e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2c3b2776-8dc1-427a-b0c0-8dffeb6d7d33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2c3b2776-8dc1-427a-b0c0-8dffeb6d7d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_25bbe3fc-b24c-450d-ad47-92a6dd7d5e41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityTaxIdentificationNumber_25bbe3fc-b24c-450d-ad47-92a6dd7d5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ed9d0b93-8d0a-4fe0-8e6d-be2420be9033" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityAddressAddressLine1_ed9d0b93-8d0a-4fe0-8e6d-be2420be9033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3ef9f2ca-a1ad-44d2-b95c-96e230d19d43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityAddressCityOrTown_3ef9f2ca-a1ad-44d2-b95c-96e230d19d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d3a2e691-3fa6-4e62-b3f9-21da37cf9b12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityAddressPostalZipCode_d3a2e691-3fa6-4e62-b3f9-21da37cf9b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_94061f2b-26cb-4beb-8347-0e15266bc419" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityAddressCountry_94061f2b-26cb-4beb-8347-0e15266bc419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_821cb7ba-7ad2-482b-8fde-db28fde56268" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_CountryRegion_821cb7ba-7ad2-482b-8fde-db28fde56268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dce422a0-39b3-48c4-b864-b89d1e783d24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_CityAreaCode_dce422a0-39b3-48c4-b864-b89d1e783d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_55cc061c-5736-4e48-84de-3e568b2e21ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_LocalPhoneNumber_55cc061c-5736-4e48-84de-3e568b2e21ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_34153f0f-92d4-4b69-a270-f26736825de7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_Security12bTitle_34153f0f-92d4-4b69-a270-f26736825de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a161c1c7-2756-469a-8421-b41240676b20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_TradingSymbol_a161c1c7-2756-469a-8421-b41240676b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f192aac-bff7-45c2-addc-9f2f63bfc604" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_SecurityExchangeName_7f192aac-bff7-45c2-addc-9f2f63bfc604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c2af4201-de7d-4faa-a35a-1107385beb1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityCurrentReportingStatus_c2af4201-de7d-4faa-a35a-1107385beb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9f101025-39cf-442d-8c27-e9329faf20bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityInteractiveDataCurrent_9f101025-39cf-442d-8c27-e9329faf20bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d6956d25-0826-47c3-a6c8-68348987c11a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityFilerCategory_d6956d25-0826-47c3-a6c8-68348987c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0d38823a-4f71-459d-b9b6-513d714e16f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntitySmallBusiness_0d38823a-4f71-459d-b9b6-513d714e16f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_47d9f4a3-0ec6-475d-bc1c-22e1e7125e2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityEmergingGrowthCompany_47d9f4a3-0ec6-475d-bc1c-22e1e7125e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b6ab0c69-effd-40e4-98bc-5cd2c51a7097" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityShellCompany_b6ab0c69-effd-40e4-98bc-5cd2c51a7097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_86931b8e-acb3-4421-8a20-2c539cb2367a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_86931b8e-acb3-4421-8a20-2c539cb2367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c6705cf-78ba-46ce-bdb2-9814b68501e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_AmendmentFlag_5c6705cf-78ba-46ce-bdb2-9814b68501e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5744898b-1651-4944-9f16-7cbfc606b10d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentFiscalYearFocus_5744898b-1651-4944-9f16-7cbfc606b10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f788eec8-2028-47dc-9a2d-ce4daf7e3f5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_CurrentFiscalYearEndDate_f788eec8-2028-47dc-9a2d-ce4daf7e3f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_037d7ccc-a24a-458e-9ff7-3c49d66d4449" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_DocumentFiscalPeriodFocus_037d7ccc-a24a-458e-9ff7-3c49d66d4449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0c209b7f-489b-494f-8202-42059576def7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2665f714-5e87-4eaa-8c0c-31cb8ef41026" xlink:to="loc_dei_EntityCentralIndexKey_0c209b7f-489b-494f-8202-42059576def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2425c827-2387-420e-a72b-a62669abf87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_769ecd3a-6d1b-41d3-b58c-0011f2fdf9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2425c827-2387-420e-a72b-a62669abf87a" xlink:to="loc_us-gaap_AssetsAbstract_769ecd3a-6d1b-41d3-b58c-0011f2fdf9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_769ecd3a-6d1b-41d3-b58c-0011f2fdf9e6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fe28721-323a-4a03-a9ef-91a22529aa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fe28721-323a-4a03-a9ef-91a22529aa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_61e1d6b2-2bee-4ab4-9a3b-c149b72b12c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_61e1d6b2-2bee-4ab4-9a3b-c149b72b12c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_c54e9d81-0db4-4b7d-9888-2112daf06460" xlink:href="vrna-20230630.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_c54e9d81-0db4-4b7d-9888-2112daf06460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f8d1bf7f-cb56-4b6e-a062-e75308f11e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:to="loc_us-gaap_OtherAssetsCurrent_f8d1bf7f-cb56-4b6e-a062-e75308f11e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28fc3f41-69b4-4032-ba7a-91c4afc5b998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28e6632d-e6f1-4acf-a9cd-65375f5ba595" xlink:to="loc_us-gaap_AssetsCurrent_28fc3f41-69b4-4032-ba7a-91c4afc5b998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_769ecd3a-6d1b-41d3-b58c-0011f2fdf9e6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fbb8e02e-d148-4c51-af7e-1fad58e2caef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fbb8e02e-d148-4c51-af7e-1fad58e2caef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_693ddaeb-29d0-4be6-9666-9f3cc2c151f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:to="loc_us-gaap_Goodwill_693ddaeb-29d0-4be6-9666-9f3cc2c151f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_e70e85c2-0fa6-4f9c-902f-29d83f7d9252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_e70e85c2-0fa6-4f9c-902f-29d83f7d9252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a86d31b-1973-4b45-9f7a-c84648d91972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a86d31b-1973-4b45-9f7a-c84648d91972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_85e2a0da-60ad-4f62-bfe3-4d1562d6087e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_c46075f8-c567-44bb-a035-62114ce642a8" xlink:to="loc_us-gaap_AssetsNoncurrent_85e2a0da-60ad-4f62-bfe3-4d1562d6087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c7f9a5ec-8542-409b-bb60-64124edb43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_769ecd3a-6d1b-41d3-b58c-0011f2fdf9e6" xlink:to="loc_us-gaap_Assets_c7f9a5ec-8542-409b-bb60-64124edb43c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2425c827-2387-420e-a72b-a62669abf87a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6293b519-8eb5-40e1-a4ff-e63430b0c02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_AccountsPayableCurrent_6293b519-8eb5-40e1-a4ff-e63430b0c02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d51cde61-3e0b-4408-9814-1509b621ebba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d51cde61-3e0b-4408-9814-1509b621ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c479885-dddc-4a1f-9968-ebf4dff72a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c479885-dddc-4a1f-9968-ebf4dff72a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_2d4ace4d-a74c-4890-9e8c-2259f754e7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_TaxesPayableCurrent_2d4ace4d-a74c-4890-9e8c-2259f754e7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_30d5d9e1-940e-4ee5-9c03-cf61816c25ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_30d5d9e1-940e-4ee5-9c03-cf61816c25ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a8cb56b4-ddc8-4eba-a2da-fdbbdaa30490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_68b3468e-efbe-434f-b6ac-8c69fcbc48a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_a8cb56b4-ddc8-4eba-a2da-fdbbdaa30490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_b95c3018-93e3-4708-a947-d16e73e42615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_b95c3018-93e3-4708-a947-d16e73e42615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ead7c13b-d15e-4e8e-bc65-e167533f3a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b95c3018-93e3-4708-a947-d16e73e42615" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ead7c13b-d15e-4e8e-bc65-e167533f3a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_910e4792-d5c1-451f-8410-9c4642497b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b95c3018-93e3-4708-a947-d16e73e42615" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_910e4792-d5c1-451f-8410-9c4642497b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_ecdb030f-69cd-492c-af2b-61928bc35404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b95c3018-93e3-4708-a947-d16e73e42615" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_ecdb030f-69cd-492c-af2b-61928bc35404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_007809a8-4835-486b-8b56-cad85e1ee73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_Liabilities_007809a8-4835-486b-8b56-cad85e1ee73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_23a9d671-7947-4377-b9b8-e205af64bb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_23a9d671-7947-4377-b9b8-e205af64bb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fe31b811-a05b-4780-8daf-c2db93a0bead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_CommonStockValue_fe31b811-a05b-4780-8daf-c2db93a0bead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_178c0ede-fcc9-4ef6-adc8-205c9c02f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_AdditionalPaidInCapital_178c0ede-fcc9-4ef6-adc8-205c9c02f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_15a78c1c-b93b-4130-a930-19f11681ea47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_TreasuryStockValue_15a78c1c-b93b-4130-a930-19f11681ea47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3921059-a376-4b61-9164-35859efe1d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3921059-a376-4b61-9164-35859efe1d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22fe7743-55ff-40cc-a3ff-586d98ddd966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22fe7743-55ff-40cc-a3ff-586d98ddd966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56a629bb-7cfd-4ae2-b37d-91a1136f7777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1509d12c-4771-4195-b2cc-9530bf02f711" xlink:to="loc_us-gaap_StockholdersEquity_56a629bb-7cfd-4ae2-b37d-91a1136f7777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33c3d5c2-9376-4de7-9b2e-38f08f3ca80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9acd48bb-78d3-46a0-99e5-0cc0f4eaf91f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33c3d5c2-9376-4de7-9b2e-38f08f3ca80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bc115829-2002-481c-a433-b6a4bcdad051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a83acbd4-f746-4a87-b66e-dbcbbd1e8ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc115829-2002-481c-a433-b6a4bcdad051" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a83acbd4-f746-4a87-b66e-dbcbbd1e8ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_94b3b5b0-d54d-4bb7-b6cd-8fbe7e943a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc115829-2002-481c-a433-b6a4bcdad051" xlink:to="loc_us-gaap_CommonStockSharesIssued_94b3b5b0-d54d-4bb7-b6cd-8fbe7e943a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6af7352b-7c91-4167-bbbb-c29725e4c354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc115829-2002-481c-a433-b6a4bcdad051" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6af7352b-7c91-4167-bbbb-c29725e4c354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_31cc99f4-82ba-4c80-8fb5-8780d7c55558" xlink:href="vrna-20230630.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:to="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_31cc99f4-82ba-4c80-8fb5-8780d7c55558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cce93b39-5e86-4cc0-9fe9-bf9049cb8c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cce93b39-5e86-4cc0-9fe9-bf9049cb8c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5dad789d-fe83-4f76-9e70-060f1b7eaeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:to="loc_us-gaap_OperatingExpenses_5dad789d-fe83-4f76-9e70-060f1b7eaeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_43b120e4-16d4-4e3e-8eaa-b46c764fabb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5f05d7bd-3cc9-48e6-b322-8357ef9d3b23" xlink:to="loc_us-gaap_OperatingIncomeLoss_43b120e4-16d4-4e3e-8eaa-b46c764fabb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_1e2d062c-a67f-4798-9689-61373ea17a2b" xlink:href="vrna-20230630.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_1e2d062c-a67f-4798-9689-61373ea17a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_499c2438-07cc-475a-a859-b165c7c390bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:to="loc_us-gaap_InvestmentIncomeNet_499c2438-07cc-475a-a859-b165c7c390bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7b43c909-e5ab-48b6-a5bc-d5d85c38cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:to="loc_us-gaap_InterestExpense_7b43c909-e5ab-48b6-a5bc-d5d85c38cb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_fac94ffe-0b7b-409d-939f-d37c94293553" xlink:href="vrna-20230630.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_fac94ffe-0b7b-409d-939f-d37c94293553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c594bfea-a47d-4ef2-899a-911afa9eb00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ee808ce7-a6cb-47c7-b196-2a8620d44fd8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c594bfea-a47d-4ef2-899a-911afa9eb00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_707ac4d9-e1b7-406b-9571-920e18a8d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_707ac4d9-e1b7-406b-9571-920e18a8d42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_239f776a-b128-4cca-a766-7028f267b312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_239f776a-b128-4cca-a766-7028f267b312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e54df2b-6085-49c1-8dd6-2c93ba4a1820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_NetIncomeLoss_2e54df2b-6085-49c1-8dd6-2c93ba4a1820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7fdb8352-7ad0-4cd0-9e0e-d3d73ecd9baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_EarningsPerShareBasic_7fdb8352-7ad0-4cd0-9e0e-d3d73ecd9baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ef682887-dd65-48b8-9766-9f72bf9de8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ef682887-dd65-48b8-9766-9f72bf9de8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fb01dc8-5ff3-42e5-837d-f5488dd6e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fb01dc8-5ff3-42e5-837d-f5488dd6e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_339e024b-ff13-4dea-bcc6-df05365782ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02feae2b-4401-48d4-85b0-22e214edf428" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_339e024b-ff13-4dea-bcc6-df05365782ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f5e25db-09ad-45a0-956f-6a08cfaf4092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f5e25db-09ad-45a0-956f-6a08cfaf4092" xlink:to="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df378238-a280-4d21-b8bc-78d4d503ccb2" xlink:to="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_791f14cb-cb41-44a4-92f0-a003f8bb9baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_CommonStockMember_791f14cb-cb41-44a4-92f0-a003f8bb9baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3985016a-25dc-4358-9bc4-f9b9a1ce0d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3985016a-25dc-4358-9bc4-f9b9a1ce0d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_9ff5343f-8dda-4fab-99c9-625383e0a133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_TreasuryStockMember_9ff5343f-8dda-4fab-99c9-625383e0a133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8d4f062-36c9-4a78-97b4-f8f6140cc2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8d4f062-36c9-4a78-97b4-f8f6140cc2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32aaf444-c43e-408e-bcd6-c2463252ce6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1847024-5c88-42a6-9f5f-b20b7421298e" xlink:to="loc_us-gaap_RetainedEarningsMember_32aaf444-c43e-408e-bcd6-c2463252ce6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed0d6cbf-4ec9-4bba-85c2-42008c4139ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_7407e755-8b20-4539-8d6f-f486c5710347" xlink:href="vrna-20230630.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_68af90f1-faf7-4404-bfac-7051ba015a23" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_7407e755-8b20-4539-8d6f-f486c5710347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb937371-930a-40f0-afc8-f6d048daf14c" xlink:to="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19547b6d-5db9-4f1c-8436-7bbf19541844" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_84f3a746-0620-46f1-aa66-aa0ccf67482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_84f3a746-0620-46f1-aa66-aa0ccf67482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d03d005-252d-4bb8-a6b4-7ecdd9417af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockholdersEquity_0d03d005-252d-4bb8-a6b4-7ecdd9417af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_855a8651-90ec-4246-831d-c1b1616682f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_NetIncomeLoss_855a8651-90ec-4246-831d-c1b1616682f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcbb909-347d-4729-95cb-9b6fcc267d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1dcbb909-347d-4729-95cb-9b6fcc267d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_64b1457b-1235-4fc7-ad8e-b0702125e26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_64b1457b-1235-4fc7-ad8e-b0702125e26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_df714fef-57d2-4fa4-b460-c8267da90a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_df714fef-57d2-4fa4-b460-c8267da90a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0ca95e61-c2de-474e-aa44-fa4bbcebea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0ca95e61-c2de-474e-aa44-fa4bbcebea3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8ad21b94-2843-418a-8ee3-a55cb4b9d7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8ad21b94-2843-418a-8ee3-a55cb4b9d7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52fb60fb-2c6e-4c96-93f7-cad4f77920f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52fb60fb-2c6e-4c96-93f7-cad4f77920f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aa78cc55-0768-45ed-aad7-34de976784a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aa78cc55-0768-45ed-aad7-34de976784a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_81216142-851d-43d4-a511-f527b64ea779" xlink:href="vrna-20230630.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_81216142-851d-43d4-a511-f527b64ea779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7c79d21-6632-42b3-8beb-c468581a3fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7c79d21-6632-42b3-8beb-c468581a3fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dbd0450d-3ed3-419b-a7e7-24fa386892a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dbd0450d-3ed3-419b-a7e7-24fa386892a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e0facf7-bf4b-4998-adb0-a071d91685f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_616b7b4c-3da2-4095-82a4-2315e8076272" xlink:to="loc_us-gaap_StockholdersEquity_7e0facf7-bf4b-4998-adb0-a071d91685f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20230630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5956715a-fe0d-452a-8400-71e2f2883119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5956715a-fe0d-452a-8400-71e2f2883119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b672f675-2c74-4d24-a38b-ca84feee9c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5956715a-fe0d-452a-8400-71e2f2883119" xlink:to="loc_us-gaap_NetIncomeLoss_b672f675-2c74-4d24-a38b-ca84feee9c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5956715a-fe0d-452a-8400-71e2f2883119" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9c884abf-a54e-4af8-ac70-b79ca055af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9c884abf-a54e-4af8-ac70-b79ca055af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a9909e4f-1f33-48b7-9b34-2214ed1b32e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a9909e4f-1f33-48b7-9b34-2214ed1b32e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_06b03ec0-b6bb-4ce4-9e8c-52fe2634b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_06b03ec0-b6bb-4ce4-9e8c-52fe2634b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f9400698-4a08-4e88-b724-d2008dd088d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_ShareBasedCompensation_f9400698-4a08-4e88-b724-d2008dd088d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1c17d748-9788-494b-b9cf-19c2e220b37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1c17d748-9788-494b-b9cf-19c2e220b37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7233ceff-6599-4d4d-bcfe-21c26ee60b08" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1cc15d18-4a24-487d-b9de-61970152fb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1cc15d18-4a24-487d-b9de-61970152fb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_9e7f3bda-669b-4236-955f-1497d8059fdb" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_9e7f3bda-669b-4236-955f-1497d8059fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_886c8364-689b-438c-b345-ffb216b7b185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_886c8364-689b-438c-b345-ffb216b7b185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b942e386-9192-4124-8e43-c53742df116a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b942e386-9192-4124-8e43-c53742df116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c90fc135-2c11-49fc-bff5-7708f8e7b90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c90fc135-2c11-49fc-bff5-7708f8e7b90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_638b765c-51e8-4cb1-812c-f1063a9f3016" xlink:href="vrna-20230630.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_638b765c-51e8-4cb1-812c-f1063a9f3016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_b864d3b6-26f0-4e24-bf4b-fdd240f27db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_b864d3b6-26f0-4e24-bf4b-fdd240f27db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_3adc91c5-4d31-4ee6-b127-f3eabf6d96f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4cc025-ec20-4ecc-822e-e3a36071922b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_3adc91c5-4d31-4ee6-b127-f3eabf6d96f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d509943-367a-477a-8212-da7c87de82d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5956715a-fe0d-452a-8400-71e2f2883119" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d509943-367a-477a-8212-da7c87de82d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72b319c7-f6cc-4d59-bbd3-ac7ed9ddf9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72b319c7-f6cc-4d59-bbd3-ac7ed9ddf9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c6762fa-b0db-4c6c-bfcc-09156f6cf691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72b319c7-f6cc-4d59-bbd3-ac7ed9ddf9af" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c6762fa-b0db-4c6c-bfcc-09156f6cf691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a78f97a3-61fa-494f-a5a4-c02b66ba84c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72b319c7-f6cc-4d59-bbd3-ac7ed9ddf9af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a78f97a3-61fa-494f-a5a4-c02b66ba84c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96a2da2a-d3a7-4bf4-a419-46e862bd8575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_96a2da2a-d3a7-4bf4-a419-46e862bd8575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_876dcef2-af29-4c16-922e-2410dabddeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_876dcef2-af29-4c16-922e-2410dabddeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e257a48c-b93a-4770-9a29-9d32af89057e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e257a48c-b93a-4770-9a29-9d32af89057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_63ba5b4a-5bd5-47be-87dc-6b41bf72cf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_63ba5b4a-5bd5-47be-87dc-6b41bf72cf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55b5d3af-df5c-4d30-8451-d28d4326f246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb399341-e0ba-4245-9114-92193aeb91ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55b5d3af-df5c-4d30-8451-d28d4326f246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55de0141-09e8-4914-8bd0-7538874a2485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55de0141-09e8-4914-8bd0-7538874a2485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_818fdbe7-b149-4b8c-9dca-44f1f32c887d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_818fdbe7-b149-4b8c-9dca-44f1f32c887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_488b3e87-c0e7-4eec-b5e6-d036c1ac97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_488b3e87-c0e7-4eec-b5e6-d036c1ac97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_592cb16b-b5c8-46f8-99f5-4b1526716153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_592cb16b-b5c8-46f8-99f5-4b1526716153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_08887524-6ea3-4d4b-965a-f61717be6e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5e722ffa-4683-4a6c-9421-197ac3392526" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_08887524-6ea3-4d4b-965a-f61717be6e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_71d41413-ceb4-487c-9cb1-1387b87360bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_08887524-6ea3-4d4b-965a-f61717be6e33" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_71d41413-ceb4-487c-9cb1-1387b87360bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6aee6e57-c454-4a42-b3c9-117f56907b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_08887524-6ea3-4d4b-965a-f61717be6e33" xlink:to="loc_us-gaap_InterestPaidNet_6aee6e57-c454-4a42-b3c9-117f56907b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20230630.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26fd6d50-9105-4e08-b263-6876b9c862b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_d3393319-8c6b-4c4a-8aa8-fdfd17e4da53" xlink:href="vrna-20230630.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26fd6d50-9105-4e08-b263-6876b9c862b5" xlink:to="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_d3393319-8c6b-4c4a-8aa8-fdfd17e4da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="vrna-20230630.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f3730f63-d150-4fe4-b022-94e5dea5277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d2487a5d-0776-4e46-94f3-984cb382b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f3730f63-d150-4fe4-b022-94e5dea5277e" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d2487a5d-0776-4e46-94f3-984cb382b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterest" xlink:type="simple" xlink:href="vrna-20230630.xsd#EquityInterest"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6955c5c-920f-43a5-907e-7326984638d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0751f7f3-a58e-4d8b-ad0a-dce774372afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6955c5c-920f-43a5-907e-7326984638d5" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0751f7f3-a58e-4d8b-ad0a-dce774372afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20230630.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_63091292-52e2-4fce-93d0-6c691967ebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1abbe0da-25fc-423a-817b-cbc50dadf9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_63091292-52e2-4fce-93d0-6c691967ebd4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1abbe0da-25fc-423a-817b-cbc50dadf9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20230630.xsd#Termloan"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aaa251b7-85bd-4dbb-ac01-772dda5506ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_355e551f-d9fb-4e0c-9822-2964ba57d5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaa251b7-85bd-4dbb-ac01-772dda5506ce" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_355e551f-d9fb-4e0c-9822-2964ba57d5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20230630.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_177dda39-c019-4c28-827f-3796b7e8dd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d61c8f83-b7df-41ab-8055-d1b0b9d3c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_177dda39-c019-4c28-827f-3796b7e8dd16" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d61c8f83-b7df-41ab-8055-d1b0b9d3c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Capitalizationandnetlosspershare" xlink:type="simple" xlink:href="vrna-20230630.xsd#Capitalizationandnetlosspershare"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Capitalizationandnetlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9e18f3fd-0a35-4715-a279-7e40f8914f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8331bdf1-3fe5-4201-bcfd-e59e493a15b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9e18f3fd-0a35-4715-a279-7e40f8914f88" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8331bdf1-3fe5-4201-bcfd-e59e493a15b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Commitmentandcontingencies" xlink:type="simple" xlink:href="vrna-20230630.xsd#Commitmentandcontingencies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Commitmentandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5bb237b-1184-48c3-ad66-7a8b07233197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_525f7420-d3dd-4ade-b048-6ab3d1ddf79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5bb237b-1184-48c3-ad66-7a8b07233197" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_525f7420-d3dd-4ade-b048-6ab3d1ddf79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20230630.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0dbca7d0-c2d8-434a-9693-ec562e02c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a7e39eb0-3e67-4204-98d2-ce2fa699abf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dbca7d0-c2d8-434a-9693-ec562e02c76b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a7e39eb0-3e67-4204-98d2-ce2fa699abf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5631e8ee-e852-43b8-9a20-a6ca34c03267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dbca7d0-c2d8-434a-9693-ec562e02c76b" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5631e8ee-e852-43b8-9a20-a6ca34c03267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_991ea3de-0c92-4678-bbfe-857035838ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dbca7d0-c2d8-434a-9693-ec562e02c76b" xlink:to="loc_us-gaap_UseOfEstimates_991ea3de-0c92-4678-bbfe-857035838ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df3d4bbd-e45f-47f9-9406-09a42b274a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dbca7d0-c2d8-434a-9693-ec562e02c76b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df3d4bbd-e45f-47f9-9406-09a42b274a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20230630.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cd373554-76aa-4d9f-aa4f-8e63e47ea6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_46d9c615-ed99-4442-8785-7d86d6233c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cd373554-76aa-4d9f-aa4f-8e63e47ea6bb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_46d9c615-ed99-4442-8785-7d86d6233c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e941e23c-7197-42a8-9677-a89e67375853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ed0f72d7-8153-4c22-a8b6-3f2c70a31320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e941e23c-7197-42a8-9677-a89e67375853" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ed0f72d7-8153-4c22-a8b6-3f2c70a31320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_67d1b5ef-bf2a-4724-8a2e-3e02b13794d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e941e23c-7197-42a8-9677-a89e67375853" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_67d1b5ef-bf2a-4724-8a2e-3e02b13794d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_72b5ee0d-f8f7-41f8-8ab7-78f401a77646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e941e23c-7197-42a8-9677-a89e67375853" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_72b5ee0d-f8f7-41f8-8ab7-78f401a77646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareTables" xlink:type="simple" xlink:href="vrna-20230630.xsd#CapitalizationandnetlosspershareTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CapitalizationandnetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ece62f9e-8c7b-47f1-a4a4-a4a32e1e6229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_346db7ea-21df-4e14-a4b6-f74a61e25cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ece62f9e-8c7b-47f1-a4a4-a4a32e1e6229" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_346db7ea-21df-4e14-a4b6-f74a61e25cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8589404d-2532-46cb-a3ca-aa7b80ab60e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8589404d-2532-46cb-a3ca-aa7b80ab60e8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16422c2b-c915-4971-a2a0-af697e3e55bd" xlink:to="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_beb418dc-a57a-4428-86f4-b2750dc2894a" xlink:href="vrna-20230630.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a8f3a8d2-61eb-4d60-b3e2-79827110e513" xlink:to="loc_vrna_AmericanDepositorySharesMember_beb418dc-a57a-4428-86f4-b2750dc2894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7443035-476a-4bdf-8771-a50e5641d9d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ATMProgramMember_34565d20-fb13-4938-b270-f86aeaa9c942" xlink:href="vrna-20230630.xsd#vrna_ATMProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e101890e-67d6-4099-af13-18ca28ec0897" xlink:to="loc_vrna_ATMProgramMember_34565d20-fb13-4938-b270-f86aeaa9c942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22224545-f6f4-4a39-8ec0-4cf2f939da60" xlink:to="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_54f9522e-cf86-468b-9bfe-16305628274a" xlink:href="vrna-20230630.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_54f9522e-cf86-468b-9bfe-16305628274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PaymentsForApplicationFees_0cb8df12-8033-4712-8599-be7518d79140" xlink:href="vrna-20230630.xsd#vrna_PaymentsForApplicationFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_PaymentsForApplicationFees_0cb8df12-8033-4712-8599-be7518d79140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9315dd8-4a1c-4cef-9c5b-5c15f74465c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9315dd8-4a1c-4cef-9c5b-5c15f74465c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_12bc58a3-7cd0-473c-bc6b-8c45b2ff50ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_12bc58a3-7cd0-473c-bc6b-8c45b2ff50ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2df8ad08-21d6-42b4-8bac-6c0531dbb173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2df8ad08-21d6-42b4-8bac-6c0531dbb173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42e00b5e-f9aa-403e-8bf3-aa9810141e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42e00b5e-f9aa-403e-8bf3-aa9810141e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_02b14d42-a24e-4ff8-81e0-9baef7a3813a" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_02b14d42-a24e-4ff8-81e0-9baef7a3813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockCommissionFeePercentage_50613f42-3a39-49f3-a0ab-e4ef4d0c56b5" xlink:href="vrna-20230630.xsd#vrna_SaleOfStockCommissionFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8baae020-122f-44d6-bacc-c1bf87e0a905" xlink:to="loc_vrna_SaleOfStockCommissionFeePercentage_50613f42-3a39-49f3-a0ab-e4ef4d0c56b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6b17e3d7-4a95-4628-b3e3-1370647f472a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f17936ad-daa8-448b-acbd-13ea245c2009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6b17e3d7-4a95-4628-b3e3-1370647f472a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f17936ad-daa8-448b-acbd-13ea245c2009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_fc7bca43-84c6-454a-b71a-fe27c32b3278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6b17e3d7-4a95-4628-b3e3-1370647f472a" xlink:to="loc_us-gaap_NumberOfReportableSegments_fc7bca43-84c6-454a-b71a-fe27c32b3278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#EquityInterestDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_302865e1-dd8d-4448-82c0-710fd947c22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_302865e1-dd8d-4448-82c0-710fd947c22b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:to="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5250df6d-46bd-4e82-9c4c-5871aee27b04" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_e930407e-7c1f-4994-86ac-024f269ebaf8" xlink:href="vrna-20230630.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eeb7bbe4-f4b0-4b70-8af0-d693b8be1f3a" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_e930407e-7c1f-4994-86ac-024f269ebaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_daf76928-3b2e-47f0-b2e5-9afd25e49ca5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1147dfa4-c59c-49ff-969d-df5c61bb1df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1147dfa4-c59c-49ff-969d-df5c61bb1df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a2bd880c-0ba8-4cba-a28e-16e71184d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a2bd880c-0ba8-4cba-a28e-16e71184d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_f9290973-c86a-47b5-9b3d-f311748c1920" xlink:href="vrna-20230630.xsd#vrna_EquityInterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ef3d1a1c-2b66-444f-b699-96880c4b19d9" xlink:to="loc_vrna_EquityInterestReceivable_f9290973-c86a-47b5-9b3d-f311748c1920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8823275b-8d27-4da6-9bde-094c128ca95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_2e15711d-65a7-407d-98f6-60ef9a53c81e" xlink:href="vrna-20230630.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8823275b-8d27-4da6-9bde-094c128ca95b" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_2e15711d-65a7-407d-98f6-60ef9a53c81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_6e8493bb-e700-4a94-b63f-51152b5964ff" xlink:href="vrna-20230630.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8823275b-8d27-4da6-9bde-094c128ca95b" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_6e8493bb-e700-4a94-b63f-51152b5964ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f7636aab-beb9-4b33-a65d-de5aad183500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8823275b-8d27-4da6-9bde-094c128ca95b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f7636aab-beb9-4b33-a65d-de5aad183500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28c603b5-560b-4757-83d4-353d8a4213f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8823275b-8d27-4da6-9bde-094c128ca95b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28c603b5-560b-4757-83d4-353d8a4213f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#TermloanDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e7ad9046-2d18-4c79-9ad2-305f0436035b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e7ad9046-2d18-4c79-9ad2-305f0436035b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7cea6696-f234-4c7b-a2cf-2ff4a59485a3" xlink:to="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d762e9df-77c2-4d55-b902-86518beb33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a8efa80b-ccaf-4b15-b75c-a44a584a3b85" xlink:to="loc_us-gaap_LineOfCreditMember_d762e9df-77c2-4d55-b902-86518beb33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_33847d3c-6951-450d-9acb-3463325a1031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_8c84d2a1-6ebe-4ee1-a832-ba95745a59fa" xlink:href="vrna-20230630.xsd#vrna_OxfordTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermLoanMember_8c84d2a1-6ebe-4ee1-a832-ba95745a59fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember_70048695-beae-497b-a47f-00b1c1ced7a7" xlink:href="vrna-20230630.xsd#vrna_OxfordTermALoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermALoanMember_70048695-beae-497b-a47f-00b1c1ced7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember_4a64c455-cf58-4100-a63e-5b9e6c907d75" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermBCDELoanMember_4a64c455-cf58-4100-a63e-5b9e6c907d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember_8533ba33-7c8d-401a-9628-9402b074d08b" xlink:href="vrna-20230630.xsd#vrna_OxfordTermBLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7310dda-cbb9-4544-a43f-4dcbddde2514" xlink:to="loc_vrna_OxfordTermBLoanMember_8533ba33-7c8d-401a-9628-9402b074d08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:href="vrna-20230630.xsd#vrna_InterestRatePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodAxis_688bd008-1b38-4a23-8f3a-bad1f871080e" xlink:to="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_db20e3b0-3bab-4a3d-9a0a-4b1a2779c561" xlink:href="vrna-20230630.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodDomain_ff691eb4-c398-41e6-8623-18fa7f3077d9" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_db20e3b0-3bab-4a3d-9a0a-4b1a2779c561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5e921fe4-b2d6-4f96-b262-55c8711d83e4" xlink:to="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cf4e7ef0-8ea8-483f-b78e-a7166cb2c2a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ef79871-fdb4-4d03-ae9f-93d279e1f638" xlink:to="loc_srt_MinimumMember_cf4e7ef0-8ea8-483f-b78e-a7166cb2c2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_505e3733-f546-4be5-b485-0c5c26d13142" xlink:to="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a4d5c999-fe81-40b9-929b-6089855011e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ccae4f8f-c819-485d-b9f3-1e9557a49d4c" xlink:to="loc_us-gaap_BaseRateMember_a4d5c999-fe81-40b9-929b-6089855011e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9546a84f-2c9b-4c78-a5ed-3bf932eccf0f" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8bdba99-6969-4760-894f-4f591f633949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8bdba99-6969-4760-894f-4f591f633949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_29a66a01-3d98-455c-a5b1-0c30694fe62c" xlink:href="vrna-20230630.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_29a66a01-3d98-455c-a5b1-0c30694fe62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_5310dd23-e3df-48ec-aa7b-6fa5f3fd66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_5310dd23-e3df-48ec-aa7b-6fa5f3fd66ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8ac0019b-4440-4c34-a4dd-decda3de4c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8ac0019b-4440-4c34-a4dd-decda3de4c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2c6d60de-23cd-4cf7-afa8-f908709ae2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2c6d60de-23cd-4cf7-afa8-f908709ae2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_08bded2f-7064-4d6d-8d62-6e4db2f00633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5b567516-3884-4e68-80ec-fc451f3939a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_08bded2f-7064-4d6d-8d62-6e4db2f00633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd77063e-00e9-48c5-a24b-aac0779cc94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd77063e-00e9-48c5-a24b-aac0779cc94a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6a512ed-dddf-4938-9754-912b63f80e96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_86f321be-2f4c-4785-94d8-34916bea6cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_86f321be-2f4c-4785-94d8-34916bea6cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35a1b78c-3091-4f3b-8552-f3098ef353ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4f4848fd-9d5a-4c0d-9ee1-2c84aa60402b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35a1b78c-3091-4f3b-8552-f3098ef353ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ce11e2d-e9c5-4959-ae1a-4f52fa8a18e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03471402-89df-4364-9987-7366e7c08540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c852e443-4ac3-40f5-a763-b0aa9d6a5092" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03471402-89df-4364-9987-7366e7c08540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd258c48-6935-4c61-afdd-7edc45229db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd258c48-6935-4c61-afdd-7edc45229db7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_97956cb0-c057-4757-a19a-14d4d19c88af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_97956cb0-c057-4757-a19a-14d4d19c88af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_efa709f5-ed78-4a02-942f-7167fdd50f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_efa709f5-ed78-4a02-942f-7167fdd50f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_906830a8-ecab-4cfb-a43c-848779e60cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_906830a8-ecab-4cfb-a43c-848779e60cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_91bd7e8a-7139-4eb4-87ab-8b28c26d7ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_91bd7e8a-7139-4eb4-87ab-8b28c26d7ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8b40c781-aebc-40d0-930d-5015657f1a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8b40c781-aebc-40d0-930d-5015657f1a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_faaa98f5-5cbf-4405-9268-b855744088ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f9fb042a-b80a-45c5-b30f-e03d7a79f190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_faaa98f5-5cbf-4405-9268-b855744088ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1975aff-c284-4be4-b480-f9f24caeb1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1975aff-c284-4be4-b480-f9f24caeb1b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:to="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_57cb7e87-6ed6-45da-8ff0-2cb74f221a85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b7f3a43-cc45-44a8-b282-82ed42019828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9ac2924-94e0-4ac5-8764-cba20f879f91" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b7f3a43-cc45-44a8-b282-82ed42019828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_264ec38a-0b49-4ddc-9d0f-4cd8abbaf6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a5ad971-989b-4263-a699-616ce1965ce4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_248ee8d3-8773-45f7-8c78-6fc2ca064be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_248ee8d3-8773-45f7-8c78-6fc2ca064be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9cfb9c89-8520-4b86-8022-7e7c51c11c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9cfb9c89-8520-4b86-8022-7e7c51c11c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa977eba-368e-4199-b4c3-0e72907935d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_f027e110-7519-4577-94e3-bc24789a2f8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa977eba-368e-4199-b4c3-0e72907935d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#CapitalizationandnetlosspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27a9e916-71e7-4493-9826-17ed844d2f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_850d9789-4a18-4267-a9aa-402a4e9ba7ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a9e916-71e7-4493-9826-17ed844d2f83" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_850d9789-4a18-4267-a9aa-402a4e9ba7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_9947b135-b1d1-4883-8756-166d398f165b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a9e916-71e7-4493-9826-17ed844d2f83" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_9947b135-b1d1-4883-8756-166d398f165b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2fd4610-be69-472d-ba0f-15e802abfbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_9947b135-b1d1-4883-8756-166d398f165b" xlink:to="loc_us-gaap_NetIncomeLoss_e2fd4610-be69-472d-ba0f-15e802abfbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a9e916-71e7-4493-9826-17ed844d2f83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_65fe0ea7-8d1e-4ee9-a89f-8819cdcd1665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_65fe0ea7-8d1e-4ee9-a89f-8819cdcd1665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e7a1014-857c-4db8-86da-66ea99f6a03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e7a1014-857c-4db8-86da-66ea99f6a03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dcb145cd-32db-4f7c-8ee6-8ea1e3495b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:to="loc_us-gaap_EarningsPerShareBasic_dcb145cd-32db-4f7c-8ee6-8ea1e3495b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cf35f840-50e4-4fbe-9925-79873543e052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_69ba830c-4450-40d2-b21f-91842c1cd5b4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cf35f840-50e4-4fbe-9925-79873543e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c74cd671-83fb-43b3-ac75-91c76d454476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a9e916-71e7-4493-9826-17ed844d2f83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c74cd671-83fb-43b3-ac75-91c76d454476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CommitmentandcontingenciesDetails" xlink:type="simple" xlink:href="vrna-20230630.xsd#CommitmentandcontingenciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CommitmentandcontingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce1ae46e-8dc2-4e01-ac94-4f338bc44e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7976c217-54dd-4dc4-9a79-469f0f2ac471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce1ae46e-8dc2-4e01-ac94-4f338bc44e29" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7976c217-54dd-4dc4-9a79-469f0f2ac471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_23319e94-a56c-40a8-a840-663d56dceefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce1ae46e-8dc2-4e01-ac94-4f338bc44e29" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_23319e94-a56c-40a8-a840-663d56dceefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_b4d5ecaa-fd95-4c18-ab07-5b65882749e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce1ae46e-8dc2-4e01-ac94-4f338bc44e29" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_b4d5ecaa-fd95-4c18-ab07-5b65882749e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts_eb067169-90d5-4297-8000-8e81590fdf8a" xlink:href="vrna-20230630.xsd#vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce1ae46e-8dc2-4e01-ac94-4f338bc44e29" xlink:to="loc_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts_eb067169-90d5-4297-8000-8e81590fdf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vrna-20230630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20230630_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"F17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0?.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    !ZAP !P  " P   AN     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&?+9SRLBC''I7OE?('[4( ^+D6!UTR'/O\\E %G_ (:K\;_] KP__P" \_\
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M_G0!]W5YA\;_ (E:Q\-=#TR\T*VL;B2[N6BD%Y&[  +GC:R\UZ?7A'[5R@^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'FO49/BCX$B?:WC#1"?]F^C8?F#0!U5%5-+U2QUK38=0TFZCN[.<$Q31'*N
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MT<$]_;R"X,:[?,*,N&..IPV,^@%>H_LU?\D9MO\ K\G_ /0J\]_:U=3K'AE
M?F6"X)'H"R8_D: /2?V=]+L+?X+Z/>P6<$=U=&X,\ZQ@/*1/(HW-U.%4#\*\
M1_:8\/6.B?$V"XTVWBMTU&Q6>5(UV@RAW4M@<<@+^.:]X_9\_P"2$^'O^WG_
M -*9:\9_:ME4_$/2(1G>FE*Q^AED _\ 030![Y\'W:3X.^&"Y+$6"+D^@X'Z
M"NSKBO@[_P D<\,_]>*_S-=K0!\B?M.>'M3LOB5_;<T+MIVH6\:03@9571<-
M&3V/&['<'V->C^ ?VBO!VH:9::1XALET"546([8@UH3C'&.4''0C ]>]>PZB
MNAZTL^AZH;&]WJ!-8S,CG!Z90\_0U\Z_&[X(^%_"_ANY\2>'+W^S'B9=VFS2
M[EFW,!^[R=P(SG'(P.U 'TEID>G1Z?&VC):K9R_O4-H%$;[N=PV\'/7/>OB?
MPC&LO[1&FK(,@>(@V/<3Y'ZBO8?V4-9O[O0?$&E7,SR6=A+!);*QSY9D\S>!
MZ#Y <>I)[UX=+=CPQ\;7O+S(72_$)EE^4YQ'<9/'T% 'WG7PIX>_Y. TO_L9
MXO\ TJ%?;HUO2SI*ZI_:-H-/=/,6[,RB(KC.=V<8Q7P]X:GBF^.^DW$4BM"_
MB6%UD!^4J;D$'/IB@#Z(_:DA27X36SM]Z+58F7'KY<@_D:YO]E'2]-FTK7-1
MEM+>34(;F.-)V0&2-"N< ]@2#TZX]JZ;]J*14^$D*L<%]4A51ZG9(?Y USO[
M)7_((\3?]=[?_P!!>@"S^U7H=A_PA^E:XMM&M^NH"U,RKAGC:.1L$]\%!C/3
M)]:;^RGIEB_A+5]1>S@:]74/*6X:,&14$:G:&Z@9)-:/[5CJ/AAID9/S-K$;
M >H$,V?YBH/V4?\ DG^L?]A0_P#HI* ,']JWP[8VZ:'KUM;Q0W<TDEO<.B@&
M88#*6]2/FY]Z[/\ 9BD=_A 59B0FHS*H/880X_,FN?\ VLI5'AGP]$?O->2L
M/H$ /\Q6]^R__P DBD_["4W_ *"E 'SI;V%G/\>XM/O8TELI/$P@ECE^ZT9N
MMI!]B,YK[@N-$TNZT=])N-/MGT]XS&;7R@(]N,8V]!Q7Q CK)\?%=#E6\39!
M'<?:J^[: /@_P7H]FWQKTK1[J%+JS765MWCF7<LB"3&".X..E?;&O>&-+\0>
M%[G0[RRMVM)H6B2/RP%C)'!7CY2#@@CIBOC3P5(LO[0NF21G<CZ_N4^H,IK[
M@EE6&%Y7^ZBECCT% 'Q#\"':/XW^'2C%2995..X,+@U]J:G;Z4T O-9ALS%9
M@R">[5=L QRVYON\=37Q3\"O^2W>'/\ KM)_Z)>O5_VK?$>H6T6B^'K:9HK*
MZ1[BY53CSBI 0'U Y./7!["@#MM9_:%^&^E[[2.\FU)4^5DLK0LGT!;:I'T)
M%?*WQ!UG1?$/CW4]5\+V,EAIETZ/%;R1K&R'8H?Y5) RX8\'O7T3\$?AAX"O
MOAW8ZY?65GK-_.I>Z>Z(D6!@3\FPG:N .XR>O3%>&_&F#1K?XM:NGAD6"Z;^
MY\N/3U00QD1('4!/E!W!B<=R>] 'U)\8(#?? /6UD.X_88I27.<E71\_7BOG
MC]GGP7HWC+Q]<IXAMA=VUA:&X6W?[DC[U4;O4#).._&?2OHCXMS&#X!ZVX&<
MZ?&G/^TR+_6O%OV4/^1\UK_L&_\ M5* /HS3_ ?A32=7@U32?#NFV%[ C)'-
M:6RPD!A@YV@ \>M>#?M3^"_*O-/\8V<?RS 6=[@=& )C<_497/\ LK7TS6#X
MX\,0>,O!.J:#<8_TR K&Q_@D'*-^# &@#S7X*>.X8OV?;B^O7W/X:CGCE!/+
M*@,B#\F"CZ5Y3^SMX:G\6_%:7Q!J ,L6E;KN61AP]Q(2$S[YW-_P"N&T?Q3=
M^'/!?BOPQ)OB?53!&Z$<HT4A+CVR,@U]4_L_^$O^$6^%-E+-'MO-6/VZ;(Y"
ML/W8_P"^ I^K&@#TZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#N>PKZXTS3K;1])M--L4V6UG D$*YSA%4*!^0H \\^$GP=_X5;=:I-_;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#I:*\?\ "GB7XQ^,/"]EKVF1^!HK6]0O&EPMXK@!BO(!(ZCU-=?X8_X67_;
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M\=7L^E>*K&VT_4F@%Y9&V1ECN8,E6(W,W((]>>>/E->N4 (JJBA4 55&  ,
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M'H.M=+/XSBN/A;?>,-(@?$.FSWD4%VA1@\:,2CCMAE(.#]#0!U%%>1>&M?\
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M?_\ !7!_\37F5QHNE:#^UKX=M=#TRSTVW?0I)&BL[=849B9P6(4 9P ,^PH
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M3\-_]<'_ /1KT =_7C#ZWI6@_M6:K=:YJ=GIMN_AM(UEO+A849C+$0H+$#.
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M?';P?:7/CGS]0NEN&LK[^R(5^Q+AB5\L'$F1QEJ]FTRQ\2>'?"6J-XA\3?\
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MGA!R$D5BK8/H<9'L17/_ &CXU72B6"R\$6*,,^1=2W4DB>Q9/E/X5G?LU?\
M)&;;_K\G_P#0J ,C3?B%\0-:^(?BSPIX?A@NI+;42D%_>1*MOIMN"0=VP NQ
M.-H.3P>V<7O$FL?$;X600>(=?\06OBS01.D>H0C3TM9;97. R%/O $@<GN..
M<BU\(O\ DHWQ._[#2_\ M2MGXZ*&^"7B,, 1Y,9Y'<2I0!V.HZW8:7X>N-;N
MYP+"WMFN7E'.8PN[(]21T'>O,M"N?B;\1M.'B+3_ !!:^#]*N27T^S&G)=RR
MQ=FD9SQGKQV[>J?$AI_^&5)&MRQD.DV.X]RI:'=_X[FO1O"0@'@K1!98%O\
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M R467.\^@SC/J*ZKX=^-K?Q_X,MM;@A^S2LS0W-L3DPS+]Y<_D1[$5U%>1?
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MU#5DND3U(CB&<^F>*Z*/PWJ=M\,[[0[O59]:U2XLKA&N[DA3++(K< =%4%L
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MI>,B]VBC0?>]-W%7O@OX4U3P9\.TT?7+?R+F.[G<+YBOE"WRME21R.<5W]%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA/6_!>J>)M-N+B:VTF/S+RV\K$\><X&TG!S@X.<<'G@UQG_#5?@C_H%>(/\
MP'@_^/4 >VT5D^%O$=IXN\+V.NZ;'/%:WL9DC2X4*X&2.0"1V[$T>)O$VE^$
M/#]QK6O3F"RM\;W5"YR2   .222!0!K45X[9_M/> KK45M9(]6M8V;'VJ>V7
MRQ[G:Y;'_ :]?@GBNK>.>VD26&5 \<B-E74C((/<$4 /HHHH **** "BBB@
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M0N$0(O".!]U0.!VKRCX]:3:Z-XI^&NF:5;F&SM9/(@C!9MJK)" N223QZG-
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M,0!\P5@Q;?N.<-G- 'MGAOXV:K?_  "UKQ?>64$NK:/*+8A5(CF9C&%D*@\
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M0!T/CGXI_$+3?C?K/A/PBHU &&**QLQ;HWE.T,<C2YQDXR_WFVC.3P*LZ_\
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M;^+5-*M-0MU=8KN!)T6088*RA@"/7!JS0 4444 %%%% !1110 4444 %%%%
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M [Y^J?!_BJQ\;>$[/Q!I45Q#:7F_RTN5"R#:[(<@$CJI[]* -NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ.M7
MUSINAWE[86$FI7-O"TD=G$P5IF SM!/<T 7J*\F_X6SXW_Z)#K/_ (%#_P"-
MT?\ "V?&_P#T2'6?_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&_
M_1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P#
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MO^%L^-_^B0ZS_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\
MHD.L_P#@4/\ XW1_PMGQO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\ Z)#K/_@4
M/_C='_"V?&__ $2'6?\ P*'_ ,;H ]9HKR;_ (6SXW_Z)#K/_@4/_C='_"V?
M&_\ T2'6?_ H?_&Z /6:*\F_X6SXW_Z)#K/_ (%#_P"-T?\ "V?&_P#T2'6?
M_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&__1(=9_\  H?_ !N@
M#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P# H?\ QN@#UFBO)O\
MA;/C?_HD.L_^!0_^-T?\+9\;_P#1(=9_\"A_\;H ]9HKR;_A;/C?_HD.L_\
M@4/_ (W1_P +9\;_ /1(=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\ X%#_ .-T
M?\+9\;_]$AUG_P "A_\ &Z /6:*\F_X6SXW_ .B0ZS_X%#_XW1_PMGQO_P!$
MAUG_ ,"A_P#&Z /6:*\F_P"%L^-_^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_Q
MN@#UFBO)O^%L^-_^B0ZS_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O
M^%L^-_\ HD.L_P#@4/\ XW1_PMGQO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\
MZ)#K/_@4/_C='_"V?&__ $2'6?\ P*'_ ,;H ]9HKR;_ (6SXW_Z)#K/_@4/
M_C='_"V?&_\ T2'6?_ H?_&Z /6:*\F_X6SXW_Z)#K/_ (%#_P"-T?\ "V?&
M_P#T2'6?_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&__1(=9_\
M H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P# H?\ QN@#
MUFBO)O\ A;/C?_HD.L_^!0_^-T?\+9\;_P#1(=9_\"A_\;H ]9HKR;_A;/C?
M_HD.L_\ @4/_ (W1_P +9\;_ /1(=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\
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M_1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P#
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M='_"V?&__1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\
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M^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_QN@#UFBO)O^%L^-_^B0ZS_P"!0_\
MC='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\ HD.L_P#@4/\ XW1_PMGQ
MO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\ Z)#K/_@4/_C='_"V?&__ $2'6?\
MP*'_ ,;H ]9HKR;_ (6SXW_Z)#K/_@4/_C='_"V?&_\ T2'6?_ H?_&Z /6:
M*\F_X6SXW_Z)#K/_ (%#_P"-T?\ "V?&_P#T2'6?_ H?_&Z /6:*\F_X6SXW
M_P"B0ZS_ .!0_P#C='_"V?&__1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_
M^!0_^-T?\+9\;_\ 1(=9_P# H?\ QN@#UFBO)O\ A;/C?_HD.L_^!0_^-T?\
M+9\;_P#1(=9_\"A_\;H ]9HKR;_A;/C?_HD.L_\ @4/_ (W1_P +9\;_ /1(
M=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\ X%#_ .-T?\+9\;_]$AUG_P "A_\
M&Z /6:*\F_X6SXW_ .B0ZS_X%#_XW1_PMGQO_P!$AUG_ ,"A_P#&Z /6:*\F
M_P"%L^-_^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_QN@#UFBO)O^%L^-_^B0ZS
M_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\ HD.L_P#@4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR2[AF91@,%8@J?<'U]: ,OX02I::KXBTK7;6YA\9"9+C5YYY%D6[!!$;QLH
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M^V\2>+?%,OB"_L8'@LE6R2UCA#XWL54G<Q QG/X=, %SXJ_\DC\4?]@N?_T
MUYUJWPUTL_!=O%<M[J#^)K72!J46KF[=98W6+S B ':J8&T*!TQWYKT7XJ_\
MDC\4?]@N?_T UQ6C_"W5]:^'VE:3+XYU!/#5W9023::;:-I=I16,:W!^8)GH
M,' XZ4 )JFK7&NQ_!W5;X?Z3>74<TQQC+M;9)QZ$\U+X]_X0#4?&5U:>(;#7
MO%FIQ1)OTO3DGN([%2O!V1D*I8<\DGZ5VNL^"+?4K_PM+9W L;?PY<>;%;K%
MN$BB/8J [AM &.>>E9.H?#G5H_&.IZ]X2\7S:$=8$?V^W-C'<AV1=JNA8C8<
M>Q&3^% '!>%O%NIZ)^S_ .-[RQFO5?1=5NK+31?@B>UB_=A%<-DAD\P\'H1C
MM7:^&?A!X7L[;1]8VW<NN1"&ZEU47TIDN9!M9MQ+89&(P5QC'YU>\.?#"RT;
MPCXA\/:GJ$^KVNO7DUU/+.NV7]ZB*V6R<ME-V[ Y/3BJVB_#_P 5:1]ALC\1
M+R;1;%X_*M!I\2S-&A!$;SY)*X&#P"1Q0!Y]J"ZCX\^(OBG^T_!5UXPL-)O/
ML-I;C6$M(+0*.3L++N=CR6Y[#M73>%=*\3:+\,?&MCXCTZYTZP6"X?2K:ZOT
MNY(86A;,>]2?E!'&>>:Z#5?AQ?IXMO?$7@OQ1-X=O-25!?Q-:)=07!485MC$
M8;!Z@_S.=>S\*ZBOA/5=*UGQ'<ZM=:G'*C7D\"(L.^/9A(TP HZXSR<\T >7
MZ!\*]$U7X'V.M7]Q?2ZVND"YM-0:[=6LBL>Y%C4':JK@#ID\G.>CKKQ)K/B_
MP'\--(O-0GLSXGF,>IW43>7+-'$/F4$=/,QU'\B16]#\'-9M/"T?A>R\?W\.
M@O;K#=VALHW=^,2".0G,2L<G;\V,D9Q72>(?AII.M>$]+T2RFGTIM%:.32[R
MV;]Y:N@P#S][CJ#UZ]>: .%\;^$-)^%DWA[Q'X%2;2YVU>WLKNWCN)&CO8I"
M=RNK,<GC@_U (]LKSZV^&VJZAKFFZCX[\6S>(DTJ87%G:)8QVD*S#I(X4G>P
M[= /SSZ#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &5XBU'5=+TL7&@Z&^N77F!3:I=1P$*<Y;<_''''O7CO@SQ-XPM_B
M)XZGL_ $]W<W%U;&ZMAJUNAM2(<*I8G#Y'.5Z5[O6+H_A:QT3Q!K>L6DD[7&
MMRQRW*R,"BF--@V  $#'7)/- '&^(-#\5Z)\45\;>%M(AUR*\TU;&]TUKM()
M8R&W!T=OE/88^OKD8&F:KJTW[14FJ^)=(BT9K7PK(\MO#="Y:.$3Y!D90%W$
MY^49X YKT/Q-H'BC4]2CN?#/C%M"C$(CDMGTV*ZC<Y)WC<00W('7' XH\'^"
M(/"TU]?W.H7.L:SJ;*U[J5W@/)M&%55'"(.RC^@P >'7/Q"\*:[X/\9>(-9U
MJ#_A)-=L9K.QL"CEK.V (CA!VXW,?G8@X)(]*]L^&7B+2?$7@#2VT6\2[6RM
M8;6X*J1Y<JQ)N4Y Z9%:_BK0_P#A)O".J:)]H^S?VA:R6_G;-_E[EQNVY&<>
MF15G1=._LC0;#3?-\[[';1V_F;=N_8H7.,G&<=,T >:?%/2SKGQ8^'6E&]NK
M**[&II-+:2>7(8Q#&[(&'(W!=I(YP37/WG@'3=*^-]CX3T&ZO]*T#5M*-WJ%
MA:W;A;AHW(QN)+*&P,D')&1W->J:WX1_MGQWX7\2?;?)_L#[7_H_E;O/\^(1
M_>W#;MQGH<^U,N_!HNOB?I_C#[=M-GI\EE]D\G._<Q;=OSQC/3'XT <7X+TV
MV\%_'C5_"6@"6WT2YT1-26S,K.D,PE"$H&R1D-D\_P!,7/A+_P CA\1_^Q@?
M^5=/%X,$?Q6F\:_;\F721IGV/R>G[T2;]^[VQC'XUSD/PT\4:3XBUW4O#/CJ
M+38=9O6O);>314GV,>VYI!G\A0!Z77F'@)S<_'7XF33<O"=.AC/]U?)?C] :
M]"T>VO[/2+>#5]074;U%Q+=+ (1*<]=@)"\8'6N LE_X1O\ :.U*.0;+?Q7I
M4<\39X>>V^1D^H0[OQH Q;'PE8^,?CE\0[77I;B;3+4Z<[:>DS1Q7#O:@!I-
MI!;:$X&<?,3BG^#&O_!7C'Q[X4\.0SZK8Z7;07NE:=-<']T[QY,(=L[03C&>
MP]228++P[J>L_'KXAW>@>(KC0K^S&FJLB0K/%*CVWS+)$V WW!@Y!'/K7?>"
M/ L?A!M2O;O4IM8UG5IA-?ZA.@0RE1A55!PJC)P.>OI@  \^\.B+XGZDUK\1
MO$<T=[&<OX/CC>P2/_?!.^<>X.*U?%5E;:;\<_A=8VMO';6$$.H)!"BA8T(M
M^ HZ9^[^E=[XE\'Z#XOLQ;>(=-ANPG,<A&V2(^J.,,I^AK&\0?#:UUKP[I%C
M#JVH6VHZ)(LNG:L[B6XB<?WB>'!  (/7 H POC$,Z_\ #KRO]?\ \)1;8Q][
M9GY_PQC->AZX9!X>U$P[O,%K+LV]<[#C%<GH_P /-0_X2JS\0^,_$TOB.^TY
M'6P06:6L-N7&&?8I.YB.,D_R&-JP\.ZA:>.-7UNXU^ZNK"_ABCATEP?)M2J@
M,R_,1EL$\ =3G/& #GO@3Y?_  I'PYY6W;Y4N=O3/G/G\<YS[UY!;Y7X3Z+L
M_P"/%OB(NW'W/)W/^&W</SKU.'X4:QHT5YIOA#QQ=:)H-W(\AT\6,<S6^_[P
MAE)!0'MP<=>O-;EU\,/#UQ\,T\$+')%IL48$4B-B5) =PES_ 'MV2>QR1TH
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M%_SU3_OH4>?%_P ]4_[Z%9'_  AGA?\ Z%O2/_ "+_XFC_A#/"__ $+>D?\
M@!%_\30!K^?%_P ]4_[Z%'GQ?\]4_P"^A61_PAGA?_H6](_\ (O_ (FC_A#/
M"_\ T+>D?^ $7_Q- &OY\7_/5/\ OH4>?%_SU3_OH5D?\(9X7_Z%O2/_   B
M_P#B:/\ A#/"_P#T+>D?^ $7_P 30!K^?%_SU3_OH4>?%_SU3_OH5D?\(9X7
M_P"A;TC_ , (O_B:/^$,\+_]"WI'_@!%_P#$T :_GQ?\]4_[Z%'GQ?\ /5/^
M^A61_P (9X7_ .A;TC_P B_^)H_X0SPO_P!"WI'_ ( 1?_$T :_GQ?\ /5/^
M^A1Y\7_/5/\ OH5D?\(9X7_Z%O2/_ "+_P")H_X0SPO_ -"WI'_@!%_\30!K
M^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P  (O\ XFC_ (0SPO\ ]"WI
M'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>%_\ H6](_P# "+_XFC_A
M#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5D?\ "&>%_P#H6](_
M\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3_OH4>?%_SU3_ +Z%9'_"
M&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T :_GQ?\]4_P"^A1Y\7_/5
M/^^A61_PAGA?_H6](_\  "+_ .)H_P"$,\+_ /0MZ1_X 1?_ !- &OY\7_/5
M/^^A1Y\7_/5/^^A61_PAGA?_ *%O2/\ P B_^)H_X0SPO_T+>D?^ $7_ ,30
M!K^?%_SU3_OH4>?%_P ]4_[Z%9'_  AGA?\ Z%O2/_ "+_XFC_A#/"__ $+>
MD?\ @!%_\30!K^?%_P ]4_[Z%'GQ?\]4_P"^A61_PAGA?_H6](_\ (O_ (FC
M_A#/"_\ T+>D?^ $7_Q- &OY\7_/5/\ OH4>?%_SU3_OH5D?\(9X7_Z%O2/_
M   B_P#B:/\ A#/"_P#T+>D?^ $7_P 30!K^?%_SU3_OH4>?%_SU3_OH5D?\
M(9X7_P"A;TC_ , (O_B:/^$,\+_]"WI'_@!%_P#$T :_GQ?\]4_[Z%'GQ?\
M/5/^^A61_P (9X7_ .A;TC_P B_^)H_X0SPO_P!"WI'_ ( 1?_$T :_GQ?\
M/5/^^A1Y\7_/5/\ OH5D?\(9X7_Z%O2/_ "+_P")H_X0SPO_ -"WI'_@!%_\
M30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P  (O\ XFC_ (0SPO\
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MPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>%_\ H6](_P#
M"+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5D?\ "&>%
M_P#H6](_\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3_OH4>?%_SU3_
M +Z%9'_"&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T :_GQ?\]4_P"^
MA1Y\7_/5/^^A61_PAGA?_H6](_\  "+_ .)H_P"$,\+_ /0MZ1_X 1?_ !-
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M_P# "+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5D?\
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M -"WI'_@!%_\30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P  (O\
MXFC_ (0SPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>%_\
MH6](_P# "+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5
MD?\ "&>%_P#H6](_\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3_OH4
M>?%_SU3_ +Z%9'_"&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T :_GQ
M?\]4_P"^A1Y\7_/5/^^A61_PAGA?_H6](_\  "+_ .)H_P"$,\+_ /0MZ1_X
M 1?_ !- &OY\7_/5/^^A1Y\7_/5/^^A61_PAGA?_ *%O2/\ P B_^)H_X0SP
MO_T+>D?^ $7_ ,30!K^?%_SU3_OH4>?%_P ]4_[Z%9'_  AGA?\ Z%O2/_ "
M+_XFC_A#/"__ $+>D?\ @!%_\30!K^?%_P ]4_[Z%'GQ?\]4_P"^A61_PAGA
M?_H6](_\ (O_ (FC_A#/"_\ T+>D?^ $7_Q- &OY\7_/5/\ OH4>?%_SU3_O
MH5D?\(9X7_Z%O2/_   B_P#B:/\ A#/"_P#T+>D?^ $7_P 30!K^?%_SU3_O
MH4>?%_SU3_OH5D?\(9X7_P"A;TC_ , (O_B:/^$,\+_]"WI'_@!%_P#$T :_
MGQ?\]4_[Z%'GQ?\ /5/^^A61_P (9X7_ .A;TC_P B_^)H_X0SPO_P!"WI'_
M ( 1?_$T :_GQ?\ /5/^^A1Y\7_/5/\ OH5D?\(9X7_Z%O2/_ "+_P")H_X0
MSPO_ -"WI'_@!%_\30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P
M(O\ XFC_ (0SPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>
M%_\ H6](_P# "+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3
M_OH5D?\ "&>%_P#H6](_\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3
M_OH4>?%_SU3_ +Z%9'_"&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T
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MS+G'.,YKT:OG?2M&\7_$WXUZ+XOU;PA+X4T_20K/]I!$DQ1F8#YE5F))Q]T
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M)K!G0HNH3>;/:-@[E9B _/& PXP:K?&?4]4TGP/;7&A7CV=Z=5M$21790<R
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MAZS\3:AI&DC1(;FY2SDP[?O67$9.1&22,N!G"XH ]8IDTJP022N"5C4L0.N
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M!;+X'.,4 >M45XEIGQ*UVV_9ONO$*W2ZEJ\%PUA:WC(!YI,PC25@>,X;//7
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M<IH/@SQ!>>.8?%WCR]T^6^LK=[?3['3$?R+8/]]]S_,S$<=  *[ZB@ HHHH
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M?I"R,DD^/EDD>0 _+U  _&O1J** "BBB@ HHHH **** "BBB@ HHHH ****
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M\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\
M09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\
MH,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z
M- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\
M?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O
M45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\
M-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^
M&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!F
MV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S
M;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^
MC0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/
M^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/
M_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-
M?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&
MO^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV
M_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_
MWT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;
MU%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^
M$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\
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M\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\
M09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\
MH,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z
M- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\
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M  PULZ+&EZ7S."#DC=&G3'OUH [*BBB@ HHHH ***AO)&AL9Y4^\D;,,^H%
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M5^#-,UVZTXZ:]_#YPMC+YNQ"3M.[ SE<-T'6@#<HHHH **** "BBB@ HHHH
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MP>#R.] &I17/> -4O-;^'>@ZIJ<OG7EW8133R;0N]RH).  !SZ"NAH ****
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M^7GMNP,_D*YNZ^(^IZAK5_I_@3PG-XB7393!=WCWJ6D"RC[T:LP.]AQG XH
M[ZBN,\5:MXF/PHO-:TNU?1=<MK<W1LY?+GV^6VYXR1E6#*K $<\C&#71Z!K-
MOXA\.:?K%G_J+ZV2= >H#*#@^XSB@#0HHHH **** "BBN+^*?B#4_#?A6TO-
M&N?L\\FIVL#-Y:OF-Y &&&!'([]: .THHHH **** "BBN)^#OB'4_%7PGT;6
M=>N?M5_<^?YLWEJF[;/(@^50 /E4#@4 =M1110 4444 %%%% !1110 4444
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M9KOA1_%DOC#P_!9$G56RZI(0NW:Y+<\L,;B#M)'2@#@?A=\+$\=_"G6]3O\
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M/&WBCQ"+_P __A('MV^S^3M\CRD9?O;CNSNST&/>@#F/V??^28/_ -A.Z_\
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MYSLCC7(7)ZG)/YG( GQ>,@^#WB?RMV[^SY,[?3O^F:=I_P!F/P.M=WE_9?\
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M^5M\G"!=N<G=TSG H X3P59_$/X<^'U\)6_A.UUNSLY9?L6J+JD=NAC=V?\
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MF0QRQ2H&212,%6!X((."#1;V\-I:Q6UI#'!!"@CBBB4*J*!@* .  .,"I**
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M* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\
M 3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P
M$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_
M $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I
M/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH
M P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !
M/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3
M_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\
M0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_
M] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#
M!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_
M^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_
M +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P!
M'6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T
M =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'
M_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[
M*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\
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M* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\
M 3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P
M$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_
M $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I
M/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH
M P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !
M/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3
M_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\
M0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_
M] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#
M!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_
M^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_
M +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P!
M'6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T
M =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'
M_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[
M*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\
MLJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =
M:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!
MUK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^
M$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ
M/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"R
MK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK
M_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6
MO_ 3_P"RK>HH @LKK[;9I<>1-;[\_NITVNN#CD?AFIZ** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,#QEXVT/P'HG]J>([HPPLXCC1%W/*_7:J]^ 3Z"N9\
M"?&[PM\0=<;2-'BU&WO/+:14O(%4.JXR059AW[XJK\;_ (<:IX_T'3I?#TT*
MZEI,[310SX"3 @9&2",Y48SP><UB>"/BG>WGCJU\)_$KPM'H_B0Q%+2]CC W
M@J> >2H8*?F5BI(QQ0![517@?P_\=ZGX*U/Q_P"&_&>J76HSZ"DE_9S7T[2R
M2Q*,!<L<X8&(@?[9KGY=7\7Z?^R]<^);[Q'JW]I:KJ:2PSF\D#PP[]H53G*@
ME6.!@8(H ^G**^6?&EQ\3?!WA;0?B%>>.KB>34IH@=,CW+!"'C:1 5SM<;5(
M.5!SW/6K_B6?XC?#?6O"_B?6_&T^J)J]TJWFGC<+>('!**F=I&TD9"J010!]
M+T5X+\0M6\87/[16G>%O"GB&;2UU'2@GSLS11?ZQWD$>=I?;&0"1^(ZBMX:O
MO&7@#X\6G@?7_%5WXAL-8M&D2>Y9BT9*N5=0S,5(:,C ;&#GTH ]GT[QEH.K
M>*-0\.:??B;5=-7==6XB<>6./XBNT_>'0FMROD[P5\/]?OOC?XBT:W\=ZE:7
MNF 27.IQB3S+X!T^5_WH.#D=6;I7:^(=3\8_$SXSZMX,\.>)9_#&EZ+"'EGM
M<B21AMR?E96.6; &X# SU- 'OE%>'?#/7?%GAKXQZE\.O%>N2:_!':?:+:[F
MR74X5ADL2V"K$$$G! QWSP7@*'XE?$3P#J]_%X_O["VTEY'C_?2--<2[ Y5I
M P94QC') R?EH ^KJ*^5]%F^)WCKX3W_ (L;QW<V-OH$4IB@MRT<EWY2[W,C
MH5YVD 9W9QR!U/3ZMX]\<:M^S/H^OZ$]PVIR3M!J5W:Q9E2)&D4R #IG:F2.
MF3TZT ?0-9WB#6;?P[X;U'6;S_46-L\[@=6"J3@>YZ?C7DOP(U*:^U"^,/Q%
MG\5V;6P9K348Y([JVDW#G:[/E<$C*L1DBM_]H6YEM_@CK/DMM\UX(V/^R9DR
M* #P?\3K^?X,3>/?&UG%%&K/(D.FPL"8@XC7AW.6+;N<@8Q7/#]JKP06 _LK
MQ!S_ -.T/_QZIO$D"6_['<*1#"G0;)S]6\IC^I-<_P#!W6OBQ'X;\,V>G>&-
M*E\*&54:_>5?.%N9CYCX\\'(RV/D[#@T ?0]><>/?C?X:^'?B%-&UJSU2XN7
M@6XW6<,;(%8D 99U.?E/:J7BW]H3PIX-\57N@:II^LRW5DRK(]O!$4.Y0PP6
MD!Z,.U>=?%37;O1/VFM UG2M'N-8N8=-C>+3X,B2;(F&!A6.0#GH>E 'K/@3
MXT^$OB#J1T[2)+NUO]A=;:]B",ZCJ5*EE..N,YQ]#53QE\>_!G@K7)=(O6OK
MZ]@;;.EC"KB$XS@EF49]AG%>=?#>:?XH?M 3>,;NVM=!DT6(I)IBN3<.VUH\
MME5SC>0QP.BC'-6M:\,>//A3\1=>\8^$]+M_$.D:O+)<7<!3=+&K.788'S#!
M+8*[AC[PH ]M\)^*M,\:>&[;7-#>1K.XW!?-38P*DJ01[$5QWCGXZ^&?A_XE
M;0]9L=6GN5B24O:0QLF&Z<M(ISQZ5K_"[QIHOCGP?_:6@6"Z:J3NES9JJCRI
MCAFY4 -G=G=CG//.:O\ Q'_Y)9XK_P"P+>?^B'H X30_VE?!^O\ B#3]'L]-
MUQ+C4+F.VB:6WA"*SL%!8B4G&3S@&O7Z\E_9J_Y(S;?]?D__ *%7&:*?'?QN
M\0Z_?:=XUN_"^DZ;=&"U@L]X+=<!MCJ2< $DD\G@4 ?0]W=0V-E/=W<@C@MX
MVEE<C[JJ,D_D*S_#7BC1_%^BIJWAV\^V6+NR++Y3QY93@C#@']*\$T+6/%OB
M_P  >/\ P;KWB*>/4?#3L?[2A!+3QQF020L05)5C&1D\X8YSC%7?V;?"NK+X
M?C\3+XINETX_:(5T9@WD*^1^\^_MSW^[^- 'T)7F_P ;/B-JOPV\+V&I:);6
M=Q-<WH@87:,RA=C-P%93GY1WKPSQ/XCU32K6XU#_ (7C/J&OPD,NFZ;'.;:0
M[N0LBXBX!)Y7'&*Z'XU:W=^(_P!GGP5J^I%6N[NXC>9E& S>2X+8[9QG\: /
MIJO,/%O[0'@KPAKTVCW37U]=V[^7.+&%76)NZEF902.^,X/'6O3Z^=-0\.^.
M_@YXW\0>*/#FDV_B+0=5E>>[CVYEC0LSX('S+C<W(#*1R1TP >Z^%_$NG>,/
M#5IKNBO(]E=AC&9$*,-K%6!'LRD?A6M7A?B7XSVL'P#7Q%X$LTTN>ZOSIPA$
M2XLYF#2R' ^4DC+ XY+@D=16QX#^'WQ T37=)UK5_B#<ZM:3H7U'3KDR,BAH
MVP(RS$'#E>0$X'X$ ]<HKYN\,#Q[\<[O6-<L?'%YX8TRTN3#9VMGO&>-P#;'
M7L5RQ)R2>,5?\'^/_$]_\*?B+IFN:C)+K'AB&2./48FVN<K(HPPP20T3$-UY
M% 'T%17@WP=TWQOXATS1?'.O^-KR32[=9472@7<7,:!XRTC%@"^]2<D,>.HZ
M#S=_B7J?C*?4=9U?XHW7A.>.5O[/TBUMKAHV4 %0S1?+C/&6W'@Y&* /H[XK
M>)];\&?#^ZU_PY;VES/9R1M-'=H[J8BVTD!64Y!*G.>@-=#X=UNW\2>&=.UF
MSXAO[9)U4]5W#.T^X/'X5Y=X1\37_P 1/V:=;N?$+"2\6QO+62?8!YA6,E7P
M.,\CIW%:/[.=Y)=?!33$E)/V>:>)23GCS"P_]"Q^% 'J5%%% !1110 4444
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M-*SB%,?=4$_*/8<5C^$M<U6Z\-_%:6YU*[EDL-7U*.T=YV)MT1#L5#GY0,<
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MXDM\MY6HR,K/(FXX#,O#,OW2>"<<\UR'CN0W/QR^&NG29\C??W) /5T@RI_
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MWOD@*/J:M^$/&^D>-;2YDTK[1#<64ODWEE>1&*>V?^ZZ=NAZ9'!]#7)?#?\
MTCXM_$N[F&^<7MK '/41K&P"CT%)H*?9OVF?%20#;'=:-;3S@=&D!"J3[[<T
M ;TWQ4\,+X]L_"%K<2WNIW4C1LUJ@:*W95+%7?(YPIX&2.^*ZC4M2LM'TZ:_
MU2ZBM+2!=TLTSA54>Y->:^*]'T[0_B1\-+/1[*"RMQ?WK>7"@4$F#))]23W-
M>D:GI&GZU;);ZM9PWD"2+*(IT#+O4Y!P>#B@##\$_$'1O'\>H2Z MUY-A.(6
MDN(O+$N1D,HSG!'J ?:CQM\1/#W@"P6XU^Z;SI%+0V=NN^>8#DE5R.!CJ2 /
M6L#X9@+XX^(@48 UE  .W[E:N_%/1].7X?>+-7%E!_:,FC2PM=% 9/+"L0N[
MJ!DG@4 =;9W_ /:V@V^H:</+^V6RSP"=?N[UW+N /N,@'\:P_AUXLF\8^#XK
M_4(([;4H)I+2_MX\[89XVVL!DD@=" 2>"*O^#/\ D0] _P"P;;?^BEKB_ADX
MM?B9\2])C_U46IP7@&,#=/&2WZI0!Z=17GGQAOM4T#0=,\4Z3=74<>B:C%-?
MVT$C!;FV8A9%90<-C(//3DTWQ+K%WKGQ3\)>'="U":*UBC;6M1>UF9/,@7"Q
M(Q7JC.>5/!&* /1:*\*U74K@^/M:MO'?C+Q!X0N/MI709+>0Q:=);@ HQ.W8
M['!W!S[?3W*+/DIEQ(=HRX& WO0 ^JNJ73V.CWEW$%,D$#R*&'!*J2,^W%>5
MZ=I^N^,/B=XVTN?Q5JNG:+I]W 5@L)S',6>%2 LASY:#!.U<9+9)XI_A'5-7
MM)OB!X*US5+C5_[!A5[2]NB#,\,T+.%=OXB..3R<GM@  [KP%K]UXI\ Z/KF
MH1PQ7-];++(D (0$^@))Q^)KH:\H\*ND?[.OAQY_$Y\,6RVL9GOUV!MF3E%9
M^%8\8."?05@>$_%NGVOQAT#1O!_CG4_$^EZM%=)?P:G</<&W>.(NCH[*"-VT
MC XX/J* /=J*\GM+75OB7XV\4+=>(]8T;1]#O/[.M+;2+G[,TDBKF21W );D
MC Z?K3/B)KFL^!?#/AOPW:ZMJVH7>J7KP2ZG!;">^,"DN0B#@R;650V.@)QF
M@#UNN3T;Q5>ZC\3_ !+X;GBMUL]*M[66"1%82,95);<2<$<<8 _&O./#FJZ[
MIOCW1(M A^(5YI=W,8=3C\3V<CQQJ5^659&'R$'J.A%7O[ U#Q#\?O&-K;:[
M>:/9"SL6NCI[!)YOW9VJLF"4'4DCD\<CF@#V6BO)O#&O:KX.\6^+_"^KZI=Z
M[9:1IPU:PGO'WW'E[26C=_XN<8)_K@0>%O"?B+QUX-M_%.K>.=>L-6U2,W-O
M#IUSY5I:J23&OE8PXQC.3D^O<@'L%%<5\)/%-_XO^'=GJ&M%7U"*26VN9$4!
M97C<KO '3(P>@YSQ7:T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445FZ_K*Z!I$FH/8:AJ C91]GTZV,\S9.,A!R0.I]
MJ +=]?6VFV$][J$\=O:V\9DEFD;"HH&22:X"/XW>'O\ 1[F[TK7K'1[J01P:
MU=Z>8[.3=]T[\[@#V)4#@US?Q?\ &3:_\#/$+VNDZWH^R2VB<:I8M;-(K2KG
M;GJ.,'Z^]=I\5K"U'P6\1V@A5;>'3'\N,#A=@RF/H5'Y4 =L"&4%3D'D$=ZY
MOQ5X[TGPG<6MI=I>7VI7F3;:=I]N9[B4#J0HZ >I(%2^ IYKGX;^&I[EF::7
M2;5Y&;J6,*DD_C7F5O-XJOOV@/&[^&+727NK*WLK5+C5Y'VVT+1;RJH@W-N?
MYNH QSG- 'IWA?Q4OB>*Y/\ 8NL:/+;,%>'5K3R&;(R"N"0PX[&MZN%\$>,]
M;U'Q3K'A3QC8V5KK.EQQSB73W8P7,+]&4/\ ,,' .?7VJE\>M5U#1O@_J5[I
M%]<6%TDL 6>VE:-U!E4'#*01D<4 >CT5YU\<-5U#1_ATMSI-[<64YU"V3S;>
M4QMM,@R,CG![U3\<'7]0^,7A_0=%\076CVMYIEPUTT!R2JNI)13E1)V#D' )
MQ0!ZC6)HOB*35)=8%WH]_ID>F7;VZRW<6U;I5_Y:Q^J'L:XGPVNK>$?C._A2
M37M2UG1[_2#J$/\ :EP9YK>590A <C)4CM[^W,7A^*\\56/Q%T[4-:U6*.WU
MZ9();:\=)($5%81HW.U/]D<8)]: /1]#US3O$FB6VKZ+<?:;&Z4M#+L9-P!(
MZ, 1R#U%7Z\=^"7ANXL?A5I^O:9JFJ7-]<:?,L&GW5\S6:2;VV[8NB\J.?=O
M6J?PXU!;O7-/77?''B*R\7*Y.H:'J[[89^N5BB90N.,J4.1C.* /;JY3PSXJ
MO/$GC#Q+:PQ6ZZ-HTZ6,<P#&2:Y"[I@3G 5<JN,9SDY[5U=>8_L^R?:_A3'J
M3C]_J.H75U.<YR[2D$_D!0!N>#/BCX?\<ZSJFE:2+J"]TQRLL5TBJ9%#%2Z8
M8Y4$8['D<<UL1>*K&7QQ/X56*X^W06*W[2%5\KRV?8 #G.[(],8[UX/I.E7>
MD^"T^(GA^'?J7A[6[[[7$O!NK$S'S4/^Z"6'I\QZXKO_  YJEIK?Q_N=4TV4
M36EYX3MYH7'=6G)'T/MVH V-0^+6D6VK7MCIFCZ]KO\ 9\ABO;C2; SPV[CJ
MK-D9([A<U-XP\=2Z-X#L?%^B11W6F&>WEO!-$X<6DA"LRC(*N-RGD'H<BN37
M3_&/PAU#6+K1-+C\3>%+R[DU"2WA?R[RS9^7P#PZC X&2<=N<]3K>L:5X^^"
M&L:EI,IDLK_2;ED+KAD8(W##U5ATSVZ]Z .VCD26-9(V#(X#*P/!![TZN4^%
MU])J7PI\-7,Q+2-IT*LQZL54+G]*Q(=4U#P_\?I]*O[ZYFTKQ)IXGL(IIF9(
M+B 8DCC!.%ROSG'J* /1J*\FT;5O$_B&W^(7B;P]<S7&)'L- M'D)AS I#2H
MI.TEW.03W&#Q4/PNOK"\UBT*>.?$,VM+ ?[3T'7I#N+[,DI&X&S:W.4R,#!]
M: /7Z*R/%LTMMX+UN>WD>*:+3YWCDC8JR,(V(((Z$'O7E6D^&?%.N_".R\43
M^/-<AUE-+2YM$MY]EN D>5$J')E9L99F)Y)[<$ [_P ?>*[WPK_PC/\ 9\5O
M+_:WB"UTR?SU8[8I=VYEP1AAM&"<CVKK:\2\0>(I_%GP[^%&MW847%WXJTUI
MMHP#(#(K$#L"0372?$>YT6UU>)O%/Q&O_#MF85\G3M-N!;RNV3F1F4&1@<@8
MX V]^: /2:*\9\ _$"YM_A]XWO1J\OB2U\.RS-IU]<Y\RXC\O>@<D GGJ<9Z
M^PK5\*^"-=UC0-)\1ZKX[\1)K%Y'%>RQ17*BT4. WE>1C;M ./ZT >HU%=2M
M!9S2H 6CC9@#TR!FO$O%GC"]UOXGZUH,K^,(M)T-(46/PG;LTLLLB;BTTB\J
MHZ*HZX)[&M[X::KXAN8/%.FZS!X@?2K14?2KSQ!9F&YD1D;>C$@;RK#K[\XX
M% '6_#CQ+=^,/AYI.O:E%!%=7L3/(ENI" AV7@$D]O4UT]>#_#+P+KGB#X-Z
M7>)XTUC39A _]FV^G3"&&##MCS% S*2V2<GH<#&,U;C^)OB'7/@SX2N-/FCM
MM>\1ZDFD/>^6"(#O=6F"],X0''3DXZ"@#VVBO&?'&FZQ\*-!@\7:5XPU_5$M
M+F%=0LM6N_M$=U$S!6V@@>6V3V_I7LU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <+\1O#/C;6I].
MO? 'BA-%N;19%E@G!,,^[:06&UAD;3U4]3T[\SX3^$OBF7Q]9^,?B;XE@U?4
M-/0I:P6:;8UZX).U!QN)P%Z]^*]@HH ^9OVD?#2WGQ(\.#2)@FI:_&+&:!,Y
M8"10CM['=C_@'M7JOQ$^&UQXC^$<'@[PW+;6S6HMT@:Z9E39%@<E03G ].M=
M+?>"/#VI^+K/Q1?Z<)]8L8Q';W+328C4%B,)NV]6;G&>:WZ /*_B7\+]9\9?
M";0?"^EW5C%>Z;);O+)<.ZQL(X'C.TJI/5@1D#BK'Q7^&NK>.]'\.V>E75G
MVF72RSM<LX#*% .W:IR>.AQ]:],HH ^</B9I>IZU^U3HECH.JMI&HOI>ZWO%
M7=Y;*D[\CN#MVGV)X/2NO\#?"3Q+;?$;_A-OB/K]MK&JP1&.V6V4[%RI7=]U
M0,*6^4+C)SG->B7'@S0+KQG:^+)]/#:W:1&&&[\UQL0A@1M#;3P[#)&>:W*
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M <>U<%>>"/B-XB\.Q>%/$VMZ&FB82*ZO;&.7[9=1(1\I#?(A; R1G^8/J]%
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M)Y'4''\L>CT4 >=^&/AUJ-M8^,+3Q??VVHCQ-)NDEM4,> T6QQM(^7!SCD\
M$G-5O#_ASXH>'M)L_#UOK'AN72[(+!#J$D$QNA N J^7]S(48SN/X]:]-HH
M\\U?P5XFTKQY?^*_A_?Z8DNK11QZCI^JI((96C&%D5X\D,!D8QCD^O'0Z%9^
M*GTZ_P#^$NO-,EN+A=L$&G1.L4 P1RSG<Q.1S@=.E=%10!X_X>\!_$_PIX(A
M\,Z/K^@RVSPE&GN8Y?-L2V=XA*@"09)(W $$]P*V+_X16Y^%^B^&-'U%K.^T
M*>.\L-0*9VW*L6+E?0LS'';(ZXKTBB@#S#4/!?CGQO\ 8M.\?W^@P:);W"7%
MQ!I"2M)?%#D(YDP$7."0,UZ?110 4444 %%%% !1110 4444 %%%% !1110
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M5#;'.6+;2"#A5;J,9Q6)^SZWBB#P[JVF^*+;5X;:SN@-.?5[=XI6B(/&&[#
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MOE0SW&XINP3SOC3T/3-<E\#9(A\1OB-)<HDGB<7$A@2XP&8>9)O [XW[-W_
M:T-(^+/Q)L_BKH?A'QUX?T;3CJ9#E;?<S^6=X#!EF=1\R'@^GXT :WB_XZ:A
MX>^(U]X0T7P1=Z_=6:QL6M;EM[AHUD)$:Q,<#>!G-;/PX^,=GX\UJ[T*\T:[
MT+6K2,RO9W)W94$ X)"G()'!4<'ZX\F\2WWBK3OVLM>N/ FF6VIZLMM$!;W1
MPA3[+#N/WTY'U_"M[X$@^+?B;XE\8^)KP+XGB'V:;35@,8@7"INY)S@1[,=L
M'/44 =9XM^.]EHWBB;PYX6\/W_BK5K8D3Q660J,.JY56)(Z'"X!XSG-+X,^.
MUCXA\4IX:\1Z#>^&-8F.V*"\)*NW9<E5(8]@5P>F<X%<G^RWY;MXNEOL'6C=
MQ_:2_P!_!WG_ -#W9_#VI/VA!%)\4/AY'IX5M5^U?,(_]9M\Z+RO_'O,Q^-
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MDBNX;[3Q.[QEHHPRR@,3ALD<^@/J<@'LE4=;UFR\/:'>:OJLODV=G$997QG
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ML0%P 3@9/%.\%))X?U;XE>"K:XGN-(T>&.:P6:4R&W6:!F:,,><#C ]CW)-
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M\ 67B+Q9)=ZEK^KP_:GU/[4ZR6[,25$8!VJ%X&,8X].* /9J*X#X)Z[J&O\
MPOLYM8N6N[JVFFM6N7.6F6-R%8GN<8&><XS7?T %%%% !1110 4444 %%%%
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M;PKH?BK2["\T36/"OB]K=EEBNYY'BU0A/G8/N9),'+#H01Z#% 'M=%8OC/\
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M0S$-G.<U[C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNXX%664#& S@98<#J>PJ[0 4444 %%%% !1110 4444 %%%% !1110 4444
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M6R-]XJBD_,>03GH3[8Z]],L)+VWO'LK=KJU1DMYS$I>%6X8*V,J#@9 ZU:H
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M71-7D>%/6VG_ 'D3?C\U>F576PLTU"2_2T@6\DC$3W(C D= <A2W4@$GCWH
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M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
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MJ.E87C?XA:3X!_LO^V+>^G_M.Y^S0_9(@^UN.6RPXY[9/M0!U5%%% !1110
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MNWO[.*[LIX[BWF0/%+$P974C(((ZBJ7B#Q)H_A72FU+Q#J$-A:*=OF2GJ?0
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M*$\=1D9Z4SP7XIM_&G@^PUZTB,"W<9+P,VXPR*2KH3@9PP(S@9ZXH W:***
M"BBB@ HKF+OQD+7XG:?X/^PES>:?)>_:_-QLVMMV[,<YQUR/I73T %%%% !1
M5==1LFU)].6\MS?)$)GM1*OFJA. Y7.0N>,]*SO^$JTO_A-/^$6\R3^U/L?V
MW9Y3;/*W;?O=,Y[4 ;-%%% !1110 45C1>*M,F\9S^%HY)3JD%F+UT,1V",L
M%SNZ9R1Q_@:V: "BBB@ HHHH **KIJ-E+J$MA'>0/>0HLDMLLJF2-6Z,5SD
MXX)JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?(.FZG_9GQF\=O\ \*[_ .$ZWZI<
MC[/]G\W[-_I#_/CRI,9Z=!7LVLR^)(?@8NL_#[1U\%ZI#NO)M'BL8\[ 6#H4
M:,?,0 ^=H)P!WKB;/PO\7?!7Q.\6:YX1\+6%_;ZQ?3NDEY=1$&-IF=2 )D(.
M&[UV/B"7XL>(?A!<:?-X=M;3Q'J-PUK,MI=1HD%J0,OEI6R6Y7 )."3@<4 8
MWA7XL>(_BCXR\.:;X6E;2[.UM1=>(9/(1][ X,:EU. 2.",'#G^[5KX@ZU\3
M;;Q5?1Z=XN\*^%-*C8"R&I74*27*[1S\ZOSG/]WI^)I:1\)O$7PQ^(V@:KX%
MMVU33)K5+76T-PD>3P'D =AP3AP!G!4CH:RM=^&/C^Q^)GB'5-+\->'_ !/:
MZU<-)%=ZPL<PLU))4!'8$%00O"L,*/I0!T?@?XU7][\#];\7>(K:*>]T:8P?
MNAL6X9@@CR!]W+2 '''>J_@O4/C?KW]C>)Y[[2)M$U">)Y--\M$=+=G 9P=F
M>%R1\Y/L3Q47@+X.:Y#\&?%?@WQ+&EA<:C>%[:595D5M@C*/\I)"EHQP<'':
MI/!=C\<-$32/#$]AI%OHNGS1QOJ1D1Y&MU890 .3]W*CY ?<'F@#/\6?%?Q7
MKGQ$U?P]X/\ $GA_PK9:-(87N]8FCC-Q(I*L!YBM_$",!>V2>0*TO"'Q<U_7
M?A;XVEO9;3^WO#,#[;^T"O%-E7V2 <JW,;'(^4C'%9/BCX3^+M"^(VL>(/"7
MAOP_XKL=8F:=K76(8I# [$LW$C+CYB<%6Y&,CBNGT3P3XJ;X5>,++5=!T'2]
M5U>V>.UL-'@A@7_5D*K,O!.XG!9CC/44 5/A/KWQ5\;-HWB+4[_3HO#/SPSQ
M&-!->;0RF483C]X,8!7IT/4^:?!>'XG7G@G5(?AQ<Z=I]M%=F6:XN@K232>6
MO[I RL.@!R0.O6OH'X.^'M3\*_"?1M&UZV^RW]MY_FP^8K[=T\CCYE)!^5@>
M#7C_ ()\&?&OX<^&+NW\.:;IDOV^9O,M)YHFDMV "B96WA3D8X)/W>5]0#MO
MAW\2_%'CGX1ZQ>V=I:R>*=-=H$$@$<4AP"';) ! +9&0,KVSBN UGXI_$?P+
M>V>H:UXR\+^(;>2X"3Z5ITL,DD0ZG=L167@$ Y(SC-=5H_P5U_3/@)K7AM+V
M)/$&L3+<RXE/EX5E_=%^^0IR>F6QTYK@-6^#_P 2M:\+6FG_ /"$>'M-.G%5
M5[(P1W5YQC?)+O.[U.2.>Q[ &O\ &:P\9/\ 'SP\+/5K..2YF3^P69!BTY4'
MS/W9S\^3SOX_*NP^(/BWQWX&T;P)9WFM6[ZM?7IAU2X@MXV2<;UP!N08&&QD
M*IJ_\9_ _BO6?$GACQ1X&MH+S4-%E+&WFD5-WS*RGYF (X8$9!YX]J/Q"\'^
M.O&NC^!+J[TJV;5;&^:?4X;:=$C@!=2-NY^0%7L2?K0!-X\\?>--4^*7_"O?
MAHUI9WMO L]Y?W2!A'E0V.58!0K)SM));'&.6>!?'GCC2?BPOP^^)4MG?W-U
M;M-:7MJ@7=A2_P#"JC:0C]5!R/>D\=> O'&D_%AOB#\-8[.^N;JW6&[L;IPN
M["A/XF4%2$3HP((J3P'X"\::I\4_^%@_$M;.SO+>W,%G8VCAO+RI7G!8!0K/
M_$Q);MCD Y?P[XU^,7CN^\0Z9X5O].B&FWTN;Z[AC4HF2(X$ 0@_=;EE)YY8
M=_0O@;\0-5\>>$;M_$2Q_P!IZ;=&VEDC4*)1@$,0. >HXXXJK\%?!6O^$-1\
M7R>(+(6J:CJ FM6$R/YJ O\ -\I./O#@X-'P*\%:_P"#-.\01^)+$6;WFH>=
M /.23>F.OR$X^AYH ?\ 'KQSK?@+PQI&H^'KA8))=26.<-&C^9&$9BGS XS@
M<CFFZ4WQBM/"NNZEK4NCW&I3PPR:78@JB69+?O1(V%'RH<\LW(ZTW]H'P3K_
M (Y\'Z;9>%[$7MS!?B62,S)'A/+<9RY ZD>]=%\7/"FJ^-/AKJ&BZ%.D5Y,T
M;JLC[5E"N&*$]LX^F0/K0!XS=_%+XB>#->TR77/&/AGQ):W5TL4^GZ;+#(\*
MY&=VQ%93@\')&>M-^,UAXR?X^>'A9ZM9QR7,R?V"S(,6G*@^9^[.?GR>=_'Y
M5GWWPD^)&KZ?I,<G@CP]I0TV>-3_ &?Y$=Q<KWDDDWG=C'3(.3T/;T_XS^!_
M%>L^)/#'BCP-;07FH:+*6-O-(J;OF5E/S, 1PP(R#SQ[ %#Q_P#$3Q?X \-^
M&?#MS?Z9-XLU7<MUJLVU+:!0^ _*JH^\.2N %/!R*S? _P 4/%NG_$S3/"_B
MSQ%H/BJUU92([W2)HY/L[X)"DQJO<8(*]\@\5H?$/X;^,O'6@^&?$,UKI?\
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M"A%4KS@L23SQ6WX:\.^(M8^)$GCCQA8P:0T%B;#3]+BN!.\:EMS22.ORDGH
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M\1C!AU;7YQ;N,?/#%\BMGTZ_E0!J?%KQ)J_A7P9#J/AYA]L_M&VB$9"XE5G
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MV7P5X\T7Q:(;:Z\1:C<7"3V[!HV,B*=ZC)(4/GAL' K2\-ZE\3--TW3="O\
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M^5G'VK[*OE_7&_=_X[7>^,/B'X;\#:3#J'B&^\I+D?Z/$B%I)^ 3M7VR,DX
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M036U["8Y+:8#[LB9R/P/KSQ4'PZ\63>,?!\5_J$$=MJ4$TEI?V\>=L,\;;6
MR20.A )/!% '4T444 %%%% !17':OXOOK#XM>'_"T,-NUEJ=G<3S2,K>8K1C
M*A3G ''.0?PKL: "BBB@ HK-_P"$@TS_ (2G_A'/M7_$V^Q?;_L_EM_J-^S?
MNQM^]QC.?:H)=>GC\:0Z"-&OW@ELS<G4UC_T9&#%?*+?W^,X]"/P -FBBB@
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M1+6?3[J"ZB\M5\R"0.N0!D9'>O-=9*_$7XV:';Z.!+IG@V5[C4+]>4-PVW;
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MD\0*.P>/:Y*X 0[B< $X&.:B\/\ ASXH>'M)L_#UOK'AN72[(+!#J$D$QNA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!'19(V210Z,"&5AD$>AKGV\">'&\(P^%VTXMHT+AX
M[4SR?*1)Y@^;=NP&YQG&..G%=#10 4444 %%%% !1110 4444 %%%% !1110
M!G:=H.F:3?ZC>Z?:B*YU.837<I=F:5PH4=2<  8 & /3FM&BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_PH K?\)-H/\ T&]._P#
MN/\ QH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\ A1_9>G_\^-M_WY7_  H
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M\)-H/_0;T[_P+C_QH_X2;0?^@WIW_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\
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MU9_LO3_^?&V_[\K_ (4?V7I__/C;?]^5_P * *W_  DV@_\ 0;T[_P "X_\
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M_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_PH K?\)-H/\ T&]._P# N/\
MQH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\ A1_9>G_\^-M_WY7_  H K?\
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M^!<?^-6?[+T__GQMO^_*_P"%']EZ?_SXVW_?E?\ "@"M_P )-H/_ $&]._\
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M_P!!O3O_  +C_P :/^$FT'_H-Z=_X%Q_XU9_LO3_ /GQMO\ ORO^%']EZ?\
M\^-M_P!^5_PH K?\)-H/_0;T[_P+C_QH_P"$FT'_ *#>G?\ @7'_ (U9_LO3
M_P#GQMO^_*_X4?V7I_\ SXVW_?E?\* *W_"3:#_T&]._\"X_\:/^$FT'_H-Z
M=_X%Q_XU9_LO3_\ GQMO^_*_X4?V7I__ #XVW_?E?\* *W_"3:#_ -!O3O\
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MVW_?E?\ "@"M_P )-H/_ $&]._\  N/_ !H_X2;0?^@WIW_@7'_C5G^R]/\
M^?&V_P"_*_X4?V7I_P#SXVW_ 'Y7_"@"M_PDV@_]!O3O_ N/_&C_ (2;0?\
MH-Z=_P"!<?\ C5G^R]/_ .?&V_[\K_A1_9>G_P#/C;?]^5_PH K?\)-H/_0;
MT[_P+C_QH_X2;0?^@WIW_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_
MPH K?\)-H/\ T&]._P# N/\ QH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,!UP5&16Y^T!'J6N?#_P;XPN]5E$.H65LLFEJ"(5F>)I6F'S8SAMO3.!U[4
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M>._!VL>)V9O#ZQ2V6N:BJNT,4T1<&4D@/LX)+$9R>@P!5_MS4/\ HOWA;_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEO-*^A+,,=@?:HKKP9XW\97>F6_Q!OM"CT?3[I+N2VTA)2][(GW0YDP%7/)
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M"6DPK#+$CKV_ 8A^%ND?V+\0_BEI=O<75VL'V)(I+F0R2D>5*54MU. 0H[X
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MGY=PLOGP#&V0X^Z3SP>?:MFO$M"/_%J_C/\ ]AG7/_1(H ]MHKP"\^'6F?\
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MQ?[05M+9@Z *JE?,6520=H.,5K>!?@AI?A/Q$?$6KZK>>(M< ^2[O3Q&<8W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#G/$OA/\ X2+7/#NH_;?L_P#8EZ;O
MR_*W^=E"NW.1MZYSS]*D\4:5XCU,6O\ PC'B6/0C'N\\R:<MWYV<;?O,NW&#
MZYS[5OT4 <!\./A_K_@&RM=+E\71ZGHMJD@BLO[+6%@SN7W>9O8]6;CWK=3P
MF)?'LGB?4[S[8\, M]-MC%M6R4C]XP.3N=SCYL#"C'O7144 <)K_ ,-[C5-6
MUVXTK7FTRU\26Z6^K6YM!,TH5#'NC<L/+8H=IR&'?&:[2QLX-.T^WLK1-D%M
M$L,2_P!U5  'Y"IZ* /,[)?^$;_:.U*.0;+?Q7I4<\39X>>V^1D^H0[OQK!L
MO#NIZS\>OB'=Z!XBN-"O[,::JR)"L\4J/;?,LD38#?<&#D$<^M>Q7%A9W=S;
MW%U:033VK%[>62,,T+$8)4GE20<9':D@TZRMKZZO;:SMX;J\V?:9XXE62?8,
M+O8#+8' ST% '.>"/ L?A!M2O;O4IM8UG5IA-?ZA.@0RE1A55!PJC)P.>OI@
M#K*** .8\;^"+?QE:63+>SZ9J>FW N;#4+< O;R=^#PRG RIZX%9FC_#S4/^
M$JL_$/C/Q-+XCOM.1UL$%FEK#;EQAGV*3N8CC)/\ACNJ* ,#3_#VH6?CC5M<
MG\07=S8WT,4<&DN#Y5H44 LOS'EB"> .ISGC'*)\+-8T::_M_!7C:YT'1[^9
MIWL!81SF%G^]Y,C$&,'TP<=N:]*HH XN7X6>'I/AD/! 69+!5RDX?]\)=V[S
MMW][=SZ=NG%9J?#'6-4O-/'C?QI<>(--TZ=;B&Q%C';"1T^X9F4DR8]. 3UK
MT:B@#B_%7P_FUCQ/:^)O#FN2^']>MX#:M=);K/'/"3NV21L0#@]#D?H,3>$?
M C>']8OM=UK5YM=U^_18IKZ6)8E2)>D<<:\(N>2,G)%==10!YU=_#OQ;JUO)
MINM?$B]N='F!2:"#388+B6,]4,R]B.#A1D5L^++NP\ _"G4I+&)+:UTW3FAM
M8AT#;=D:\]<L5'KS7657O;"SU*W$&HVD%W"'5Q'/&'7<IRIP>,@@$'L: .>^
M&?A]_"WPRT'2)T\N>"T5ID_NR.2[C_OIC4VJ>$O[2^(&A>)OMOE_V1!<1?9O
M*SYOFJ!G=GC&/0Y]JZ.B@#F_&W@JT\;:7;V\]U<6%W97"W5E?6Q DMY5Z,,\
M$>HJCHGA3Q9:ZM:W7B'Q[<:K;VQ)%K#IT5JLIVD?O"I);KG P,@5V5% '!ZO
M\.M0/C&\\2>#O%$OAV\U*-(]03[%'=1W&P85@K$;6 [\_3DYG\#?#H>"M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !17+^.?&8\%6VBS&P^VC5-7@TP@3>7Y7F!CYGW3NQM^[QG/45U%
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MK:^'7@<> O#<NG2:B^J7=Q=/=7-Z\7EF5VP/N[FQA54=>U %7XQ?\D<\3?\
M7BW\Q7(_$&QEU2/X86,5]<6#7-TL;7-JVV5%-MAMK=B1D9[9S7I/C'P[_P )
M;X-U/0?M7V3[? 8?/\O?Y>>^W(S^8K.U7P1_:=UX3F&H>5_PCDXFV^3N^T8C
MV8^\-OKGF@#B+OPIIWP[^,'@Q_"/G6,&MM<VNHVYGDD2YV1;E=MS'Y@><_\
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M.!VD$>] Y.T_O,XZ9 XKHO&'@)_$6M:=KVBZS-H.O:<C10WL4*S*\;=4DC;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6O\ P >C_A*X_P#H#:U_X /6]10!@_\ "5Q_] ;6O_ !Z/\ A*X_^@-K7_@
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M6O\ P >C_A*X_P#H#:U_X /6]10!@_\ "5Q_] ;6O_ !Z/\ A*X_^@-K7_@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$LB0%@03&C,53.3]T"NJHH XF?X/> [DW F\/1-'<%BT(GE$:ENK(@?:A]U
M-=/)H>G2^((-<DM\ZC;V[VT<V]OEC8AF7;G:<E1SC-7Z* ,ZUT#3+/7[[6[:
MVV:CJ"1QW,V]CYBQ@A!@G P">@&>]4=!\$>'O#&H75YH6G_8Y;K/F!9Y&3D[
MCM0L53)Y.T"M^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975013312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,875,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975365088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 270,727<span></span>
</td>
<td class="nump">$ 227,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Tax incentive receivable</a></td>
<td class="nump">10,150<span></span>
</td>
<td class="nump">9,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,060<span></span>
</td>
<td class="nump">3,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">287,831<span></span>
</td>
<td class="nump">242,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Equity interest</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">16,098<span></span>
</td>
<td class="nump">16,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">303,929<span></span>
</td>
<td class="nump">259,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">13,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,949<span></span>
</td>
<td class="nump">19,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan</a></td>
<td class="nump">19,857<span></span>
</td>
<td class="nump">9,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">19,887<span></span>
</td>
<td class="nump">9,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,836<span></span>
</td>
<td class="nump">29,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary &#163;0.05 par value shares; 651,659,630 and 631,338,246 issued, and 635,787,302 and 606,301,054 outstanding, at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">41,753<span></span>
</td>
<td class="nump">40,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">596,059<span></span>
</td>
<td class="nump">529,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Ordinary shares held in treasury</a></td>
<td class="num">(975)<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(359,143)<span></span>
</td>
<td class="num">(333,097)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">273,093<span></span>
</td>
<td class="nump">230,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 303,929<span></span>
</td>
<td class="nump">$ 259,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975793616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share)</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">651,659,630<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">635,787,302<span></span>
</td>
<td class="nump">606,301,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975592608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments', window );">Research and development (Note 8)</a></td>
<td class="num">$ (2,474)<span></span>
</td>
<td class="nump">$ 14,982<span></span>
</td>
<td class="nump">$ 10,136<span></span>
</td>
<td class="nump">$ 32,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">12,439<span></span>
</td>
<td class="nump">5,526<span></span>
</td>
<td class="nump">22,028<span></span>
</td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,965<span></span>
</td>
<td class="nump">20,508<span></span>
</td>
<td class="nump">32,164<span></span>
</td>
<td class="nump">45,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,965)<span></span>
</td>
<td class="num">(20,508)<span></span>
</td>
<td class="num">(32,164)<span></span>
</td>
<td class="num">(45,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Research and development tax credit</a></td>
<td class="num">(1,934)<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">6,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">3,402<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(740)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases', window );">Foreign exchange gain/(loss)</a></td>
<td class="nump">740<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="num">(3,585)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">3,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(8,497)<span></span>
</td>
<td class="num">(17,687)<span></span>
</td>
<td class="num">(25,067)<span></span>
</td>
<td class="num">(42,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(310)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,807)<span></span>
</td>
<td class="num">$ (17,766)<span></span>
</td>
<td class="num">$ (25,550)<span></span>
</td>
<td class="num">$ (42,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Profit/(loss) per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Profit/(loss) per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">634,469,423<span></span>
</td>
<td class="nump">484,777,837<span></span>
</td>
<td class="nump">627,996,124<span></span>
</td>
<td class="nump">483,226,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">634,469,423<span></span>
</td>
<td class="nump">484,777,837<span></span>
</td>
<td class="nump">627,996,124<span></span>
</td>
<td class="nump">483,226,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ResearchAndDevelopmentExpenseNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769970588736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Sales Agreement</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th">
<div>Ordinary shares </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th"><div>Ordinary shares held in treasury</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 148,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (603)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (263,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Issuance of ordinary shares to treasury (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Issuance of ordinary shares to treasury</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,058,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">126,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(288,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">148,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(603)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(263,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,058,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">110,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(306,653)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,058,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">126,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(288,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,058,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 110,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(306,653)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">606,301,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 230,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(333,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,321,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">56,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 276,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(350,110)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">606,301,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 230,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(333,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">635,787,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 273,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(359,143)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">276,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(350,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 5,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">635,787,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 273,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (975)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (359,143)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975726960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,550)<span></span>
</td>
<td class="num">$ (42,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gain)/loss</a></td>
<td class="num">(1,672)<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Other non-cash items</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of redemption premium on debt</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">9,364<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent', window );">Tax incentive receivable</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(6,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(417)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(6,285)<span></span>
</td>
<td class="nump">6,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Income taxes</a></td>
<td class="num">(939)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(951)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,093)<span></span>
</td>
<td class="num">(34,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">56,909<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from draw under the Oxford Term Loan</a></td>
<td class="nump">9,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholding taxes from share-based awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="nump">68,809<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">42,900<span></span>
</td>
<td class="num">(36,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">227,827<span></span>
</td>
<td class="nump">148,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">270,727<span></span>
</td>
<td class="nump">111,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 685<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Tax And Tax Credit Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975805824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_OrganizationAndBusinessDescriptionTextBlock', window );">Organization and description of business operations</a></td>
<td class="text">Organization and description of business operations <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the &#8220;Company&#8221;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2023, the Company submitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#8220;COPD&#8221;) and is preparing for a potential commercial launch in 2024, subject to approval of the NDA. In conjunction with the submission, the Company paid a $3.2&#160;million Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) application fee to the FDA. The Company has requested a small business waiver of this application fee and, as such, the amount has been recorded within Other current assets in the Condensed Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $359.1&#160;million as of June 30, 2023. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of June 30, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the six months ended June 30, 2023, the Company sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the at-the-market offering program entered into in March 2021 (the &#8220;2021 ATM Program&#8221;). The shares sold were at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of approximately $56.9&#160;million after deducting issuance costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2023, through a registration statement on Form S-3, the Company replaced the 2021 ATM Program, with an open market sale agreement with Jefferies LLC (&#8220;Jefferies&#8221;) to sell its ordinary shares, in the form of ADSs, with aggregate gross proceeds of up to $200.0&#160;million, from time-to-time, through an &#8220;at the market&#8221; equity offering program under which Jefferies will act as sales agent (the &#8220;2023 ATM Program&#8221;). Jefferies is entitled to a commission at a rate of up to 3.0% of the gross proceeds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine, if approved. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_OrganizationAndBusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Business Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_OrganizationAndBusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769979936224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text">Basis of presentation and summary of significant accounting policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on March 7, 2023 (the &#8220;2022 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2022, was derived from audited consolidated financial statements included in the 2022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, pharmaceutical development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under this model, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. This update became effective for the Company on January 1, 2023 and the adoption of this update did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139770058009552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Interest<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Equity interest</a></td>
<td class="text">Equity interest <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the six months ended June 30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769978611744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769978666912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term loan</a></td>
<td class="text">Term loan<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On October 14, 2022 (the &#8220;Effective Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;) for an aggregate amount of up to $150.0&#160;million (the &#8220;Oxford Term Loan&#8221;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $10.0&#160;million, which was funded on the Effective Date (the &#8220;Oxford Term A Loan&#8221;), and up to four additional term loan advances in an aggregate amount of $140.0&#160;million. The Oxford Term Loan has a maturity date of October 1, 2027. On March 24, 2023, the Company received $10.0&#160;million under the second term loan advance (the &#8220;Oxford Term B Loan&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Oxford Term A Loan and Oxford Term B Loan (together, the &#8220;Oxford Term Loan Advances&#8221;) bear interest at a variable rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#8220;Basic Rate&#8221;) and shall not increase by more than 2.00% above the Basic Rate as of the funding date of each such term loan. For the six months ended June 30, 2023, the effective interest rate was approximately 11% per annum. There was no material difference between the carrying value and the estimated fair value of the Oxford Term Loan Advances outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769979802720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,276,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,050,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,306,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,305,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,237,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,680,224)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769978611744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Capitalization and net loss per share</a></td>
<td class="text">et loss per share <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on Nasdaq each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022 (in thousands except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three and six months ended June 30, 2023 and 2022, outstanding share options, RSUs and warrants over 48.5 million and 46.2&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769978686512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingenciesThe Company had previously accrued up to the maximum exposure of $6.9&#160;million related to a matter with a supplier and also had certain invoices in the amount of $1.5&#160;million in accounts payable to the same supplier. Both items were settled for $2.1&#160;million in the three months ended June 30, 2023 resulting in a reversal of $6.3&#160;million in Research and development costs in the Condensed Consolidated Statement of Operations and Comprehensive Loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975082464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on March 7, 2023 (the &#8220;2022 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2022, was derived from audited consolidated financial statements included in the 2022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div>Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, pharmaceutical development.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards and recent accounting standards not yet adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently adopted accounting standards and recent accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under this model, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. This update became effective for the Company on January 1, 2023 and the adoption of this update did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769979999520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769980139472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,276,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,050,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,306,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows restricted stock unit (&#8220;RSU&#8221;) activity, in ordinary shares, in the period:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,305,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,237,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,680,224)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769979335424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earning Per Share</a></td>
<td class="text">The following table shows the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022 (in thousands except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769970400512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_PaymentsForApplicationFees', window );">Prescription drug user fee</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 359,143<span></span>
</td>
<td class="nump">$ 359,143<span></span>
</td>
<td class="nump">$ 333,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrna_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,321,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SaleOfStockMaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SaleOfStockCommissionFeePercentage', window );">Commission fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares | ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.08<span></span>
</td>
<td class="nump">$ 23.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PaymentsForApplicationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Application Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PaymentsForApplicationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SaleOfStockCommissionFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SaleOfStockCommissionFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrna_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrna_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975011840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975138928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Interest (Details) - Nuance (Shanghai) Pharma Co Ltd<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_EquityInterestReceivable', window );">Equity interest receivable</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975363552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 3,609<span></span>
</td>
<td class="nump">$ 12,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent', window );">Professional fees and general corporate costs</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">People related costs</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 7,467<span></span>
</td>
<td class="nump">$ 13,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Listing, And General Corporate Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769976439728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term loan (Details) - Line of Credit<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 14, 2022 </div>
<div>USD ($) </div>
<div>loanAdvance</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_LineOfCreditFacilityNumberOfLoanAdvances', window );">Number of loan advances | loanAdvance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term Loan | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt instrument interest rate increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term A Loan | Debt Instrument Interest Rate, Period One | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term A Loan | Debt Instrument Interest Rate, Period One | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term B, C, D, E Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Oxford Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_LineOfCreditFacilityNumberOfLoanAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Loan Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_LineOfCreditFacilityNumberOfLoanAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBCDELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermBCDELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975171344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 5,074<span></span>
</td>
<td class="nump">$ 3,053<span></span>
</td>
<td class="nump">$ 9,364<span></span>
</td>
<td class="nump">$ 6,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">2,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 3,951<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 7,138<span></span>
</td>
<td class="nump">$ 3,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975679520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share Option Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance outstanding</a></td>
<td class="nump">19,306,304<span></span>
</td>
<td class="nump">19,276,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,824,000<span></span>
</td>
<td class="nump">1,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="num">(1,050,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance outstanding</a></td>
<td class="nump">21,930,304<span></span>
</td>
<td class="nump">19,306,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769975370464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - RSU Activity (Details) - Restricted Stock Units - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">30,237,224<span></span>
</td>
<td class="nump">34,542,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(3,680,224)<span></span>
</td>
<td class="num">(4,305,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">26,557,000<span></span>
</td>
<td class="nump">30,237,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769972887232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share - Computation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (8,807)<span></span>
</td>
<td class="num">$ (16,743)<span></span>
</td>
<td class="num">$ (17,766)<span></span>
</td>
<td class="num">$ (24,837)<span></span>
</td>
<td class="num">$ (25,550)<span></span>
</td>
<td class="num">$ (42,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">634,469,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,777,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,996,124<span></span>
</td>
<td class="nump">483,226,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">634,469,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,777,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,996,124<span></span>
</td>
<td class="nump">483,226,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share (in shares)</a></td>
<td class="nump">48,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,500,000<span></span>
</td>
<td class="nump">46,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139769979367904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Loss in period</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Accrual, Reversal Of Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>vrna-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:vrna="http://veronapharma.com/20230630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrna-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBCDELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>vrna:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>vrna:segment</measure>
    </unit>
    <unit id="loanadvance">
        <measure>vrna:loanAdvance</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001657312</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38067</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-12">GB</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-13">44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-14">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">283 4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">635875302</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">270727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">227827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">894000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">2499000</us-gaap:PrepaidExpenseCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">10150000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">9282000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">6060000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">3388000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">287831000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">242996000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">11000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">73000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">542000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">854000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">16098000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">16472000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">303929000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">259468000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">2493000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">2910000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">7467000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">13752000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">545000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">283000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">444000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">1409000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">10949000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">19029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">19857000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">9768000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">30000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">205000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">19887000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">9973000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">30836000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">29002000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-73" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-74" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-75"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-76"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">651659630</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-78" unitRef="shares">631338246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">635787302</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">606301054</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">41753000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">40526000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">596059000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">529187000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">975000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">1549000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">-359143000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">-333097000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">273093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">230466000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">303929000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">259468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">-2474000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">14982000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">10136000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-7" decimals="-3" id="f-98" unitRef="usd">32607000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">12439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">5526000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">22028000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-102" unitRef="usd">12966000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">9965000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">20508000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">32164000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">45573000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">-9965000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">-20508000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-32164000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">-45573000</us-gaap:OperatingIncomeLoss>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">-1934000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">5409000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">379000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-7" decimals="-3" id="f-114" unitRef="usd">6711000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">3402000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">165000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">6079000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-7" decimals="-3" id="f-118" unitRef="usd">180000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">740000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">91000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">1033000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">175000</us-gaap:InterestExpense>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">740000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-6" decimals="-3" id="f-124" unitRef="usd">-2662000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">1672000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">-3585000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">1468000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">2821000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">7097000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">3131000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">-8497000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-132" unitRef="usd">-17687000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-25067000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">-42442000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">310000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-136" unitRef="usd">79000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">161000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-140" unitRef="usd">-17766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">-25550000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-151" unitRef="shares">634469423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-152" unitRef="shares">634469423</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-153" unitRef="shares">484777837</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-154" unitRef="shares">484777837</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-155" unitRef="shares">627996124</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-156" unitRef="shares">627996124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-157" unitRef="shares">483226039</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-158" unitRef="shares">483226039</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="0" id="f-159" unitRef="shares">631338246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-160" unitRef="usd">40526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-161" unitRef="usd">529187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-162" unitRef="usd">-1549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-163" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-164" unitRef="usd">-333097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-165" unitRef="usd">230466000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-166" unitRef="usd">-16743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-167" unitRef="usd">-16743000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-15" decimals="0" id="f-168" unitRef="shares">20321384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">1227000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-170" unitRef="usd">55682000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">56909000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-17" decimals="-3" id="f-172" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">-270000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-174" unitRef="usd">1756000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-3" id="f-175" unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-176" unitRef="usd">1827000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-177" unitRef="usd">4290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-178" unitRef="usd">4290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="0" id="f-179" unitRef="shares">651659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-180" unitRef="usd">41753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-181" unitRef="usd">590915000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-182" unitRef="usd">-1208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-183" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-184" unitRef="usd">-350110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-185" unitRef="usd">276749000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-3" id="f-186" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-25" decimals="-3" id="f-188" unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-24" decimals="-3" id="f-189" unitRef="usd">-226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-26" decimals="-3" id="f-190" unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-191" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-193" unitRef="usd">5074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">5074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="0" id="f-195" unitRef="shares">651659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-196" unitRef="usd">41753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-197" unitRef="usd">596059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-198" unitRef="usd">-975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-199" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-200" unitRef="usd">-359143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-201" unitRef="usd">273093000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="0" id="f-202" unitRef="shares">489177550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-203" unitRef="usd">31855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-204" unitRef="usd">385070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-205" unitRef="usd">-603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-206" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-207" unitRef="usd">-263716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-208" unitRef="usd">148005000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-38" decimals="-3" id="f-209" unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-210" unitRef="usd">-24837000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-40" decimals="0" id="f-211" unitRef="shares">80696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-40" decimals="-3" id="f-212" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-213" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-214" unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-43" decimals="-3" id="f-215" unitRef="usd">186000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-38" decimals="-3" id="f-216" unitRef="usd">-186000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-44" decimals="0" id="f-217" unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-44" decimals="-3" id="f-218" unitRef="usd">-322000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-43" decimals="-3" id="f-219" unitRef="usd">322000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-39" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-45" decimals="-3" id="f-221" unitRef="usd">793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-39" decimals="-3" id="f-222" unitRef="usd">793000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-45" decimals="-3" id="f-223" unitRef="usd">-118000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-39" decimals="-3" id="f-224" unitRef="usd">-118000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-3" id="f-225" unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-3" id="f-226" unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="0" id="f-227" unitRef="shares">494058246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-228" unitRef="usd">32182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-229" unitRef="usd">388204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-230" unitRef="usd">-739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-231" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-232" unitRef="usd">-288739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-233" unitRef="usd">126307000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-234" unitRef="usd">-17766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">-17766000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-53" decimals="-3" id="f-236" unitRef="usd">148000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-52" decimals="-3" id="f-237" unitRef="usd">-148000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-54" decimals="-3" id="f-238" unitRef="usd">689000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">689000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-54" decimals="-3" id="f-240" unitRef="usd">25000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">25000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-54" decimals="-3" id="f-242" unitRef="usd">3053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">3053000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-55" decimals="0" id="f-244" unitRef="shares">494058246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-245" unitRef="usd">32182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-246" unitRef="usd">390543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-247" unitRef="usd">-591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-248" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-3" id="f-249" unitRef="usd">-306653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-250" unitRef="usd">110880000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">-25550000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">1672000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">-3256000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">88000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">44000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">51000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">63000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">9364000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">6801000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">314000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">328000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">-1605000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">694000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">380000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">6461000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">2016000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">143000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">-417000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-270" unitRef="usd">-680000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">-6285000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-272" unitRef="usd">6347000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">-305000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-274" unitRef="usd">-338000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">-939000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">164000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">-951000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">-113000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">-27093000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">-34029000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">-29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">56909000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">67000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">9996000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">1482000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">1904000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">68809000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">-1415000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">1184000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">-1397000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">42900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">-36870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-299" unitRef="usd">227827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="-3" id="f-300" unitRef="usd">148380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-301" unitRef="usd">270727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-60" decimals="-3" id="f-302" unitRef="usd">111510000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">1215000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">685000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">115000</us-gaap:InterestPaidNet>
    <vrna:OrganizationAndBusinessDescriptionTextBlock contextRef="c-1" id="f-307">Organization and description of business operations &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc (the &#x201c;Company&#x201d;) is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) are listed on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;) and trade under the symbol &#x201c;VRNA&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2023, the Company submitted a New Drug Application (&#x201c;NDA&#x201d;) to the U.S. Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#x201c;COPD&#x201d;) and is preparing for a potential commercial launch in 2024, subject to approval of the NDA. In conjunction with the submission, the Company paid a $3.2&#160;million Prescription Drug User Fee Act (&#x201c;PDUFA&#x201d;) application fee to the FDA. The Company has requested a small business waiver of this application fee and, as such, the amount has been recorded within Other current assets in the Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $359.1&#160;million as of June 30, 2023. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company expects that its cash and cash equivalents as of June 30, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the six months ended June 30, 2023, the Company sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the at-the-market offering program entered into in March 2021 (the &#x201c;2021 ATM Program&#x201d;). The shares sold were at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of approximately $56.9&#160;million after deducting issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In March 2023, through a registration statement on Form S-3, the Company replaced the 2021 ATM Program, with an open market sale agreement with Jefferies LLC (&#x201c;Jefferies&#x201d;) to sell its ordinary shares, in the form of ADSs, with aggregate gross proceeds of up to $200.0&#160;million, from time-to-time, through an &#x201c;at the market&#x201d; equity offering program under which Jefferies will act as sales agent (the &#x201c;2023 ATM Program&#x201d;). Jefferies is entitled to a commission at a rate of up to 3.0% of the gross proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine, if approved. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.&lt;/span&gt;&lt;/div&gt;</vrna:OrganizationAndBusinessDescriptionTextBlock>
    <vrna:NumberOfWhollyOwnedSubsidiaries
      contextRef="c-1"
      decimals="INF"
      id="f-308"
      unitRef="subsidiary">1</vrna:NumberOfWhollyOwnedSubsidiaries>
    <vrna:PaymentsForApplicationFees contextRef="c-61" decimals="-5" id="f-309" unitRef="usd">3200000</vrna:PaymentsForApplicationFees>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-310" unitRef="usd">-359100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-62" decimals="0" id="f-311" unitRef="shares">20321384</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-63" decimals="0" id="f-312" unitRef="shares">2540173</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-64"
      decimals="2"
      id="f-313"
      unitRef="usdPerShare">2.88</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-65"
      decimals="2"
      id="f-314"
      unitRef="usdPerShare">23.08</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-62" decimals="-5" id="f-315" unitRef="usd">56900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrna:SaleOfStockMaximumAggregateOfferingPrice contextRef="c-66" decimals="-5" id="f-316" unitRef="usd">200000000</vrna:SaleOfStockMaximumAggregateOfferingPrice>
    <vrna:SaleOfStockCommissionFeePercentage contextRef="c-66" decimals="3" id="f-317" unitRef="number">0.030</vrna:SaleOfStockCommissionFeePercentage>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-318">Basis of presentation and summary of significant accounting policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed on March 7, 2023 (the &#x201c;2022 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2022, was derived from audited consolidated financial statements included in the 2022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, pharmaceutical development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting standards and recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under this model, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. This update became effective for the Company on January 1, 2023 and the adoption of this update did not have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-319">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed on March 7, 2023 (the &#x201c;2022 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2022, was derived from audited consolidated financial statements included in the 2022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-320">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, pharmaceutical development.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-321"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-322"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-323">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently adopted accounting standards and recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under this model, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. This update became effective for the Company on January 1, 2023 and the adoption of this update did not have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-325">Equity interest &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Nuance Agreement&#x201d;) with Nuance Pharma Limited (&#x201c;Nuance Pharma&#x201d;) effective June 9, 2021 (the &#x201c;Effective Date&#x201d;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-67" decimals="-5" id="f-326" unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-67" decimals="-5" id="f-327" unitRef="usd">25000000</us-gaap:AccountsReceivableNetCurrent>
    <vrna:EquityInterestReceivable contextRef="c-67" decimals="-5" id="f-328" unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-329">Accrued expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-330">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">3609000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">12314000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">1377000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent contextRef="c-4" decimals="-3" id="f-334" unitRef="usd">1364000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-335" unitRef="usd">2481000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">74000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-337" unitRef="usd">7467000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-338" unitRef="usd">13752000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-339">Term loan&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On October 14, 2022 (the &#x201c;Effective Date&#x201d;), the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Oxford Finance Luxembourg S.&#xc0; R.L. (&#x201c;Oxford&#x201d;) for an aggregate amount of up to $150.0&#160;million (the &#x201c;Oxford Term Loan&#x201d;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $10.0&#160;million, which was funded on the Effective Date (the &#x201c;Oxford Term A Loan&#x201d;), and up to four additional term loan advances in an aggregate amount of $140.0&#160;million. The Oxford Term Loan has a maturity date of October 1, 2027. On March 24, 2023, the Company received $10.0&#160;million under the second term loan advance (the &#x201c;Oxford Term B Loan&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Oxford Term A Loan and Oxford Term B Loan (together, the &#x201c;Oxford Term Loan Advances&#x201d;) bear interest at a variable rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#x201c;Basic Rate&#x201d;) and shall not increase by more than 2.00% above the Basic Rate as of the funding date of each such term loan. For the six months ended June 30, 2023, the effective interest rate was approximately 11% per annum. There was no material difference between the carrying value and the estimated fair value of the Oxford Term Loan Advances outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-68" decimals="-5" id="f-340" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-69" decimals="-5" id="f-341" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <vrna:LineOfCreditFacilityNumberOfLoanAdvances
      contextRef="c-68"
      decimals="INF"
      id="f-342"
      unitRef="loanadvance">4</vrna:LineOfCreditFacilityNumberOfLoanAdvances>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-70" decimals="-5" id="f-343" unitRef="usd">140000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-71" decimals="-5" id="f-344" unitRef="usd">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-72" decimals="4" id="f-345" unitRef="number">0.0238</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-73" decimals="4" id="f-346" unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c-74" decimals="4" id="f-347" unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-75" decimals="2" id="f-348" unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-349">Share-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,276,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,050,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,306,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,930,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Restricted stock units activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows restricted stock unit (&#x201c;RSU&#x201d;) activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,305,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,237,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,680,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-76" decimals="-3" id="f-351" unitRef="usd">1123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-77" decimals="-3" id="f-352" unitRef="usd">1330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-78" decimals="-3" id="f-353" unitRef="usd">2226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-79" decimals="-3" id="f-354" unitRef="usd">2869000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-80" decimals="-3" id="f-355" unitRef="usd">3951000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-81" decimals="-3" id="f-356" unitRef="usd">1723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-82" decimals="-3" id="f-357" unitRef="usd">7138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-83" decimals="-3" id="f-358" unitRef="usd">3932000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">5074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-360" unitRef="usd">3053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">9364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-362" unitRef="usd">6801000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,276,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,050,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,306,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,824,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,930,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="0" id="f-364" unitRef="shares">19276496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-14" decimals="0" id="f-365" unitRef="shares">1320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-14" decimals="0" id="f-366" unitRef="shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-14" decimals="0" id="f-367" unitRef="shares">1050192</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-23" decimals="0" id="f-368" unitRef="shares">19306304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-5" decimals="0" id="f-369" unitRef="shares">2824000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-5" decimals="0" id="f-370" unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-5" decimals="0" id="f-371" unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="0" id="f-372" unitRef="shares">21930304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows restricted stock unit (&#x201c;RSU&#x201d;) activity, in ordinary shares, in the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,305,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,237,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,680,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-84" decimals="0" id="f-374" unitRef="shares">34542344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-85" decimals="0" id="f-375" unitRef="shares">4305120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-86" decimals="0" id="f-376" unitRef="shares">30237224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-87" decimals="0" id="f-377" unitRef="shares">3680224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-88" decimals="0" id="f-378" unitRef="shares">26557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-379">et loss per share &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Net loss per share is calculated on an ordinary share basis. The Company&#x2019;s ADSs that are listed on Nasdaq each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022 (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the three and six months ended June 30, 2023 and 2022, outstanding share options, RSUs and warrants over 48.5 million and 46.2&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <dei:EntityListingDepositoryReceiptRatio contextRef="c-3" decimals="0" id="f-380" unitRef="number">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-381">The following table shows the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022 (in thousands except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-382" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-383" unitRef="usd">-17766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">-25550000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-385" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-386" unitRef="shares">634469000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-387" unitRef="shares">634469000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-388" unitRef="shares">484778000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-389" unitRef="shares">484778000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-390" unitRef="shares">627996000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-391" unitRef="shares">627996000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-392" unitRef="shares">483226000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-393" unitRef="shares">483226000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-394"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-395"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-396"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-397"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-398"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-399"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-400"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-401"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-402" unitRef="shares">48500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-403" unitRef="shares">48500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-5" id="f-404" unitRef="shares">46200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-5" id="f-405" unitRef="shares">46200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-406">Commitments and contingenciesThe Company had previously accrued up to the maximum exposure of $6.9&#160;million related to a matter with a supplier and also had certain invoices in the amount of $1.5&#160;million in accounts payable to the same supplier. Both items were settled for $2.1&#160;million in the three months ended June 30, 2023 resulting in a reversal of $6.3&#160;million in Research and development costs in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-3" decimals="-5" id="f-407" unitRef="usd">6900000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-408" unitRef="usd">1500000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:LossContingencyLossInPeriod contextRef="c-5" decimals="-5" id="f-409" unitRef="usd">2100000</us-gaap:LossContingencyLossInPeriod>
    <vrna:LossContingencyAccrualReversalOfResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-410" unitRef="usd">6300000</vrna:LossContingencyAccrualReversalOfResearchAndDevelopmentCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#DD7%_H:EWLZ2OC[OKA!+GZ'**8NX,_\?',*R?E_HR]_>/238+A=DK@UGSO
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MK9;P7P[M].)*E$KD/*.:9>A6PP_TD59(K- 556OT'OI9H3'Z=OL6O7SQ"KU
MO$1?UZ)2M,S4^42#!N-IDN[?]Z9Y'QEX7XP^BE*O%7I79BP[;C\![6T Y#&
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M9R^CNG*NA:"/,?D[U%B<PZLW.A25>I;91#UA,9U/>+$ZG.@=RT&\&9M\G;-
MW4EGU9)Q7U%!]9J".EV*Z-54[;!24D!C@I?!UVH4^O\KX*2.35/K-JG2 Q#
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MN0IU!(Z?)R!K=18:E?,\:R26O^=L\?K5Y'1\_D)ZQ]OTCE]"WS10O]# _P5
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MO2$T2PKRE,2F<3MTB];+=(@TZ >JN].=Y73OEFYS-@^?.[U&.U<1EJ-,%VY
MMUH;NUMI*]W>Z1?=5?9DWOTAN%:^U#:0X15<Q\/O3K)NWC<?T37I8ENZB&LR
MO5;H&7LQ@'[E,'/]AP38_M-9_ -02P,$%     @ 5T0#5XI8N?.@ @  S 4
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;)U6WV_;. S^5PAO&%;
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M 1\<^'SI'.V-D*#[?YK^ 5!+ P04    " !71 -7/MITD(D'  "Y$P  &0
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M<8WK%@4^@/VEQ^S=OK" _FO=U6]02P,$%     @ 5T0#5[4-A8ZP @  T 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?53;;MLP#/T5PBN&%@CJ
M:Y,N2PPD;8=N0(&@[;:'80^*3<=&9<F3Y*;]^U&RXV5;FA==:)[#0]'D;"O5
MDRX1#;S47.BY5QK33'U?9R763)_+!@5]*:2JF:&KVOBZ4<AR!ZJY'P7!V*]9
M);QTYFPKE<YD:W@E<*5 MW7-U.L2N=S.O=#;&>ZK36FLP4]G#=O@ YJOS4K1
MS1]8\JI&H2LI0&$Q]Q;A=)E8?^?PK<*MWCN#S60MY9.]?,[G7F %(<?,6 9&
MVS->(>>6B&3\ZCF](:0%[I]W[)]<[I3+FFF\DOQ[E9MR[EUZD&/!6F[NY?86
M^WPN+%\FN78K;#O?./8@:[61=0\F!74ENIV]].^P![@,W@!$/2!RNKM 3N4U
M,RR=*;D%9;V)S1Y<J@Y-XBIAB_)@%'VM"&?219:I%G/ %RJS1@VGCVS-49_-
M?$/TULG/>JIE1Q6]036&.RE,J>%&Y)C_C?=)UJ MVFE;1D<)O[3B'.)@!%$0
MQ4?XXB'7V/'%;_"MV*O+#9C(P27.N(8?B[4VBOZ.GX=2[AB3PXRV8Z:Z81G.
M/6H)C>H9O?3]NW <?#RB-QGT)L?8TP?JP+SE"+* 79UN^CH=TGJ4[;#6_\J?
M2>HW;<A$04V)4$A.C5N)#9Q6@BRRU?1\^FP*5!YTY;G&#.LU*HC#KE9VB>"*
M%%09XV!41:M]=$F,BIKFF89!0ZUM*)XV&DX@'HV##[2'T2@.$U@I6:"VG4_(
M ON:;5"@(D,F52,5,]C#PU$\F=AU3$B4#3V90LYL%IU#-$HN0Y@D\"B-E?)O
MUB<P&27CB8T?CR87$1RJGK_7936JC9LE]L5:8;J&&ZS#N%IT7?K'O9MU=TQM
M*J&!8T'0X'QRX8'JYD=W,;)Q/;N6AB: .Y8T<E%9!_I>2&EV%QM@&.+I;U!+
M P04    " !71 -7Z;S-Z/X#   ]"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6R=5MMNXS80_15"NU@X@!I)U,67V ;L[/8&;!O$R?:AZ ,MC2TB
M$JDEZ3CY^PXI1W%21VWZ8),<SIR9X9RA.-U+=:=+ $,>ZDKHF5<:TTR"0.<E
MU$R?RP8$[FRDJIG!I=H&NE' "F=45P$-PRRH&1?>?.ID5VH^E3M3<0%7BNA=
M73/UN(1*[F=>Y#T)KOFV-%80S*<-V\(*S&USI7 5="@%KT%H+@51L)EYBVBR
MS*R^4_C&8:^/YL1FLI;RSBY^*69>: .""G)C$1@.]W )566!,(SO!TRO<VD-
MC^=/Z#^ZW#&7-=-P*:L_>&'*F3?R2 $;MJO,M=S_#(=\4HN7RTJ[?[)O=9.A
M1_*=-K(^&&,$-1?MR!X.YW!D, K?,* ' ^KB;AVY*#\SP^93)?=$66U$LQ.7
MJK/&X+BP15D9A;L<[<Q\53(%+J^"Y++&6FOFCFMPP]85Z+-I8-"-50[R ^2R
MA:1O0&;DJQ2FU.2+**!X:1]@>%V,]"G&)>T%_'4GSDD<^H2&-.[!B[N<8X<7
M]^7\P]+E?,4>D6*&+)1B8@MN_N=BK8U"OOQU*OD6.SF-;7MHHAN6P\S#)M&@
M[L&;?_H09>%%3^1)%WG2ASY?5)7,V_K(#6EKU^9Q>5R[+P]V#J>B[\4_'?U-
M"60CT?.>BRTQEA9$EW*OB<$=]B(D[8[V!)W68/8 MH\U,)67A(D"N^<>;X7&
M';I=8[-B1%N?;$& 8I43L@)ISVU!;/\BJC::#+A [W*G44.?3<A-J0!(W?(.
M+.\(L@8<:U;\X8T=RR?[1X]FUV\%^)%$?H1:=HSC$$?J4YJY<92-R>H_!!_[
MXS1"^R'B#/TH'EE)3,F--&CPD:1^.$QPC/TPM9[&?IS9=>:/PHCT$"CM")3V
M$JBES.^-J\G"WHC</)[B22_,>WGB6$%D\WP/HU>?8 VE*KC CT&KHIW,LJH!
MQ64Q(;_MZC6HCED'#$WP\Z(-'K#UM&05$SDR45N]SY"#LXDCOZUH-/;I,/.3
M<49^PB8WR "L( W], P)7NT;X%8VH(D3G6'[@,JYI? @PD*$?C2F9Z_<?'4<
M.?B(K8\XS/"7=#Z0%31Q/K =N;)HHQ,.Z$'V$OX512-D2>C0>SB0=1S(>CF
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MSQ^>R;\F=U)@I<D'D4/^=[QOM$R"PE'0+KP(^+D5,[((WI P"!=$0VEN$%[
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M(3D4=,/UK=A]@<Y/9/@RP97]DET;&P4.R39*BZH#HX**U>V?/G7KL ?P)R.
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MLA&2:AB7WM)'^ZK"Z?1 ^E!0/*(\ZI5'IY6#:#A@R>.H+Q\7&!WE#B:7_H'
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M#?UE;MPJ&LN_VV@.(6E"B@5 8C6:HX+FR#H.[\@SBW<Q6G*A(UGRA$*B&]-
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M,!^>N59:?/3&\S"YHL?2!@JCD,:C@ Y+2WIIR;^G">YY*LKD2$:0Q/$EI?1
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M)A#ATO+$O7S@9%L<^+X0SDE:W&X0C!&5!N+]BA!^>) $]>\>TW\!4$L#!!0
M   ( %=$ U=]D%]UQ0(  # (   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;*U6;6_3,!#^*U:8T";!DB9]@=%&ZEHF0$R:-@8?$!_<Y-I8<^Q@.^WV
M[SD[;4AIEFD37QJ_W//</7>VK^.-5'<Z S#D/N="3[S,F.+,]W6204[UJ2Q
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M&IR.L#2JZD_5Q,C"/?$+:;!AN&&&+1V4-<#]I91F-[$.ZC\)\1]02P,$%
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M!UXBX+P46IYZUK\L.M.-S=X*S5SK0YP[L=^=J)?/@Y;/LO;_ %!+ P04
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M5/OI7;-</R\?FRAA,N.LX=_*\1=02P,$%     @ 5T0#5R+@:-=[ 0  .A(
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 5T0#5]XY+G7O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M5T0#5YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !71 -7D/'K0^8%  "?'P  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M5T0#5RRR?'93!@  "1P  !@              ("!*@X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %=$ U<,3;JMF0(  *<&   8
M          " @;,4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !71 -7'(UUVI0%  !A&   &               @(&"%P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 5T0#5^?.KL?'#0  1J(
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M965T.2YX;6Q02P$"% ,4    " !71 -7BEBY\Z "  #,!0  &0
M    @('Y1P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M %=$ U=9;PHO8@0  $8*   9              " @=!*  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 5T0#5S??:67' P  '@D  !D
M             ("!:4\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !71 -7DQ;D6)L#  !L"   &0              @(%G4P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %=$ U<5M\GM^@(
M *L&   9              " @3E7  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 5T0#5S[:=)")!P  N1,  !D              ("!
M:EH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !71 -7
MM0V%CK "  #0!0  &0              @($J8@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( %=$ U?IO,WH_@,  #T*   9
M      " @1%E  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 5T0#5]H,";CX @  N 8  !D              ("!1FD  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !71 -7^VWWH=,$  #O&
M&0              @(%U;   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( %=$ U?7!N"(2@(  % %   9              " @7]Q  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 5T0#5V":1J5>
M @  704  !D              ("! '0  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !71 -7EK@BWJD"   2!P  &0
M@(&5=@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %=$
M U>K9FVAMP0  )T@   9              " @75Y  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 5T0#5_EKF^*4 P  >A   !D
M         ("!8WX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !71 -7VLPQ7/H"   V"0  &0              @($N@@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %=$ U>N8 0RI (   L'
M   9              " @5^%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 5T0#5R[ TBBP!    QD  !D              ("!.H@
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !71 -7?9!?
M=<4"   P"   &0              @($AC0  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( %=$ U=ILF?0- ,  $H2   -
M  "  1V0  !X;"]S='EL97,N>&UL4$L! A0#%     @ 5T0#5Y>*NQS
M$P(   L              ( !?),  %]R96QS+RYR96QS4$L! A0#%     @
M5T0#5S@,<:?L @  3Q,   \              ( !990  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( %=$ U<O ()43 $  &L1   :              "
M 7Z7  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %=$
M U<BX&C7>P$  #H2   3              "  0*9  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     D "0 LPD  *Z:      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>165</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and description of business operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</Role>
      <ShortName>Organization and description of business operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of presentation and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Equity Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterest</Role>
      <ShortName>Equity Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Term loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Termloan</Role>
      <ShortName>Term loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Sharebasedcompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Capitalization and net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Capitalizationandnetlosspershare</Role>
      <ShortName>Capitalization and net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitment and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Commitmentandcontingencies</Role>
      <ShortName>Commitment and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Accruedexpenses</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Sharebasedcompensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Capitalization and net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CapitalizationandnetlosspershareTables</Role>
      <ShortName>Capitalization and net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Capitalizationandnetlosspershare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Equity Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterestDetails</Role>
      <ShortName>Equity Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/EquityInterest</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/AccruedexpensesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Term loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TermloanDetails</Role>
      <ShortName>Term loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Termloan</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share based compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Share based compensation - Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails</Role>
      <ShortName>Share based compensation - Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Share based compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails</Role>
      <ShortName>Share based compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Capitalization and net loss per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails</Role>
      <ShortName>Capitalization and net loss per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vrna-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Commitment and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CommitmentandcontingenciesDetails</Role>
      <ShortName>Commitment and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Commitmentandcontingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 13 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. vrna-20230630.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="vrna-20230630.htm">vrna-20230630.htm</File>
    <File>exhibit311q223.htm</File>
    <File>exhibit312q223.htm</File>
    <File>exhibit321q223.htm</File>
    <File>exhibit322q223.htm</File>
    <File>vrna-20230630.xsd</File>
    <File>vrna-20230630_cal.xml</File>
    <File>vrna-20230630_def.xml</File>
    <File>vrna-20230630_lab.xml</File>
    <File>vrna-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vrna-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="345">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrna-20230630.htm": {
   "axisCustom": 1,
   "axisStandard": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 345,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 88,
   "dts": {
    "calculationLink": {
     "local": [
      "vrna-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrna-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vrna-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 251,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 17,
   "keyStandard": 148,
   "memberCustom": 9,
   "memberStandard": 11,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Accrued expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://veronapharma.com/role/Accruedexpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Term loan",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://veronapharma.com/role/Termloan",
     "shortName": "Term loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Share based compensation",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://veronapharma.com/role/Sharebasedcompensation",
     "shortName": "Share based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Capitalization and net loss per share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://veronapharma.com/role/Capitalizationandnetlosspershare",
     "shortName": "Capitalization and net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitment and contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://veronapharma.com/role/Commitmentandcontingencies",
     "shortName": "Commitment and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accrued expenses (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://veronapharma.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Share based compensation (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://veronapharma.com/role/SharebasedcompensationTables",
     "shortName": "Share based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Capitalization and net loss per share (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://veronapharma.com/role/CapitalizationandnetlosspershareTables",
     "shortName": "Capitalization and net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Basis of presentation and summary of significant accounting policies (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails",
     "shortName": "Basis of presentation and summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-67",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Equity Interest (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://veronapharma.com/role/EquityInterestDetails",
     "shortName": "Equity Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-67",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Accrued expenses (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://veronapharma.com/role/AccruedexpensesDetails",
     "shortName": "Accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-68",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Term loan (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://veronapharma.com/role/TermloanDetails",
     "shortName": "Term loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-68",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share based compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-23",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Share based compensation - Share Option Activity (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails",
     "shortName": "Share based compensation - Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-4",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-86",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Share based compensation - RSU Activity (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
     "shortName": "Share based compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-84",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityListingDepositoryReceiptRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Capitalization and net loss per share - Computation (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
     "shortName": "Capitalization and net loss per share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Commitment and contingencies (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://veronapharma.com/role/CommitmentandcontingenciesDetails",
     "shortName": "Commitment and contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentExpenseNetOfAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ResearchAndDevelopmentExpenseNetOfAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-32",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-38",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and description of business operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations",
     "shortName": "Organization and description of business operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of presentation and summary of significant accounting policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Equity Interest",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://veronapharma.com/role/EquityInterest",
     "shortName": "Equity Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 20,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio",
        "terseLabel": "Number of ordinary shares per ADS"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r213",
      "r239",
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r250",
      "r323",
      "r332",
      "r340",
      "r341",
      "r358",
      "r359",
      "r362",
      "r393",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r249",
      "r250",
      "r277",
      "r278",
      "r279",
      "r322",
      "r323",
      "r332",
      "r340",
      "r341",
      "r358",
      "r359",
      "r362",
      "r388",
      "r393",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r249",
      "r250",
      "r277",
      "r278",
      "r279",
      "r322",
      "r323",
      "r332",
      "r340",
      "r341",
      "r358",
      "r359",
      "r362",
      "r388",
      "r393",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r213",
      "r239",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Accruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r89",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CommitmentandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r114",
      "r329",
      "r337",
      "r338"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r26",
      "r29",
      "r79",
      "r321",
      "r333",
      "r334",
      "r371",
      "r372",
      "r373",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r379",
      "r380",
      "r381",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Common shares withheld for taxes on vested stock awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r76",
      "r77",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r37",
      "r44",
      "r81",
      "r232"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of redemption premium on debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r33",
      "r232",
      "r317",
      "r375"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r95",
      "r109",
      "r131",
      "r172",
      "r180",
      "r182",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r297",
      "r299",
      "r304",
      "r361",
      "r391",
      "r392",
      "r397"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r105",
      "r117",
      "r131",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r297",
      "r299",
      "r304",
      "r361",
      "r391",
      "r392",
      "r397"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r131",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r297",
      "r299",
      "r304",
      "r391",
      "r392",
      "r397"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation and summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r46",
      "r107",
      "r343"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r41",
      "r46",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r41",
      "r80"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r131",
      "r151",
      "r152",
      "r154",
      "r156",
      "r163",
      "r164",
      "r187",
      "r201",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r304",
      "r342",
      "r369",
      "r376",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r90",
      "r99"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r194",
      "r195",
      "r339",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Commitmentandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r379",
      "r380",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in pounds sterling per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary \u00a30.05 par value shares; 651,659,630 and 631,338,246 issued, and 635,787,302 and 606,301,054 outstanding, at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r245",
      "r246",
      "r248"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r130",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r226",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Termloan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r86",
      "r87",
      "r94",
      "r135",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r318",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r21",
      "r82",
      "r236",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Debt instrument interest rate increase"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r135",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r318",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r44",
      "r170"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r254",
      "r282",
      "r283",
      "r284",
      "r288",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Sharebasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r124",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r149",
      "r151",
      "r154",
      "r155",
      "r156",
      "r160",
      "r302",
      "r303",
      "r326",
      "r330",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Profit/(loss) per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r124",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r151",
      "r154",
      "r155",
      "r156",
      "r160",
      "r302",
      "r303",
      "r326",
      "r330",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Profit/(loss) per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Capitalization and net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Capitalizationandnetlosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "People related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r60",
      "r103",
      "r120",
      "r121",
      "r122",
      "r136",
      "r137",
      "r138",
      "r140",
      "r146",
      "r148",
      "r162",
      "r188",
      "r244",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r301",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign exchange (gain)/loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r108",
      "r191",
      "r325",
      "r352",
      "r361",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r84",
      "r91",
      "r102",
      "r172",
      "r179",
      "r181",
      "r183",
      "r327",
      "r351"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r132",
      "r147",
      "r148",
      "r171",
      "r289",
      "r292",
      "r293",
      "r331"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r83",
      "r93",
      "r123",
      "r169",
      "r316"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r126",
      "r128",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r35",
      "r37"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r18",
      "r131",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r298",
      "r299",
      "r300",
      "r304",
      "r350",
      "r391",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r88",
      "r97",
      "r361",
      "r378",
      "r385",
      "r396"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r106",
      "r131",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r298",
      "r299",
      "r300",
      "r304",
      "r361",
      "r391",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r5",
      "r6",
      "r131",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r298",
      "r299",
      "r300",
      "r304",
      "r391",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r16",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r196",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CommitmentandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.",
        "label": "Loss Contingency, Loss in Period",
        "terseLabel": "Loss in period"
       }
      }
     },
     "localname": "LossContingencyLossInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CommitmentandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r41",
      "r42",
      "r45"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r45",
      "r92",
      "r101",
      "r104",
      "r118",
      "r119",
      "r122",
      "r131",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r153",
      "r172",
      "r179",
      "r181",
      "r183",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r303",
      "r304",
      "r351",
      "r391"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting standards and recent accounting standards not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r172",
      "r179",
      "r181",
      "r183",
      "r351"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r116",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income/(expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of withholding taxes from share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "terseLabel": "Purchases of furniture and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r115",
      "r189",
      "r190",
      "r344"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from draw under the Oxford Term Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r40",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r74"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r54",
      "r98",
      "r328",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r67",
      "r96",
      "r336",
      "r338",
      "r361"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r103",
      "r136",
      "r137",
      "r138",
      "r140",
      "r146",
      "r148",
      "r188",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r301",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in sale (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Allocation of Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r251",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r111",
      "r112",
      "r113",
      "r163",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r358",
      "r369",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance outstanding",
        "periodStartLabel": "Beginning balance outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of share options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r131",
      "r151",
      "r152",
      "r154",
      "r156",
      "r163",
      "r164",
      "r187",
      "r201",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r237",
      "r238",
      "r240",
      "r241",
      "r243",
      "r304",
      "r342",
      "r369",
      "r376",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r60",
      "r103",
      "r120",
      "r121",
      "r122",
      "r136",
      "r137",
      "r138",
      "r140",
      "r146",
      "r148",
      "r162",
      "r188",
      "r244",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r301",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r162",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r60",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r60",
      "r67",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r60",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r60",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted share units vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r60",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r53",
      "r361",
      "r378",
      "r385",
      "r396"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r24",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r8",
      "r60",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Issuance of ordinary shares to treasury (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r24",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r60",
      "r67",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Issuance of ordinary shares to treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r165",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r150",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r149",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "label": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "terseLabel": "Professional fees and general corporate costs"
       }
      }
     },
     "localname": "AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AccruedResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Fees, Current",
        "label": "Accrued Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "label": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "negatedTerseLabel": "Equity settled share-based compensation reclassified as cash-settled"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Shares",
        "label": "American Depository Shares [Member]",
        "terseLabel": "American Depository Shares"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Sales Agreement",
        "label": "At-The-Market Sales Agreement [Member]",
        "terseLabel": "At-The-Market Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtInstrumentInterestRatePeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate, Period One",
        "label": "Debt Instrument Interest Rate, Period One [Member]",
        "terseLabel": "Debt Instrument Interest Rate, Period One"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePeriodOneMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_EquityInterestReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Interest Receivable",
        "label": "Equity Interest Receivable",
        "terseLabel": "Equity interest receivable"
       }
      }
     },
     "localname": "EquityInterestReceivable",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases",
        "label": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases",
        "terseLabel": "Foreign exchange gain/(loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Research And Development Tax Credit",
        "label": "Gain (Loss) From Research And Development Tax Credit",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "GainLossFromResearchAndDevelopmentTaxCredit",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "label": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "negatedTerseLabel": "Tax incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_InterestRatePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Period",
        "label": "Interest Rate Period [Axis]",
        "terseLabel": "Interest Rate Period [Axis]"
       }
      }
     },
     "localname": "InterestRatePeriodAxis",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_InterestRatePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Period [Domain]",
        "label": "Interest Rate Period [Domain]",
        "terseLabel": "Interest Rate Period [Domain]"
       }
      }
     },
     "localname": "InterestRatePeriodDomain",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_LineOfCreditFacilityNumberOfLoanAdvances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Loan Advances",
        "label": "Line of Credit Facility, Number of Loan Advances",
        "terseLabel": "Number of loan advances"
       }
      }
     },
     "localname": "LineOfCreditFacilityNumberOfLoanAdvances",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_LossContingencyAccrualReversalOfResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Accrual, Reversal Of Research And Development Costs",
        "label": "Loss Contingency Accrual, Reversal Of Research And Development Costs",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "LossContingencyAccrualReversalOfResearchAndDevelopmentCosts",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/CommitmentandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_NuanceShanghaiPharmaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuance (Shanghai) Pharma Co Ltd",
        "label": "Nuance (Shanghai) Pharma Co Ltd [Member]",
        "terseLabel": "Nuance (Shanghai) Pharma Co Ltd"
       }
      }
     },
     "localname": "NuanceShanghaiPharmaCoLtdMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholly Owned Subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_OrganizationAndBusinessDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Business Description",
        "label": "Organization And Business Description [Text Block]",
        "terseLabel": "Organization and description of business operations"
       }
      }
     },
     "localname": "OrganizationAndBusinessDescriptionTextBlock",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_OxfordTermALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term A Loan",
        "label": "Oxford Term A Loan [Member]",
        "terseLabel": "Oxford Term A Loan"
       }
      }
     },
     "localname": "OxfordTermALoanMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermBCDELoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term B, C, D, E Loan",
        "label": "Oxford Term B, C, D, E Loan [Member]",
        "terseLabel": "Oxford Term B, C, D, E Loan"
       }
      }
     },
     "localname": "OxfordTermBCDELoanMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term B Loan",
        "label": "Oxford Term B Loan [Member]",
        "terseLabel": "Oxford Term B Loan"
       }
      }
     },
     "localname": "OxfordTermBLoanMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan",
        "label": "Oxford Term Loan [Member]",
        "terseLabel": "Oxford Term Loan"
       }
      }
     },
     "localname": "OxfordTermLoanMember",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_PaymentsForApplicationFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Application Fees",
        "label": "Payments For Application Fees",
        "terseLabel": "Prescription drug user fee"
       }
      }
     },
     "localname": "PaymentsForApplicationFees",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ResearchAndDevelopmentExpenseNetOfAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Net Of Adjustments",
        "label": "Research And Development Expense, Net Of Adjustments",
        "terseLabel": "Research and development (Note 8)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseNetOfAdjustments",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SaleOfStockCommissionFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commission Fee Percentage",
        "label": "Sale of Stock, Commission Fee Percentage",
        "terseLabel": "Commission fee percentage"
       }
      }
     },
     "localname": "SaleOfStockCommissionFeePercentage",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_SaleOfStockMaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_TaxCreditAndIncomeTaxesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit And Income Taxes Receivable, Current",
        "label": "Tax Credit And Income Taxes Receivable, Current",
        "verboseLabel": "Tax incentive receivable"
       }
      }
     },
     "localname": "TaxCreditAndIncomeTaxesReceivableCurrent",
     "nsuri": "http://veronapharma.com/20230630",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r364": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r365": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r366": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r367": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r368": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001657312-23-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-23-000017-xbrl.zip
M4$L#!!0    ( %=$ U>!Z?VEK <  "DB   2    97AH:6)I=#,Q,7$R,C,N
M:'1MY5I;;]LX%G[?7\%-L)T$L!W+E]2QTP"9)@/D96:G*': ?5G0(F41D40-
M2=GQ_/K]#BG?[=9M"B2;S8-CB8>'Y_J=0]+7J<NSF^M4<G'SM^N_-YOL3L=5
M+@O'8B.YDX)55A43]H>0]I$UFS751UW.C9JDCG7:G2[[0YM'->5AW"F7R9L%
MG^N+\'Q]X1>Y'FLQO[D6:LJ4^'"B!KU!]/YJP#M"]'J#RXCW!^/>>)!(<7DU
MZ"3)?Z(33 5YF&/=/),?3G)5-%-)ZP_?=THWFBGATF'4;O_CQ-/=7">Z<%C,
M8'+X&GCL<'+RR35YIB;%T.MS$J8NAL<\?IP8716B&>M,F^%IXO]&]5/;_XUH
M2C/AN<KFPY\^JUQ:]JN<L4\ZY\5/#<L+V[32J"006O67A+"0VS_.:D7 )U.%
M7"@6=4B;^Z=4C95CW:@5;:JR;@YN)K"(T^4P&H#MFE(Q7"#-:]/JX_VGSP^_
M/'R\_?SPVZ_L*+W@YBTM?KRPO;W"/C38'9\JP?[-XY@;(;-,-=@_4V[RUEVK
MP6)IG$KFS*7<O3OM#T;'ZC,JN1!(KF8F$[?F.54(>&W8I#<OI'/48@\LY5/)
MC)PJ.0,.N%19]GO%#>(IF[-/LM3&,5VP7[3)6=1N_LYTPOXEC2YXL YG91;#
M(E=OP2*=%ON96]@!&N=S]ECH62;%1#:"84PPA]!8L=! 3S#DJF"\F+.J<*:2
M$!AXZJ$5=N(LQY-1/&,)C_'*,)TCSYT.=#L$A8REM=S,B23GCQ+KKO&T>"<@
M#);,/"YC#2*(E0$.@ZS =$@BI&&S5,4ILQ5]K.;/I)$U$U(@5S8#8!/VSY1+
MH: M9>P%)+XE1-,":DXQ3;#Q?-T,;\7GW2_X7+)$%; J.6AEQ08<#G(,F[5Q
M523($>X4^*@BSBH!GO#4FLD:\+*BO"IA:(H1BITL6P5!;7^[M33B3"ABW""*
M*@,!/*_A'K^<]?+$W*8LR?3,+L+"R(FRSG LQ.EED!M2-M:\:Q?"[$C[5AS<
M:['/&]9X=SKH1.]'MG9A#>V4!#I)%!Z]G1X8-])[!!96XTR2Y9A$&(PS95,B
M)[(< $ @0,]"V3C3ML(\@@:CL^":TNA8"KRV[ R>$!*N]>9^=QI=MD?W3W'*
MBXEDMTB]3U4&LJC+FU'_3)X'"C )7Z*^"._//6-%=;\($4++,<K4M< )CB31
M-M=EAY=, N=ZH00+D=K;X00**AS/J(2]J^T0Z?1:_1<+DC->FWKW\TY:-%FP
MFP?3K_NX03@?\\H>/X4 =RSAH'JE .&Z,F" -)TJZY,?5++P?*@-6<'&.O08
MF7'O\1K#5UYKU+!$@PH0 EFLSI3P&P!;C:T2BAM%"JA0:3P8%L2ILH3^/E^L
M+Q4>*K25$ BMOY]4HFM0<95Q0CBHY85851',"#5IO93BVU@2(4 (\Z5X!NB\
MMH@:'QE11R?Q3F =G_Y'QQ=B$ETPA0VWZ/$(]KA%R%%K0;&$UGCA5T2:XF.5
M*3>GBK-O68IR'P+>NR% -TC76A./KD^U0F5E2D27]14RCK417@#?I$QD@<*7
M(<@P(DN*7B)! Q8""5&N2B#:&PJE^& HW4]Y5OD,)CO+)$'[H*:PD-W3!BP+
MWQ&(%![W=P8^<C 1:&)#_S'6E3LLP3&8R9?4DIJKY.L-*!LOVC:?##)8 O)X
MQ],";\/YXC".!+ON^H<V)'6!]R-[@^ ;T(.JC8[CRI 7UJ!]#]=<6X?W="0!
M7C8&HS_#?I*='9B2()R0UUO4M>!H:Z7?2]$VJZB6<IT'J5)NEW60$,&'GQ0>
M*KT]:AB;8\?T*+-Z8[5%WWBVB9X9<IWWKZA?[G]OO^R/$L0B)ANK_"2X6(^+
M5:J29[^A_NWT-$O1./H:IXU=EAS_ BQS;+B=E%\ P[%&4:-QH2"?9W*&Z 'V
M6,(V_*?N:A'R\L]*07P?WE41^_W7^?]%'WR+G2KU#PH^ITT ;2=B)>&DNEPL
M^]&9Y(^$_Z%^^PK@.P]_ ++8M7Z3Z^O6,>S(]J0T%YAHY3*C#X9)W:]@"GR-
MMJ(1BI!%!;)5#D_!5EZ9&DGW[N_?6($YW*C>HHXD!JG4@ .DSWZXT)\<U;YN
M!!A6Q51G4TE87/!)?0!F:L"0>9GIN<3H+-4!)?A&),'S/Z10M0[Z8Q-MO;6_
MX($]=PJ[OAUKYW0^O/2SG.^4%R?OB"MIZ-0]XZ65P\67$;"QS/A\J KO!3]I
MM,F.!)L2P*(4UJ?[7LXP7-^!7%VU.E&?KD$<Y'1BL7!]0]+R-R073NR.=2];
MG7[WX'"[%1T<^Q+;RU;4[OQPKOU>J]OK'\7VPALB& /FMB4O/IQT3[;</^R4
M3RS:O#NAB-BV>##V"Z0C*7N'S/+UA-U6DPI%L]OP]V_+>*QM\7PU@4XOI.//
M\\V*^5TJA5NO5^6[=Z<] );_K#OTPW=*&\H?&;]MLL')408[@K3&*5^D2MB*
M#H/8PDC_6X9_U7;^7O39?X/]TI>]^YN(CZF2";M_DG%%NW_V6[TS.%A%7X-&
M?JFA<A C/J91JL^6T'+(I:+U%NA\ZR<(RV"[\%5^CP'6?]I0:NOO=X;A]'8J
M=W[LL,I9WR:T5U/X&(E;N=TI7_E]1/T9?JIQX7\B\E]02P,$%     @ 5T0#
M5[C)V,>J!P  B"(  !(   !E>&AI8FET,S$R<3(R,RYH=&WE6MMRXS82?=^O
MP-JU$[M*DG6/+7E<Y<REU@^;;*:F,H];( &**),$ X"2E:_?TP!UESR:<2KV
M>OT@BV2CT9>#TPU"UZG+LYOK5')Q\[?KOS>;[+V.JUP6CL5&<B<%JZPJ)NR+
MD/:>-9NUU#M=SHV:I(YUV]T>^Z+-O9KR\-PIE\F;A9[KBW!]?>$GN8ZTF-]<
M"S5E2KP]49V.&$9\>!7SX65?1OVK >?]?B^*>U$[DKW.?SHG& KQ,,:Z>2;?
MGN2J:*:2YA_]V"W=>*:$2T>==OL?)U[NYCK1A<-D!H/#UZ!CJ>F@Q-HL3CZX
M)L_4I!AY7T_"H,7CB,?W$Z.K0C1CG6DS.DW\W[B^:ON_,0UI)CQ7V7STPV>5
M2\M^EC/V2>>\^*%A>6&;5AJ5!$&K_I!P!#[YRUGM)/1DJI +ISM=\O3#0ZHB
MY5BOT^H>="+G9H)H.5V..I=0N^94C/1(\]*\>O?AT^>[CW?O;C_?_?(S.\HO
M0&#+BS_?V/Y>8^\:[%_<W+,O+?9/GA8-%DOC5#)G+N7NS>G@<GRL ^.2"X&5
MULQDXD:]X2)5JA!(TZA)R7LF)SLM=L=2/I7,R*F2,Y""2Y5EOU;< $#9G'V2
MI3:.Z8)]U"9GG7;S5Z83]ILTNN#LWRDW.6=E%B,B5Z\A(MT6^XE;Q $>YW-V
M7^A9)L5$-D)@3 B'T)BQT*!2*.2J8+R8LZIPII(P&.3J>19QXBS'E5$\8PF/
M<<LPG6-A.QWD=@0*&4MKN9F32,[O)>9=TVEQ3\ 83)EYDL8<)! K U*&6('A
ML$1(PV:IBE-F*_I8C9])(VLEY$"N; ;VID(P4RZ%@[:4L3>0])8P30NX.<4P
MP:+Y>AA>2\Y[C^1<LD05B"HE:!7%!A(.<3PV:\]5D6"-<*>@1Q5Q5@GH1*;6
M0M9 EA6MJQ*!)HP0=K)L!8(Z_G9K:N!,*%+<((DJ@P RKY$>/YWU]L3<IBS)
M],PN8&'D1%EG.";B=#/8#2L;:]FU"V-VK'TM">ZWV.>-:+PYO>QV?AS;.H4U
MM=,BT$FB<.GC=,>XD3XCB+"*,DF18Q(PB#)E4Q(GL1P$0"1 UT+9.-.VPCBB
M!J.SD)K2Z%@*W+;L#)D0$JGUX7YSVAFVQQ\>XI07$\ENL?0^51G$.CW>[ S.
MY'F0@)+PI3,0X?ZY5ZRHT!<!(30=HY6Z!IR02#)M<UYV>,HD:*XG2C 1N;T-
M)TA0X7A")>Q?;4.DVV\-G@TD9[P.]>[G>VG152%NGDR_GN,&\7S,*WO\$"+<
M2")!]4R!PG5EH #+=*JL7_R0DH770VW(BC;6J<?(C/N,UQR^REJCIB5ZJ$ A
ML,7J3 F_&[!59)50W"AR0(5*X\FP($V5)?;WZ\7Z4N&I0EL)@[ /\(-*= TJ
MKC).# >WO!&K*H(1H2:MEU)\BR0)@H0P7HHGD,Y+0U1T)**.7L0[P#I^^1^-
M+V!RJ@3!AEOT>$1[W )RU%H0EK@1B[P":8I'*E-N3A5GW[2$<@\!G]T T W1
MM=;$L^M#[5!9F1+HLKY"QK$VPAO@FY2)+%#X,H ,3V1)Z"41-& !2$"Y*L%H
MKPA*\4$H?9CRK/(KF.(LDP3M@YHB0G9/&[ L?$<P4KC<WQEXY& @V,2&_B/2
ME3MLP3&<R9?2DIJKY.L-*(L6;9M?##)$ O;XQ-,$KR/YXC"/A+CNYH<V)'6!
M]T_V@N ;V(.JC8[CRE 6UJA]C]9<6X?[] X"NFP,1;^'_20[.S D 9RPKK>D
M:\/1UDJ_EZ)M5E$M[3H/5J7<+NL@,8*'GQ2>*GT\:AJ;8\=T+[-Z8[4EWWAR
MB)X(N1?5+P^^MU_VKQ+$ I.-U?HDNEC'Q6JI4F:_H?[M]#1+TSCZ&J>-798<
M?P,J<VRXG92/D&&D4=3HN5"PSRLY WK /9:X#?^INUI 7OY>*9COX5T5L=]_
MG?]?],&WV*E2_Z"0<]H$T'8B5A))JLO%LA^=27Y/_!_JMZ\ OO/P+T 6N]9O
M2GW=.H8=V9XES04&6KE<T0=A4O<K&()<HZUHA")D48%LE2-3B)5WIF;2O?O[
M5U9@#C>JMZ@CB<%2:B !TJ]^I-"_.:ISW0@TK(JISJ:2N+C@D_H%F*D)0^9E
MIN<23V>I#BS!-Y"$S/\IA:IU,!\;\0_1?B0#CQ\?U+F-M',Z'PW]*.<[Y<6K
M=N!*&GK-GO'2RM'BRQC<6&9\/E*%SX(?--Y41X9-B6!1"NO7^=[.\+@^$+FZ
M:O4N.W0FXF"G$XN)Z^.2EC\NN7!B]UEWV+KL#@\^;K<Z!Y\]IK;?Z@X.C_Q>
MK<-!:]CM':7VP@<B! /AMB4OWI[T3K;2/^J6#ZRS>5A"B-B.> CV,RS' 1QZ
MCY7EZPF[K285BF:OX0_CEGBL8_%T-\%.S^3C3_/-BOE=+H5CKA>5NS>G?1"6
M_PP$NGZ(M.'MD8!MD],G1T7H"-&:F'Q5*A$<>OO#%E'YWXKTRPKL]_++_D/I
MYSZ_W=\FO$N53-C'9=7]I>[]SQ;A_ZNM]5.-E$/0XB/LKU\,T5';TH=Z__)<
M'CQJ[_G6+QR6X+[P?<.>QF3]EQ.EMO[$:!3>!T_ESF\I5J3@&X_V:@B/P R5
MVQWRE9]?U)_AER 7_A<H_P502P,$%     @ 5T0#5V+(".'+!   GQ,  !(
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M'?#HDB$^B=I779 =%LJ/;PYYK0FV]6.M7U=:M4Z?. ']X<O"@S(\-Q%+W^S
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M@B+6=U>_/M]DAY)6+BBASJVK\H%0>NV-0-X^(^%,CP?Z$;8UOY0)0Q)Z_CJ
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MG;]2(CB _<-/*WI_)KABC2JNYS%UYP+BZ'= UST-'_HOY",K%^K@N(HM23Z
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MLU*2V0%1E#5DEJ:D9JVCI\NZ.1F5FXRX4N%HXFBJVA5Z/KH?2R)$HU2ICSR
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MCE0@^TW^^EFP ]!^IN>//)]Q+(.W-[1-VXFZR.-W?W69%OQO4)SP64-(OV)
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M]([3F&*<4DR3@(,SCV_^]"3J:D!BA,_=D(.^9([VP_3B+SE@LH4$4\E6&)A
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M(+UN.O,K7CD2H#5?SWTL  33BLM!#W*]BFT"K<*N;%]]#F2HO1O-9^T;I)U
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M(VY?JO<FW;8!<EC8/3 [P_Z.Y9O60'U\96-O4$/UL* Z-*WA _T(.R:,]CL
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MAD.%,2.FN$7988R%BSWO01V!JU-4JGSL,0[O/>?#02<E;6D,^((GA'I,D'4
M7O V&G2!]I5:VW)"H% FGBJ<[HB<*39H/A&#"U<+3R)4A"\)%]$5XCC(8--
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MX%>2]XN-KG8WTK:NW=OWMG5P@,XQ/ &K(M[%Z10>?O=^[VBYAV69$V_DK3R
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M_$.]\COC@.\O=L"_'87N'?R8)%/_P_\'4$L#!!0    ( %=$ U?!1JB.N@D
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MPD_6"3?J-+-YA8;Y5*5^EE.*EEI1IK9&$9"L.==,$3!#E>5T3<K*TNDZ2PD
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MK8J/KD!(IDY_Y@(^9P;H*5C#N@.0OK:*\([R[;U>NTM&M T>!A;]H\P\UZV
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M@A[L4/>="*4W4-A "\4E9W6.KAY3K>LQU8D">8T(V2O%!%-*L]:.ZAL+Q>\
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MB=JEO* M9(;1RYKQR>IZ_1$I6OO]I_\'4$L#!!0    ( %=$ U> 1<S6-Q@
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M\YE)>\T#M03)"+:3QTB0U8PB9XU07(!KD]9;*7[7W3<_F9<1?%52:J5KEM>
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MRZ"%%/;8WO/YU_E'KKG\_LO_ 5!+ P04    " !71 -7>C<S;*D@ @#JR0(
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M1K>D3YFJM[&1).QH>S2$KT!?:C+5T=WCT^445C\V'5!TJ";NY0! :<#Z["+
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M\QF<W#L_?13=*UQG?.4PKUK+;ET,;'D$6AQYFMINQ:N#W =K?9,3FCP7=0K
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M3 W X688UR,<!<HM/E"N9JKA.F_J!5))L7);:T[C.N;L/7?CVUX(E%JY"^&
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M@9'<&G6;-BM&-^^8HDS1%8<3N_?OV".&L&0+;I<"KIXHNWTM(<$L1Q5"8L$
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M7BOJ)V'G2AQ\$=B&*BU<2@A<] &["?LY8!KG9^;OO#]UG21"W=YL6$*HM$I
M,-8D<_]N>Y<5_'5-7&N8^=)?UY%7;T&-G?;]RNCK-UM3JG@(G?\.?&.@9Q%%
ME,FIV/Z]09V#7X_+QVF'>D.9^H"Y1R*A.C\2=_N9J92CUCA5,GH<L^2[/\%T
MZR9M\0NY7_6]6?H;S4UEWJB'1JE_T%T</D@@RVX$\P\[@Z$8X@"'2?S C^8$
M])WP\*TKRC'\3$&J51+L$)9@5D=AHER %2?<J>.>9LU)U-$5X^_?>E_2C./;
M6*DV<7KEI@1#VU9D&-$T;LPKQ13RCN<@<G#<GOCY8XC95[]*H1I0O&*_W2ZV
MQ]\^:L7U60=:3Z_VZ6^9-)[U\=#DAQMB*C<<?,\!#-&)7=\U"^GL/AU7#4;J
M&CWR=6FK:D!7O#GUC0N^36B"QAOBT-'-D'S'*>K^.O)\_8?5+.EC*V>-U=[U
MW*EP578R#WS*<ARL7TE0ZADQ0[AL- ER&)4:2GQV3496K_HC JY?]%R'L/T%
ML6OBK=JV/;&0&N6C(LB1V3G ]@%J.A=L$7IV?$E[(+EA%Q: 620)@G CK2(4
MNMI$E"<:$/E TD3)_GVI]T?8_I,?"?8+%:17%%]JPA61.PS. 1M&?ZFF9@;*
M B&XKU7E<&)W41>3&?^'UUQ>1E%W+\L!HNE?Q(7F$"K==*%QK8IC E/7NHPL
MZ6L:K>0&.\3O2PI)Y3SO';6YF 0G13_TW1%8HQ#V#-0^TH6HC_J0O'L27H6-
M>P?%V7=]\&IZ(=XJ'AF)T4J0C-J)N?K<AL87_.12[E4XNLO?-QD:2N87+Y\:
MF_WX2=[@AWHL//[3KSZ2!$"8.DDE H?BE &QH;$06EWY!-)OR4!MKLT4RO"[
M4-/E@W)R?]8L&GCDI)-@-=\(9LNZ8+\OA(_=P4J*V VR6^J5T9MUF/$2[M36
MZ!1_0T@B8E\Z4);"VG)FSP$:IH#-&@@] 0LE>DRV\B.<_2:3V;Z? VS47([\
MDN3Z,H1][I_HM \8$I2Q#-K=K?1OX;&=L$:+E3K%Z-YK]VXO[3P!+(6V]:A5
MGC8GC9%%$#//UF:Y91:Y7IR,4.2;1>>G3CQW\J2:*C>%2QF7;60VLL=CE#[#
MJF S<69FOVQ>@.O;^6QV7JI1WV'45@\2'1YG"I%VY7^CLVWY-+^*="NWQJBL
M3'Y/9N^*:3R=FX;WK< >OB57@[]LVZQ4721K/&,1QBKB=/!'WMQ9)GFV=__K
M_L31;HX,1/0"\%?7&U%?HOHZF0FQPWL.V+2:7@@^R]\["?B1]"G &$14.P?\
MI,4#SYH0FX\,Q\X! _?. ?40\D@>4)S@NTQ1(XLLS0)VC4$3K6G?HO46F2QF
M!),]A-__-KEQ79U-+@S*.52D-.,;!WZUE!N391P%#B@V@S4&-[6(R3JX9,Z/
M&I)I-$_\>GD0<,\I#H3]T,D-%;YS #+W[';FCU99C^7<J'*%5\LP=V @QZ,X
MP&'I2NL=V#[!!F.'*IU!O0,;?57(]M9.B9F(KI=@\*[M"'0>$YH@TQ'29@ O
M)J==[RHNWV8W.+V11QL,)/@#&4C"PQ6?$\20<B5^[O,SNJJ>Z7,)D:<BE3,-
M5E%<-8J+'8N,EK.-]8J!4BJ=;:FL LGM;^.VBJE[40YZ);O-$ PE]<X^'$%T
M:)1KP.3&^K13>R +(@B@_R%,5"E(L8-.5"23&P:?%,E7"XG+!P#;C%/)PR&;
M(W#IK@B0J/:4=9H1M1)KRC3D>.^PREK[!;/%]7L4H'ESY3#OLKE9IR],O+8?
M)B9](TGG]^M[J6' :K85R(^Y-,?)8'%<F<Z^1M[VFTXJFT_%NM=)(\D3B0%T
MC6AN< (S*TL_&@ TL%0F0DK&S7I:;ZEJUM56#@@U"%"]E9;31NY)$9Y<2J:A
M&'(P4/T<4*4$.KO&ZX6Z+IL(T2+H+;./KR9>FDBH^R; _$$H]6H>=<//H6\7
MCZH4H;24('U!U"5L@7;./#7WQ<L7^T>J@@='[:[T7%]:,?8K(/'@5I.J+Y>5
M66PM"+;6W0]S\?D[=Z)=31?2</UZKT(WP S'^-&W()!SY(\WJ\.N]2CZ [>W
M^O-/17/VH,B7_^.7ZA;A__(E?.KC_\1(E6^1>V:?CU6*N6%T=UQM'+[&]FB4
MT3,AKNXG3V^MK0UIXD$1NU\=41B>B=7:B.J?S\7@?XF_UO%5%FD/HH33C*[$
M%'YXOP10S-H'39/EQOGQT7$74B\W5 Z(74QP4^U& GO4(=2J?.V6&LN+,0NW
MAEME<QD<ZMS*Q!<2*FR*(C0U&QT1DS]OR5^\4I'C,5;T='MB!77@<PXX%D/L
M. &J [X$6O_XEFY4AX_*"/"/7>-E=7SX38I:B-U\3R5<8:BXL@RSF%A!0BSU
MN;A>"1X0E=;P='[\2%IRP9S\((#90M./H\U7Q^L<P*U?+_2%D+F3<1!Q]<)*
MTKR4*K?TYCF M5G;0Z:OTG&!H9;Q 3MNNI"TJK;4VZ]^P1_C;PBD)R"[LX!=
MA$!:[&R\Q9/%F=K!CZ6SG2L?ZL)>6-#\8F1+YI5:!-_ZA*?N(8-?[*GP.'"9
M<]W3&5$KV1[3*7OS?"DC2:J>/N'U.0 <VH\BW8+@1H,O4?+"-A$X1)1=GZ:
M8/-.4V"L=%/_^OV_>=1',2/-.HV*3BSPJN!DN1+GS%/HD9?-G[V:1+*/K_R-
M).!Q]4P+J-.2$]_ZKD)H*(8"F*Z_(UY.6OW^-NLJZ.[[N1==Y+^&<!@Z$59$
MG$55H([\#[, !_.@;L7N1?0B$\$UH&5&/_,#/<[L1$=.R?GGW&7L<?+%Y:^$
M4.PG/<T)+Q0=0?T7W3F 99L[B[7>^F9M;/#?49ML=W>EI=.7&'@ ^7%^=^[1
M)>0Y8,9P"/X1.N4-G?E040-BHO@SQ,>+[>Y\;9J%+?6;4)[0GS^'+!D WKY\
M?(26HEFYS_;81'FC1LW%LPR5E)2.=>(70R5R!':A,3FZ528:G<,4;9PT7R'!
M-K.P.]'8?B]H]4R-K\M8Z1QP!=JU=RJ:>^)BAL ;5N!FVPS@-(_&EYHF'U=Y
ME%BU_!T[>Z\J_PV H68>MT_^%0(FJA'"\<"N8&F\5>3?ZTLY9LK6RX(3DC>>
M7O[D_)W-L /PVC,\Q \K+* P@K_<@*?!&)C"@H6G=@(-,=,2+-Q_'#=ALGFN
MU)5#S52'@_X>V?&02Y 5.T+&O\T90^2HB<]$=1'(A695G8OASEK:T+_OBZDU
MEC,SEAD,.HPI@\7KC.SP?VL(J+\4X7OS$-P<N8"^W?8J]>S/424'AB.2Y.V+
M6U1M&27?1-AO)D2F/R9WA5G$"3I7O4=[# *5?UAFE*0%,RZPO'D<=B),;AFP
M#62@4 5A#.J4PO%/93>H<IG!MA6;9*%A\(VEP[KD%U.F6AR^3J9*#OD6_;/:
M"\Z7VS;1+;H%E QB^:Y\1A^!_<CKT]:K,N7F45#XX^+>:LWKU1;I;C-"*&Y?
MDBN>;E99RP5D/IK]\U5QF_SUGUOES:X&H>B_O>!?\'- C\J%29D=^>7(Q(R%
M3\7FXA6M35_32@65+U;G1"RE)U"%)PS3E(_\OSO(_DLS3H,7Z>!STO'MX%>8
MW*O)3*9R26(/$0Z=L%I21]?JR9(-,KAVV^L)S4>*N*%0ZE@0V;QND:3OR[YO
MY:3"K8VJ)EXZ[*ZTK3G(M+JEWOP5W_D2G]KM,*+*P]'NQN"TP$(P*]KDXZ\E
M"I'N/1K56!/=81!@_I6FR+Q0TRH(OR/)!Y?8UEVXT?Q,N+IAX^4G/Z.A)XIA
MV@JW&AM%J/M5+L/UNEI9<4<UK5)($V^ZLZ>[24*ZX+9?#8&?^5^'HZV<&H(P
M+M9N,P*/\6"?#R-+PUFC>KFR"N_Z4^MV!G<3[O<H;P]OY%UHGC7$)=5Z$[4V
M<NZ$C<LEP_);RJ?XG,*^VSE+S.U"@ORHV39E*$/<4F&=)*GA#QY/R2I!)#MG
M+L4'16G<D<]]<PZ []"XMRFWK4DEU6ZR/E7E\\:GM\\@8[W$)9_B"D0E8V24
MU97ZA"1*ZE^[FE<#O(Q6S@&7;ZO<A</,\>]"O+;UN:$'DN^>(!LRY[]J2A73
M^/;KT'#^\=NQ3-0$L&%!/*ULVRJW4V6'+MZL*Q%J^(ZJ.S""U+;IV*[&F)=0
MEZQ0G8U8#FD"[ AO?KE(=S0:)@Y?"# 3>95RNY>^F&I]2W30'L<1UTRWW'3F
MB0F?MG \S<[QW@T/7),Y4&I^K& P%1ZBW$-1AR+4 ]Q=(/;:F. ^^Z5/TIT_
M[K:WCLN^;GQP>%,ARG,S1_1+<J?_)V2GT@[CGF&NZ82$6"5SY:Z.@=AW47<:
MS2=F !^ L8$F (X*K6H5ADNV*[I%HS#&0<@_4M^#\LDL= ['J_'V;@K;6[!:
MW&)LLUO)]M-9>#3F^(@W7I2CA3P3MOZ*.K3Z\F,HW\3TR']L0..Y]6-Y*(;=
M=&"B+A4W1GS\2WZ68?WHL%F%,N4!-O15PU-4N-;99=_.?X>$S@%7IXAZWGUS
M?N> V<GALZ5\[N#_."=T7"I"E:+TTXU[ )0A("+)MS3+>)^3U^,Y6/M+]S*4
MWLE4O"N1U32R/'/G)OW;N0)7T*.UFN(\X$W<2BX;F"UOAF +YBW:KC;)"YM]
M'F^HY[6/GI?D9N@*#>U1#):!0]LMY6L)O\'&RYLN52SK6@Z%F<.1<3,:_+,7
M;BOU7I6N3](%GY[NL%*MYRCCZJHK2(]PERN^FOI-FBH/]"WTK7TY>;C--Q:F
MYKRC3%6E\24.<# 4Q<<^";Y?"5_ FM00P::53;+S'_V*R<Z/^C4""[!5&N$[
MS\%J2_^.F]@O"RTF!O.VPXK/ 8Y=U5M9LOT+T)R^CI_<N6_E:! &4V#_#%:J
M%4N!415!DLZPFYBLB\IBA^FKT#Z3V86*@8F#2"6!>R', N()QVB:,%@5P?"S
M$Q\7P>J+(]<XR+ZU-C+3(;SLC]!O[!T=,//PE 7%'5=,CS*P%G383^OQ)'G,
MC65NT8H;SCZ)#[DM*EI,<G.%$W,^G>(MFS0!?DC2K<5KJ(W4<\!JG\LYH&O*
MK+2S&&8%W'N5AOXSDW'T[J9L;G;5ZB,\\^K>$H]4SVYTA2O%YM$=%<"GN*F.
MG6LZDQ7D@2 8G=B(F_',HP2/#$&^*QM.DG$J- @>./3G6"'[S$1$F>]7"WO'
M.-O[U,JJRLI)0*<=D3S@?0((X^+9 0&N5.,UO\\L#B!D.[6^"RS)#3,^21VD
MW8964TP!W&$N)N3H/7(XV-!SY!W*RNY;TYKU6??5!&/Y#C>\GE!9N@$CO O.
M\EW!SR?#B5SZU\W$A[)RMWTE^Y!*C8SUZ!9_35:JM7VX@=DDRN$*2;ML^L24
M/?;5JF.2K=9!D<=!Z_";>OK.%)6M5,O4?_\\!UP'WRC?GFQD1V*X;1NF:AC4
M)%RP]\J#7[].W&R(X36$*H?R4K@,1[-4!;RILY4O^D'U05'ME'B5A(#C4W!]
MQFOZ-UW489VAZ9N6\113+$-X6J_!@D4:%*="L<8MS:'.AWI061OB<Z>MC6GK
MR\^_K LK&*(?'FV)7/B:ZB*4$V_C(G<Q91;-O;3R6H3FQ/@]HH-F>2@Z1Z!U
MG'P]*(ZH/6XK;>' \=U/_3X0KWY&,XREILZF]Y^@=#VYDF0VN2179\DX!I82
MP$U-G99:1/!.VR2\":+"*L-\B)U<6:2;$V"%F;>GDV4>A?.J$KOO1:$RQ80C
MP[G?U-]#E(PIS@-?#Z^%QBZPX%P_Y%&(1@71ZC<_T\DY )<R*_PAB>CN<9+U
MIUEJV8IK*ZNM#B\<@OCFW%SG5H=P[O0\8(RO!H!/IVPT :S3=&+.-A9_J.XT
M]$"_.HX_H1DZ9<_%JXRAC5LE\)*=X95;HW9*-V=VRI^::)[UCJVM9[L.^JD4
MY"S!9Y<]7N5&P'F'2(+_TA3%?@ CW_^RW#J9:#@A;DG4;JZ)*6W&@1^:Y8D5
MT).]J [. >U-4! \ $/A:X2'2@AF1__H[+$-I/&%^27O#V->]^1_45^Z&+Z(
ME)T!TL$[ET%Q?S]!T3-!E9%?' [BRX*XN%,]!0^2&T<52?5\"UB>M<;<R 76
M%IQVIXMHYTQYW8'%]$FKS:RTC'W@(/92B/)UGVT+%X"[%5>@;!D<B7']7  /
MGMKQ/="ETP:^+ZD7BX.*J6X _7?^8!V<7R:I1>E,F 2$&E R3P!V[\(V!UEP
MK-EV"=8K#M8NTGKIL!NZ[_92,%<</U;2?KQU]THI69" 1-#^J*-HCT+S;S.R
MW!76]S]KG.V)7Z:8I>5>'&"%S ?G@E!O2*O)SCIQ%9)V?(L7%=IS[+94_]"\
M.E3>!F%I(KQSF1RY'E=@KJ1!F1WD-WU?EV]]44OAO==%SW/[/C@2[?_OJ'\B
MP0 CFDP3J/+CVSB:I"_!NWMX>>YZS3Y/G<Y2RMT&7I])1)<;'8SK.!%,BR@T
M]3N:>?S5O@4AR_$+FIXM=:EU<^GUU&<**B"[W"ZJ82EI<RA?[WYMMN*0XYO\
M6YSO=I%;:D>W&F#B;EC>VCA'8Q7@J&O5T\#JBKKB,M??V !UFO=!CZ7^\HJ.
M4Q"=!V??Z7:-@, ZYPA,[BX:Q6WKVC:-3X\\GZL)/W;D\[UT-9_')FE>]"LA
M=8E[CV7!4>4&KO:O/R+62Y=N1N^NRO/>X+]N2>Y^I-^^O7L.>4 9*#O)6'/_
M%L'>7JPSW)NOA:4#6JQ.9X.O'.K8)R2Y@/KQD:VY+L&CU29>Q_8/DA/S,K?F
M/9,4C;HIS.H#_$=[L. HF3^9EP0FBAU/,=$%0?4:$>*23"]%18_<+R1Y'&O7
MJWRD &E0_R);H"W+YE"!&9Q]H)?#N*Q8:+Y/V(.Q/4+X*U2@6+8"#VKS;15^
MIS<%E@[.<J/TETN/.U9-JK?\[D@K).)TZ?CZ6E,IA3*AXU3$FV^-D=G6/O).
MRB6J;C_]Z.YQW/SY *O\(^LWP6_I!4GTK*AT&]E7 H\W?:]?;/$%<UFZ3J%]
M(PX(&@,PCE+24Q^(#L9$'N%*CEVIZ4E6B:A+G3LIZ6]][8)T]?4R&)3:LVBM
M=A-:B$:X7=C-A#D*: [>Z]:Y4/G/-W%C'>0;N..V;4G@W+U-KK]/S$N5G+/-
M>O=[>]$7RU[>RWY]:JA#TL;[#$I66\"OZ8V[JN]P9;16IJI"CQ,>R9,I1*SF
M"0TSKJ]=GGRM>D(R4,V;8;*ATK)VYV V3$!+F=ES\#)T_3GY.MS,!+?6@ U(
MM![[@W=J_#/EX[*6?U(M+<6PGY[4P@BL]>>E@-K!%HHM$%(\KPZ6+R*T=G^U
MJZU'HI)ZGB=D1Z::NPAZ_3I]B@%>@2<=+/-.)9&\ZC+?]?2;_-Z<3.-DGQ&?
MC;7?[4H?2WY_1E- &9L]GJ8C1Q :PP5*(G' +A<&%:D>^2IZC5T)'J%S%6"$
M7^10#L!6W6QT PY4P=,U4/%H/E[DR.BZEZ@U,O[-P#4)[@"1V4'HXXDQRLL@
M>1L(YF!VLY_Y<$^]&GQT=)I1@&#:B8NKRT2L$&>VBX PV#^]QUW1A<.,D%ZZ
M;82:"689_<L@'>P:>*9C\<B8)F*_S7R=%][M^_P)34[@"TJR6T80-"'5XBIC
M9[E5:KZ>Q'&HA-#@VDG,H/)EZ+_9H/P/#NF8Z<G 1Z.Y5L^*,HJ<4+9$G@4G
M^8_55]S>\B2 GBB7 F/(U_"LK?=PQXG-'&Z7C@KSQ5+ZB@9$XG>D% 2HA@")
M U/C?'.GAJQ40W!M [Q6F9LG)!ZL?#E$(]3-^5V9UXIG_0^1V<V$@+5&+DJ6
MEI@D,2\C&$AJS?AWG>GV7MX/#"=D J;I8=*2NLQHJM:6/N_!.PC"PU;1A:H,
M%]QRYZ.W"4%?B.9)#NV'L]?GX_Y27%IN=^'HH&-LUOR*/FE2GR>,Y8'=L_=*
MGH-S.=(S#59A9*Z)0 $<$CH*5G,6=UM.LTMCOMDZ/"K%4R+PF9?!]RV%UA.:
M.A0'2_!-[3G\U;4LCEFO/2OF%IR21;ZGH&[?OR_\3850>6""3-O30"%#??5D
M:U*_K'-:%U 9B^0Q"B_M1=="KI*$1VI<_&?_((\6$!^![ZN07OL*)V]3@HUH
MPLU;BB*;77"=EA.@-G_;HICF^R7FW)\+?WK5_3!]N!A@@^Q# H(!'CW0*HK9
M$5\Z\=>Z5$2^3X ?9BY<'_D3KS J[JK9-?7X>?&!+4!B)#M$,;5W0TLFAP=?
M%=(<5+7=RC#J$JC[%1ZF69_3H]==FT4;]<9P=O6.[[4SA?5)"D31X_<BR2*D
M!R-+F>> Q]]'*W9<,5F\+ N;0ID:36M^=H+"OPJ6),USG0Y1[ 2[H1Z5:^,R
MO'HW%X[$(\=?][2MF@=$ <ALU100DHCUQL/:9\P5Z5O9JO&/C.)79IU2G6)=
MWJ-IUP02TFC,_;V%TZ<(PH_PMLU92478H,>TNWO3X J5?M"/WU]<.TK /W@7
MI?GJ>;*O;OVK-W+V1;S*"_$'>!WN;QAM@LS4EP+TG#R#_P;0X-F4OD%F!A6J
M'N$XHJZU+UP8E1&D:QV=HXW[ZP@=N$$RJ;6!?VSG>A=+%B;X&K74UYX#(A :
M1O5Z%OVVF7]R,^*PKA,=*9[9X6C9^2=4YC1=YX!+6^0;]</>YP Z?=?&Q6A7
MTP 'B>\WZXUG6VAY:7_?#6Y13")3H.VV-S3>4B!B\QO!'HI[]V%?KW2@N!![
M\]@A7^VX1=[#N)6.8/"<DD1J1@[[$#?7E!KF)-]7O17?KWN>VKO.MCCR#^+6
M*4$4CH7R+F[5Y6C6593$_LD=T#HP6%^_JFO5K* @6X0WUA@/U,,UF8W*F"%J
M%BW4R^C-)N29;V;;QE"'^&=M;^0Q^DQU>FR!&%R:Y2N[U/L*T?;>7-^$H&_9
MOFESTGSFRVB'^TC&(8!>]21Y%TR?)/OF41[:IOA6068%C]^)D69@>K+F'ZET
M2Q2%< 47XK!H?V07E);PPZH^ZG1M\0G0$^;(K^<B-Z_#S_^&\W?VKH @3A$
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M97O^9UL! ES8TC%NS#/PIHXCQ=V//'C3A9[7_PHEA*;=!Z3.5LO /W;-6$6
M(1X5L+'W8A7XE@FZ[#0 @%%7,%25:]PX:9H\MG"A<=QH4N<01@'JHY*==WU\
MZ[!,-.ER2S#M<B,R*<"1Q<16%=^;F.$MP!\^QZP*_#]9@JSJ8_ ]Q,\Q.!T9
MLWAJ)A0D9"5/LDY<//J*8Q^W.P>D^"WY6^I 5T2H:PA(O(;Y,!A:0)!NFZS6
MK]H*-1OXX"OVL-]0E29A55<0!]CP1 M4$+:7%SOTM1\UX<_6/E9M<GS_D_YG
MY,Y;M)#&G1L,":DI:NTEY'N;C4,1P5(.5BPR._=<M!\C'R1MJ!<FV/J*4D\Y
MB,S)/TK^ZG<.B.&3;22<W4K&H"YL<(5$<><J+F_MWF6_-8L4+'E92LVB>Q_\
MTC_$>Y%5Y3;A1V<N.PE2"-?N0_T8]]I8388ZC'%(/]S_PK+B"GC%2,4+%+A?
MGHA8!G6[1>;<&JUL1GA_W3+5*D![MV3KQ;QE;M&X:,1(?>&>"<C@!8)SM1&W
MA]Z[K%LPW5KH4;29F:/_#5-T&_S[:=(ZF\&R9/Q>L-+V*2B2=/NS$SO*]FWM
M=%,,-5T=E7B83VG(7!KMD*I'"C!_K]D-HW]OI\(;<LWAR/<.:XT\!UYKZ\I%
MEO*VA##@\%0T>1CI<[P@2_#UM@4;RQT\M+S]V7WSY@=K_B@>IB!-_QPDSJ8M
M6&"B8/QP@'Y^\6%,VB,W874,TTU<$LW\$P7>LE\JRHYRC?)QP5R;688-48.3
MT)M7VNUFR@3Y)70%\5N>JKSVR<V(9>5K1V&XW"B9OL-HG?&;H95Y^P(VM_T*
M- Z83-SS/[/%+N?&(I@JR!"G5@9<*K)%.TZA?,?UIAH/_3!:X-%0(AJ NE3=
MN[1$3=,M8T,T)K!&"EX7=_?8])"2,15 =+I;\1:![&D4=HY8.4F$/+I@;OPY
MH,N*CF1?C3/N@I4I/U;6U]"4;7X82GUYIM>0-;7A84HG.-B%0N.&F!=)VBVX
MY+##BFN=J8YY\8D&)ED*$RO7YTI?7W1_?)<U/<S?T"U.9X!H N=P2B?&6X:/
M+EO#4O%543*HBX$.D[70&!6.ELEFJ=(!H2[I67!L]<K+E2BC)SI";TL$*H-$
MJ$=46$F&^,N?\5>Q[2J2XS(MKFZ"?;#2S6<"Z!N&],8B%U(3CIY=X0_/449T
M0?;%MG(/UR7)(;#N8""J<]X*7>:]! 5L93G-FO9BC5MRGA6CZ;[=]GV4,C#H
MV8ZM5*ZRNM0L6U(:IEOS%J!$B@I1$1GU,HMI99%,^(M*.U;' _I#WI3^9-:"
MZ+(A]GY88O%(=%]Y(&BX0H:G92J!7EWA:>LKT*]^E,4JTYEI-1E \(&P!3)0
MB*T*F]MN0:Q%E#HJ[:,9[B408^[;A@)NY0@0RK[.;*L;_< EO-&YD>)!?9)@
MJ-(*RSP'A!"?7#X'A#9#@)$(F(B7DC-K]1@VYAOY%O&"JUMW+"31!9Z[?!P'
MUL">&722Z?",H1@8[^T98=2D?1)$>:*N#MPVS4D#N+WT.C55\XL\2?X2?L;C
MR-TS:?&56NY0'*8VF=$! 0P6@:%P/YJ%@\H=?-/!DQP^WW7>TZ]&7?&B=__-
MGQVF? (X3 Y'L<E6,1&0!CA$O(37V</300$9KIRLK9''><4"M_=SFZ_P,RXE
M3"DM Z\%6GV'?6S1Z[$$XL93HKQ'A1J1!^:,ZHF_3@2]3J(M)Q 84[BVT7AM
M_%!4#LVXERYV3-#,Q?34[X6E%N:)J)+D$T8-^W^E\AB[,7W798,$T"KT4]Y5
MG -*\<]U!<TIZJ3=1,J%F.0^/0 (L(\BRSDASP& VBJ.A1=J$A7YO\1C#&_>
M_Y#PZO4=(, O.P01@>5<3NY<9"*9X<&G1BT<,7\9K+3K&^)W9ISY3+)&6994
M,-4/OYEGNPDG11>^(G%,4"3L=0+'<MGLP%5])Y%:-;;!G+*TC3XN%2U&U8MI
M4K-(TQ6!() %(?WS'(EIQ'O@UIDK59,N=#?_)%3XQD<G&Y\E]'4L*]4?7SX5
MO""B5K,H//T)M7H:B^E8;W+ZD5&ZTM$NL8VO!DY$+PB.0!P@M 3[1^,7%;4^
MLS59F)TP(]];.C*W6A=&7U5D'FT QAX;6S&> QS%Y=%941\]O?-K[M"G5''>
MK1'+RY&GWVT7  ?!!(SPLNN)YP"'JHN$T!JE>5%HI@-_-=':)2!F5'W@EK+T
M#9[7+[VW57F!2<&W2>ICP?+;*M=P<8FJUZWC>OK-\OT>4S!!+_LU5O+XH\,@
M]$+Y]CF +=!WR>V"PZE5[$VD%:?3NWM%N3ZO3/(B%*[^>1)S,C^5!TC?8_CO
M+O7Q* WG?7A4DD?X.OOPG7%U-=_CSS#V/^\[]SAG>Y_17>@L8J6B])0NO*?U
M\F3-)NGI\A ] ?FPZ9U+E[]FUSU=YY:AW0D=@?N<](Q2.; "PD>\9$\K#V'V
M*R&@(\=B1=Y(=W5S],%'VRRHE(8TUOVJ>ATU5>1.NKG<AR"<I\6XN!A8"8<R
M;T%EOD[$PAK"-#,!U:+2/(S0.XH^E?EHJ52B%4'G#A/*+OHZ;VAFB @,PD*6
M(,GC"RO?+><7P09*NKA&%ZY,&'BRE)9NE4XSA*@-:@=[&M5"8A!LP3SP10T0
MDX37[("DB<?' )-WSJ(-&B'M&JX66WYBC/XY8X$!1FX)BT"YDOOU"?2,J$U:
M7>(S4;FJ)?U2Z*EF[Y+OO)LJ=RZ[BAA,$9JX$\B&H1N0UFM)DQ*?+"G5B67E
MO!2V2G[:-JASOQ=@5TWBP-MW*UIUM2AUM-Z=JH&PFFZ]UZEEX#-98>K5O4J;
M^-S[.G\Q.#S7'))H>4V? WL/CNKBXVN8"I0,XD$XZ_EX_>X#O0O[I?9,KHP^
M!0@U;<(=83%V37AJ;2@U27&2W63]7EV^MX?D.[NG>J),0M[@$!7G-PX75O>Z
MDF/E45S-&DM[M"T5DZ"^&HZG-]'6<:PU!9%S\QX_P3G1H<:!S'CJY<L?\&'0
MZ$4FB0K)78E7/LBF*"'5A)OW1&\;6O2JIX8U# W'%2Z]?D5\2?AQ1_L4C$[=
MLN[F$S""U$6%1T+P?XJ*W&Y9.E"'CWKEQK($#YMF)";'R&R0+*NEZL>YI%8:
M3QQTJ'\)[.Z W+VJ*F7&F^(?UB0;9-QJ,6%V%4QX9:F:[\'#2/MS0W0-Q;)=
M@4,=_3LX7.6(3'><^K9,4Z?Z*/2+X8DO$RU] 7,N&36:Y;TT[M6D-Q&GH]E_
M^VZ26I3^+\8KAYQY=#+_*PL*_S\M$$\T/0?T"G1"#A>P_\K/;)$XB6H$@ZZ9
MA7>8/@;(BZ3];:;\@8OJ=]L]?[)<2U(6S3BK8$Z*QQ1=]8F/;7=VIWW>=@9<
M-?.7W)%>FBVI.;NG+&UQ[>'(;!DWW"=*X5^)X$'I'56>W&X48_ORXHR][K#K
M1VLK1TL3Q*[<SU_(I3901P$A8!G6A(BPA%!^\'27.BA:G /2DORD_%PYM8N-
ME8-X/=HJW-C+$)VOX28["L0K]]'$:Q.@&8&.XU;0!#J)I,Q]"57S[M%$!FM&
M5^KUSCHE-H6?V#N?!@"O'7/W7_NCSH(ER1G=!B3QLSRPZ%)R5*-5=*T9@S6L
M":+4'^!@[3!X\JF'3@>HQ=LX;NK\#/@[V;#?6=[BLM6[8J*Y>;(K<-6RFJ@2
MIG()'B  PN]3>&#5!P?J7RH IV^PQ1I(O'> 3*KX(9U97W'F$^K2EKE'U "=
M0:#"K48(WW>2VEEAX'V,^!<7)35H[4+^F\)O@C>BW55C$4L/C$ =36_'((Z2
M,:>1,XVS,YHE>J*7!EDM\A'\'B^L&,#4RU9Q'*?'B7](%D$8O\J]U\D#-=KB
M=ZUYW[WIS;VS>OD^CT\WP"OWTBV52X3I953T0;697X&C<R??YH$$3=F#$\CN
MU3Y"+B:FV9[X1 -S\M%^UJOHN>>((/OH=ZDC^E+$U1[\<83W7GBK$FXJ_A#(
M/$_(R%KA=-T5L/7XP9F0Z2O\AITZM4UVUDI' N%\#@#.:63&62CT)B:5NMBU
MY]%778)7;KF%\BG@5%H:Q:TZZ^2ERM^ /OYLOQ1TI*+]]>H$5?G<)J@ZJ/%%
M@Q:J)6UD^O$5K0_3T<L<CD>W:B ."+H%@HT5@HL0+$>4JW:\E5M:6G*'[FO;
M0%)( J(MQ5<V?^D<0#T'7S_20XY4A"0=?LU<Z^_;+U,<[*(_O3O7<)S'N+=D
M'RDS0(-YG.[AXL+<.+[3/3#1KM:J3XH4'J:G]\+.32GACU5'FR$XL^?Z[#W<
MUW</=5SMDMAF*FYW9*+54LK&^%IT*\W:$-PK! ],/5B($@&,3GA+1^)G)/R5
MQ:@$_%FE\5?W*\("H,3%6++P),F>"'%JK*O.T_O2YFVB^98E?$V&&J2T_M4$
M^5(JJ46'6H4G>#B'=3B0.X_@>@"=M-Q?$*SSC;N28!O;HW:/.BE(VG*]E*(,
M&AE&9V%9Y'=?!S?7Q(S?I7;T-PBXTZL)\"<0N7 ( 'DDAP6'#/$* CX9JRV1
M<':)> 9F>O D-2?B%R.$RK*ZG 3&0;NJBPC175RB"WJR;ZTY F*M;6-6)W02
MVP;-3P^W53G FAC*8 (-<"TM-5/;B +NC-S@W#?EZ6][?UMX]D 5[F.+JY@)
M^J]@A>0)OEO58WEZ 68.E?E1(CULK#HA5):H<J=6#L*-I2N6O'*[RC>YD^\H
M!6BL*SC22=U/17,.&55E!PK@S32&5>YOMTHWUXZ#'H\_(#]_JA5EN[#5Z2[!
M\24;DP@(2M8T&G-;GI ITU>?M[!N"A763'D5]CT*D&S.]>/_NU;?_VZ#K^^H
M_;O_"$*D_7?O9DL +WQO!YRP>.5Y:1K'TXAJZKP9K#!>X""/'AAM50.*E-FC
M)WAV'&R>]EEVT[/KWU1C3D#1I03V8U6FCTK/ 367/[F5!UKC+G_P+ZRHLDM:
M>,EX+]D];O&S#%ST* 47'45BR'>8FO%!"@U$9KL_'&ZG5?^5QT+[EB=(M81\
M]Y%DJUR@6%,DC[;R1'-L@U][?<+!+M5:""?.QK 99]>R[!;9>B-0WUFH?FRZ
M46$VD^[/SSI5R$)Y53AHWR67Z1RPG;A'3HW;HO C$-W"M-[70$W<N+.W.&^7
MK[6L<" /J8NQ4PA*E-P0?4>0I(\^@A%" I%=J9812M#^X%Y%_^'+DNW0Q& >
M@L=24XN ^?<)X?J/3P(*80KYKZ_:)*H*%1AD?][9? 97ZO91D3_[)D;2*-3T
M8"A<.P>(2Q@:J7UO3UFY+5":<R8Z#+%]HMW1HBW .6DKL'A\=TI!P)/HS7ZE
MBZH^VPLT73^TW@UP)@4WIG?SW<5%=Y;=<EZ<%Y]8&#LV$&(ETZU5GU[].<(N
M&06J]1Y,OTH7)-SU-)3>)M) N/\]WV@9_Y%3U\C_P]Y[AS49?>N"'X* ]-X[
M""H"TGL"(DT$;/0F@M*DMU"#("!=0$! BO3>>Y461*3W4!-Z3Y 2(83A=\J<
M,W?.>>X]<^_,,S./?ZR_LK\O[[NS]UKOVME[+ZQLF;\=9A 91[7-P=.*.C;V
MR!$TV>)]C?")T?-JH?\I2!N"-3\Q0!YV+]-".+6JT&\V8T2P6I+EXX]J%M4N
M]GUKJM[&8Q9$8V5Y@N2RX/@ZC=,@40C^D_;GTS.UZLX/B)C5FU2=1],25V"E
M/BM#?KW+I/X/,6FS6JZ%M1ZNC?<9YQ+?!4';7W9P[PHBH1'+1">MD#FKSH1I
MEZ:+O 4UPT#Z,=SH=6Y7D_($$X4HFMTQEO]XT&NO@Y']\Y$][''6J<7H4R)Z
M5)91\RCX;1;;CA2%57,L(D'Z17#H:HPTI6LK.-2;LU8@M&Y7)-RJ%VP3<\+^
M$*GDQ*P,656IXLGLX4J,;3ZE'\82H$:PMZ$W%(QRAKZD/&M-N)/_1EX/FP=?
MPKPBM_$'8Q*+L)1U+:BL7DY*^X=P^; $.'(.;W=2&%FRH_&#NS7K._XTZ"[&
M3W.\@PDR\6S" R/D=$)*);P6ZO5G_A9<@\W:V<GWZ^]1@T]8'LP^(@O @L-5
MIN][VE7D9FJ2PGMH^9G6W,;OCB#,&AI7VRV0E-U0MB5.\H5M8SY]DONW6Y[S
M-SMI-<@YXCL_B6W+#(G J*+G>T!X&"A%>)GASH29ND("8WT8_Q/1'^MY+[*Z
M@T!1Z3 .SIKQXXM+"X.:\6^3EK0F,0_7N6QNJEB1^7 ]&!:/GDR>6>) !WZ]
M JQ:)B3G^3X3'>7%;DAZ]I"M\KJLG,>2NS^W-2?#3"$<6<VF)7P.RKTT3NU<
M!7OX++\(6C_"; ZRCSS^@7:PO0)N@!AVI#-)QGJ%%+L_Q.0GZ-'*P-FCJF7P
M?*UON,B/$N%=Z-JSO"WV^\?IKFVJVTMMB0$_Z!@CF&YJ-!WT!C/.<JR"]E?:
M.:"4$,9'8X?LYD@8C.GV/3?I>X#K?MH?$X1-+_0F1O=E*UHDNMRSW*;W3*R6
M-"E,0$-YYV5=4(KB,"$1?D=@,0H:6>;OB) '4]D],U6Q\^D<U$HBY8+OA7/1
MR!4?C@=);?VG=R;_9U:T:S CYQ3NXV=IR9_O[DRJR?[U"7W!*_$ZVH71FSN"
M YV(=YAE7 1%[77&?>WU8L:N"=K KH!C#<\L+ DGUBE(\6WDD3/&!"1]!>2H
ME%T!*T^O@%4/:/<<NO.2AMWFNN_"KP#6;$JCG+9T',/(=9ZS]6D7C*$#8Q8Y
M40W^SE? HW"C*^#[MRL MH4_;5O)?P6$UJY"S_GD1G W*7'2ZEBA+-8K8(Q[
M&HJZ T6W "=I_^_$E0Z#DIY J;'O4#/1[RKVK*K&<T,%(@U<!>F2%O;Q-&0I
MB/@\*E_\?Y??7UQ_<?W%]1?77UQ_<?W%]1?77UQ_<?W%]?\K7+S=\/;35L2@
MH[K^6.&8\+I(!PQQI@!Y3:A#]!1O2VZZ_7_Z;X&_]K_:3$=Z15CF_<$HLZ5.
M3R)X]&T:04O^'O%:@$Z*0F9@"T(8)&<O&(HQ0XN!/YY[Y1UM.^=9;#>"5/L^
M)_I$I[+1>%6(J41;!1>TEOP'ZP-ME%J7>9+[OK)O1D$,.[YYHE(S">,[F@\S
MO^\'!;G"@Q2/(H^6V;#6S2CU#UC9DD6,OH^(9-W@]I'IE\RIX.([FM$);K.P
ML<N[';282N0R-29M66L2Q&A_+D%[_\/2HD*.S$_8KV]12ME.]Q@KT=[;2AS%
MJBX6I* [ZNA[@R]LQH<3_0H6B OJ'.(D@M3),TIC]<)$L9*W1WH_=3(+^>-;
MYK,V.EC4F9M'Q>1,.M['TR[T9I6/Z[B#W_Q/>W[:$I$B_1\5;JX2C2)&^::2
MX<0;[4VQNX,74J??;WJQH5X>J7GCF8<@.6EZ<B \5T!O,CIJ5NA=VI&$P2S_
MT]8P5B)F=K02ZTL#$=0NS*H?1UR')JZZ(()SJ%Z ,S;V9]<#3\>^KBH*"GP'
MTS'V@^ZAA:-;-*MQW5D#OV/Z4S>Q!\WS=8X7J3!=8^"PJ))]Y@JP%80H:+E^
MPPATP^.BA,L-RX9L-4Q#0AKM95]1,G_G2-TUJ^P989>./8YJ33TV&6+8&5[=
M^PTWNUQW_-8:Y!IV<!/PK#/XXN^"'JY&L.,_KD'E=;.[&W68^-G<J:Q7DZ9B
MHG(S8HS'ZA6N7@$1R5"R8T<I137!&!N#]AN"?@XN] =L /,PT<];O-D*7_&V
M\):>F1NM0&.J,>DP_&X<#VKJ+,S3YVD;E5FULSC0 +)^2(''&\W&$1"@$T0B
M.!#(C0V8:*,-D$S.^K;D( 8?YFI)YR>%Y'%EB?RZ-^=/MD)FU4G8>JG;B[(#
M$:?TIDA-:)+I!V]G!Q&Z?Z(8FQ#X^I1PD1Z1@!MWSM]I&,/D?O?MB"I<Y%PT
MT]EC3XG[HC96]$I\F&FF2>6^-Q7?:!-D[>F/GMP;8N0 */(HCA0S;S'9:4=)
MBS$^PH!B+"TWYN>)G[[S[QI>D>8\B9F,'_+]]][IV4)>#7R0O:W@EA%)WC?E
MV5Z7604V#I_L6W<J13&W5V.L^GQ!M068&L\LT]%#^-*&,DO!.M_^[9> K($Y
M$6JF\+^P\5'%V<?1>^,R 7D7FTKV_(\.JU5LB>MHG,J0:\MA+^LNE%$;$7<+
MXF1!99_\B>\LM57+T#$)MR7\??WC)N !-@6\Z0P8$18?:3$Y(V8-+&33(.Y1
MG%8,OU]H5_SGNE>/":4:QJ6M8IM@XHFED"N@/XTCSKO$'DKA^*VN-K0@31>C
MD2NOIZ9[0SCP,][V2WWI#YYS6&T$N;A)R\2\3@+N9M9>N<"79R9)?ZK$XT-&
M/<O3_GEJ5U@AKH#H\%BLL.=[JU,VTT$GR]]M(TVSPWL4[;X&NDHWZ?MLE[@G
MZY>C6$Y"ZV%#E \;(I<T/MC[7S2#W.;17WEBFIC6?IN5_U-?FRK;.=_N6QCK
M(G-H7DL*+HE[K@L\)?ALP(U<YN1_[U>P;2R<*MQ9OE,R;C1G\K.Z5"V77_TS
MMB@3NY&-ZN]EC7G1YXZQZ(43+''.\#9>O'PJV;V@ZDKAVLSW%*]K1W1WRQ:_
M(2<W$U+NN):)Z'5]%+KXC^H\?#CZ#0'D:;5K[A!26^"[]TPF0[A[QJ.E?K;Q
M1WEA24(_%@RBC]393K,IG^<T7;HC]>/R,. G,_N\6<]9!M4Y4NV<LMI;$I23
MGE(NGHT\\5W1#\Q \[YH1*ME?,,L=[M#O,P,DZHR1)X?W+7&YY=Z@^_@2^'^
MCPVT+O#E7OE9K(DKHI+H^F>EMO<2S6O<W'=P("]R3=*/?S](/0S@U!G;:%>;
M%,PH\NF'/IR#BO.><$^^$S:DQ:?2X XGR\,/.XP$=K8JY<<#168=K@"J=PJ*
MN7;>+V;-\S:$S)_TTQ7<'O1Y;" FXCB'/R&9BU8QG_*_BTAWIMIV=VR8J/P6
M\)CRKL5P_=O9%6MKZB8I]<)\P,OCA54\?P1?1 AOT1O+T9#1B:)_MX6\DQ43
M\F(,:[ RJ"BW.= X>2+5V*HK9/)+]_Y7ZV!UWJ*NBO%_J0Q7UDEKKEN(T3)H
MKX4*(^$PN]?^^/7)8LI=*T?RHX3Y]",0_)=MTSCV+;F"0I$,'V]+NHF!.N&S
M>[=D +R1[(JP_W[AN?^3%;UN:VC*M.5JBC1R_&&4JWXSE\^:$+] 76&48-*
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MW]*QM+*V0L#J@R\XK"/'<ARC@BA9]K<9QT(O2ZRD&,J=3SEK-W_]U&AM&UJ
ME@U+96:>&" -NJW1I\6%#@PL)TOOR^Q^/F<=?"-TE)CY_G.PF(L*16$YX*/>
M9<3ZC]IR3FV*N<*=5KG:KX<]+KU$Z7:^"SI9<]Z1'29F)W<]6H38]')PH%]@
MEAPNM?IK=FCZ"UB]DE^^<\2SFO]\C]6E"\?>ZC#?)HZRQ;#V)4)^KO:FG)],
M>M&4]WI3.R6O_P _<%N+!?!T=/Q..7A7!LTZB";K Z21M9!'\R,25;8W]L]
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M_MXG$.[/)$')"LGMY;D"1JZ #^_WY_=P.LN\/]4LVIL.AO>.F<ZR*:Q. ZZ
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MXI!Q+T6_9MZ/\H$]PR_+Y@^G@CR_^[_].,VF>'C3\ JP+^9]0QR!H!*:C 9
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M\7Y6Q<65PQ@.P)*Q[:ME7*^F@!RH $O*/1J*'HJ=RL')@\&;I3"5_OMXG?K
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M_.[S?.^!>_DH5)[4"2.5#W(EL<!N&\S6BV'+C=@W!Y,-WA!S+G47;=^?4;J
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M;>$I *<KH:W735D>[<Y*>P1W?KK2KYV^,A\@YB.RE=W3&B1<!YZ8XY<@X3=
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MN"7X]C=AA9O18Y\F 8_^^1XFUNG8]^9/!A7*V<H/XH+N-/:!()02*QG'=VZ
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M$B[IKU9Q6/L T_)C^HZ=TV#UNW5_,@EVKU^[T<?1]PF'I:B(@<V^:]"[J9;
MP-S.[Z:+?+T]K$^>35K2RY)N/"<R6_TL89'S?W&9[K60W9OJ<4G32B.C!E.H
MH.9P\K.5+O"10"YADB:#5TOR:1HT#'@L4[^TCMR[!0_TX(V]!G6$C)-H7>6+
M(#[5![ "'I6.34^?JUK>&@1Q:)&QE9PS(E0!'YR &I#\?<#O>_J]C*40LWF=
M8%[>8XBK2F<G9T3#O0JXM"DO8(FJ+OS$N/+G!\.?'7W&L;:]S16IFZ:UI0@8
MPPGK\'#]";8#]01Z-PQ[8?["O7I!_DQJ,*J]O6L0[FW+<VUWD:H$BYRM"</'
MW4,QS-<@&W\=SP1JLRW&RC)QMB$;$6Z6V'^.N2'>[C(GO+@,T+E%2[X1KJX=
M>J%K;T$; O!'>5K]'8&NY2VC'_SF6'-F_W[,[6;!),FH2(&+")=2(NK%*,A6
M(3[K>%0M5(B95YU<@PR-V#H'?LFN1I^8!^+U-+JY3LD"K^@\E#G3<W<XI1IP
M=4@G- 5GWUSW^ VTQ ]85%(# B-=%&HN!1-\]4#PIY.*/-N/3>+#*-9$YQ?9
MO)G<RB2DQ_\0&#=T4S8HSJPI4F)/$#%X8;C1.%*KB@?9&BBL$=S5<.M#+"WI
MGEQH[[N 426*6DO:>3,@\T7JT;[AXQ<F!32_OK/0H+J=V;3IHMCR.$H(=YX)
M;E#=AK4%AF4S '&K2T]6"Y?C+73$OEX.O[_'W>%K\ST0H-FVJ,<*=@NA$C[Y
MFGF4FGY39OO7.>K!31Q('4QP1D^P]<4H&*['A%<$]@OA<IF&#5.UZK5'F]K>
MW;H+'&/5,OH@[N"!BA'Y[K^7]X"+/)BE\JQ+5:VY^^]_IVGB(49>)Z/T!)_U
MJ3L(IWW'20ZC(% <78\EFQ07&*[0-G6\5>MGDVU9][30&423.G"_QX-;GXE#
M(N/T(@H>XV#+XYT:5KT;G/'O9>?*[=H'[?:5UEW[WB4Q')3$K76?GV5#FVJ)
MP/*B&H=4RE2ZT)W_Q]5S=I>NG"A5=&#$H918(8?$7KWZRN!C3J_#%%,OKRK%
ML^>&G\XCXHS0-LB4MH1WRS10]ZD=$H/-@F93D# ^,R2A<3P;.GP32%S_!,[[
MK\*H\-'/G,M)6ZY^5.[;V-$,Y4,TH%9AH@-9OIZYMY$BK' UG$;?TLMN3I*;
M35UP4 N.IKF57CP)R?S9:_Q3FQJTT+&;<?;PWTO48=<W2I>$^>7(,Y.@.NQB
ME*<]^NGR0=)=@M%AFC$K1:2&<=,U*"P9)]&#Z4W-%IMY5#M45_^S%KM4-EK7
M:3[-1-&U)@QCL6Y.C :=;[1<8"SCG5N(L<O^JL^^J)8N#J?.QK^2[I=]MZ#)
MC7K=%&O'$'6A6!_-C3VH+ *^+QB%SX]N4<B>^'E'&T:&]K']Z%BE)4$35 3.
MZYW56Y @DS="G%[]B_1]+):PUG^42]G?8TFCA#*^E)] 0-[93I\TE^1'Y84Q
ML/J<AER";I4(L%/IRI8MDP#U)4!QS_9W:!OI#.2QY'C+N-;'-P7!KGK+3Q4N
M;*LN30"[:Q 9SY/:Z"E].:_"XN>VM5DA1KSDX?T\N;+LL=Y5\IWM-! /%")R
MEO,6D.-$/%T_@(\H-<6(=';R6HGR:6XQ<^K:$^;C-ONN>#K/L5A\>M$2$&J.
M\4S)><K[_L$'NF;VU0>8JH=IX0%2.[Z(Z ^2>C272K,0R/FGME<2B\X/FHF.
MVB2/%23,TCK^W..B:>/1<H\2B.KM"2=JZ+#E?)_9<1AW\3BP ZJJ"=3@^,?0
M51$H+@Y8H/I4?)%J2OWBV/JW55&;]&GX+YAB3AP("FO'%.6A#B/GEJDGX#3>
MB"7CB@\FL^OU#?:S3YY"Z=@I5NVD:K 8#$=.@E1YZYTC]>9Q9+GF,,+.W=M&
M!;3ZN9@[L=.@\QPST*+MCZZ4/_TY5P6Y763JZ/MSX2EQZT07_<4C^80578TY
M;.5A,#=0CW:)@ENCH1UM I'^&4Y25F*13'<R&P5D:/;Z/["?T!/,PNHQK:EQ
MZ*@6690+U0I0;EC'J\>0^B2?LCS%D#<^@BP(-NJAO3H6/ZMX%_<,!NWQI3@,
MEXJ*_YW;PEM>;S/P^FZ"E1&XR"/8+&>O?KT9UF2ZQV&_U'^:= T*!/M<@\;/
M[+"G!5=Y1"_@^H /9S8#TA()[U(ZR81OM2 N_8;[,<J<1Z5+VM8%R^8+"PJ+
MLUA(]4+_MRGQTKLD!&N)\1&5,-N\"\W=<YT99%4YMO[%SX9FISJ<V9(6V[ [
M";4DJ'J ,,' XL*"$'>33)_E= >>XZ]!\]AQ<-%-'5*%Q B:;GNN@%> MY7?
M&"5;1=([P;S.<7+6*Y5>K]?;:T6B3Y1N7PH??=1:GMW G\HKU:HO6/ ]/.C5
M>_<4-M;JXQV'I]7 KJ#VV^..N>@=0\W"\AP*CY2-GW\BK &)KFTF_0&-@UM@
MW6C^Q-5OID^FD/8N?)GF#=*G??-2-H;DT=I)W83B(L^S6XR,+!_ S<>%(&I5
M<%D<Q5K: T\,L]#L%</<!U6GAJO?"YU7NYZ_5MWF% Y[N$@!HTXEBH\B=Y9@
M.68_IGIWOU;NT^MXEC .B,7EJ1.X35OGKB4J<Z(L7JXB6'?/^_L13("W?BOM
MMLD'TTJGGOMMQHNA\D&+OMD%)P@! $;795E+$E8(>\=%[V!BFT_H7S36(UHA
M/O)7Z^B#V:U&M6YK62*OJEU4^^4WIH1KT&[PC=LPN51O< DQ'U>(8":'YK/:
M5]F+(%JQM,2!KK*$%X'"R,T -F"W!.I[F@X-7*6P?#[E:9S$9OY,W9KM4.;E
ML&.#+ <S7FH)_@3[NKV'BGAIB\E(!+K) "M66UIOR@K1</N=H&HA:X,>B[0D
M.M'A4<5UU,^V/';C1B);(M?1!D$@""<!&$J8V '1!T](&HTN\TT) ,T73QVS
M*69/H$,*9.HU='RMY6'BU/<&UF@::AL'P&&].CCIA1> &/:5?3;G'***)+^,
M&=.47BU42P+Y.A.A^[*D?QER!W1.&?W/&TW5]1'01K%9,@/07M:OLV\;HFP3
M"\V3&4>?K1+&QJ)BWMM)Y>,<=31Z;K*7O9!(P635B1]UN_VG;^,^%ZHIVZ/,
M\=,$QW$,1X&]"@\M/RE1?ERY#6B_FGG.NE'*6T^71N%6_]YQHFB\1:RSH\^'
MZ"^4K+N)LQ2E%\G)V0SXY<&5Z^I3]WEFTDRGX T%L3_#977%0E;\B@A&0+XS
M*W%22^#3V#KL;+G/ICWK4NH%:>S]=KLO#WXMDVP,Q#7P7N&V+8HM&'"HN)Q>
MKK"S<;?'I\D/%'-U7/KQD$"Y,Y/_HTB(8,+<I3$:JF"R,=1M0=(\:SBCDK0#
M_;U_[W,*1=V]/\(^?:XD*BSHU(N>99'ZN>71L0Z)I=^/.IGT62N;2'3%\<;R
MX;(8!(-+/Z=D-58WQ,4YN*$EO263C?E?ZH'UF8'R9BF+0OM#D%U0BX<-9H5J
MH.3/@HZ=5&OW_-*?1:KLVT8L+W>G/2XC[]5)C>CJ<*EGGU,H'KY(5<@3>C0N
MF50CJD^B"7J_EN0*$D"Z7X/N0+A\4%RWM:]J?\WWE7OSYY>0C@TF#21\]@.!
M,1E[56T3I[)M/3R/%4U][KU[PM0_U,R.D1F]3SB6#^14.&3S37X<8P7$G>Y0
MV+HYV7ASYG%,IF<>Y(<1OI4E;+=4UO&5@AG%%N,L<M KY% E!J&/9]C]\#RV
M[JM@P9^]'P-G!D03547!2MZ$NUE<GKFWHH^XP@CF^I1H0L/!%_Z1X'$$5Y$@
M66>L:=<UB/FGUC4H:K9\^AHT):',.?=F^6[;W(?VFG84YR3/].5N3_S1<,.;
MMC&"T6V2 !R[J^PI@KD><"DT#QAS@WT_V,$[^4X]N?#\=F'^BW5J,,)=@S6$
MX14QV90 PF0)%Y#O40XC0W$6^EX<N$!4\O4D*!_+]PSW'_$'*?!O]DH;9M_X
M8CAQD6UAUUCX>^(KG[?Z02JRHSZ8Z'D$ \ZR^Y#,L;V6,9DDKT -XIO]S</3
MJ^( \N=5B:$,Q,KW-2**DR%1ZHH6.D:Y#$1TLGIE.65J3A4ZG?XM_6?SMYOP
M_N];P<FQ=">@TSMH/#\LP6#BH[]<=_<4J=0W%X/PKLF7K -K![(^TO5$#T/G
M&AF@*.181!6<[@.<R\_#LU"#-XJZR=OAKGR4&,<U2'0A"^1GG228@>M.;U.\
ME$(F?WWE^)_6E;U*YZ68,F=6;EG0FVI"XH27_U[,)5^J3>HVXS([?4TMEHP[
M/>S@]10. FF\B4&QULNR^@O*O%88GM:73K>&4/]=YKIC GNJXU $) DVN-3B
MY%MLOL>*#Q+2A0^PGQ/NN!/LI6B8SGYH4<A;=CRO:-/YEJ5N;,G2P1G:N$<,
M.ZBI ,05O*Z$VQ[ -B9M&C]KN3C7^+C68;X\-Z6IY00+!$_/>B<@)(?:_PSU
MZ*$.:7<#[M8S_7@TQ]K@QFLW'+/&EJ^7=I =D3P;)/>O303*ZIP"CO1<(5AQ
MP#.G?[[9G7^=+'_T8^Y'"<XDK]C/DZ>FC4K4'NK<T:8#QTV+_]A2V8(F )6G
M@<#+ +ZQM+5KD*U6#?/"68!9@$RO/0!ZUDX!$1=^[).O6;O27'7(YY'3%R0.
M5\&1'$SUNJ!R;L-\+6D<3[$59Y'"J?-LKUR:F]3!&PI/@B<K )'^:J 2:2HX
M(HS1G*WU81 YWOZJ.=! 6U$AX\G-3G,9*9 -V'O@+-$NZ?CF_=/&L>4_ZW4K
MW2R]_.'MN.0  =&KL3UM%WF7LS.*QK.%<WU"9$)TV]WQVIJJ'4M*)%L@5=Y+
MH>&T:K*OXUG.4+<DN7BR]]Z]SD![_S;J$+R=<9!@)958;F;::4>=\XO6!W-_
M83"+W+K>MP,H+1]"6]\X;:Z;V&X&J699/S0C>6$6,HI?<V4J'6L878G&<P8Z
MP[@TL*<)I8$VWSC]C)V<.:GD73Z+-IK%X@[G@P3&D=<@UA4HC>EN&VFH5K75
MLLT\U&"1OH,7'DP@*\,!&[7'446W:-N4:UNC$HB6H!9/PI,VH+_W4+RQ8>I6
MVMD^&! N8\,9HHK1(X!-=9\'1B/]1&@<Y$Y6?B?!*@*&%%J*V0)>O[NS=@0<
M'\[!&H UTO[@9!4K:Q<II-%7T8"%6^1</=&@F$Y%J8C^98Z6AMKZADF72H&D
MP8-E*Y9].X,Q!386CK;ON8 Y&GH-HH6IS5EX^D.U6S)UIY^5Z$\]_;T4!&)Y
M41P<FQR]V0;6(6<,N#=Q:-44T5/7E&P&S;'W='MT]#Z*NH30X8ZKV,)R(?"A
MCRMZA>Y1/I%IX57%[G:;YM=V?,A]PJD2Q&/@CXT;..P#W*@HS^^0;$6CY&%I
M)RQXX:'_G:P<F[*FF]X0 C2BA*2[].2?3SH%HK@;K!0-;4&F =S?5E25.0MO
M^N*HC^9*6KCPUE*XT:143*9VYA1_&MKT=L'[J5R9WYD&-30OQ)H=%@,M8;6I
M#RIR4Y==%)GB3&0]ONVHJ]JU:4@22+V<=>9%CB,.A!;>_UC0W/H-)J?_[.J_
M.R#I0K*-%P-J, !<E:]W--/)YX-Z1HVDZQ"/<KO\/G<U@2N!# OD90M]$BS0
M$$A9+8=&'4C&<3)O_# N%&?SS""QC17;)(RELEY,5N8X['9Z=]'#1?%1R,@P
M<ZRUN=:8/^U=U>EFUGU0P*VF:-P(ZV;WZ36H)BVL/T9*<$&0Y5T4D9=XD[;7
MOP]/I.'#;./6Q6:&3.&V$\<N<<L,=5C=, 3,N=LP_*_\A=.S^3?OFO^BA.-#
MGKBK$/)^_.>O _(G4(,=)**^/48G)$#>>F!>)QL@)Z6H]A8H%*HXWM6_MDP_
M+>62H)L^YU)Y#F0RS(75*MV&"733[#!Y9:1<)@XXI^'-CGH*?EG1-0Z6BL1N
MRK\B'P?_G&/(!4)?M@+MZ!':C<V ;\7S?P:@5*GY0PXT,=\ZWJ\%3V=Y58&[
MLVEPG#&8)=JS;DY0$[8HF_]!6>G<NX9P-&W#D$9+TJ /D8=1.XKZ!RZP_Y!Y
M8??%8EL.Q;<8;6OZ$79OWCZO?YF:C\!*PJY:FX4@/R$&C 5K"IX3ANGG9)_(
M-O[/VZS(E()))E.C>6]UYK_TV6Y;B@7%(6V,6Q;26.*TR!9CON5"Q [VJO1$
M"2DWX#RL9< ,=@Q;M6;&3$6#3AT%@P"!JAW6:U#7A2PR)K6YJ2X#:MCHD9IN
M[<X0=> 6G.T1.Q?X/YQ<,G1N]R]UF'^:)B<<?SZ"_OFI1OM34(- <BO S#Y.
ME+%<8X/:ISPRFK'Y^^$_"2=@%'3,,68E.+H!M%8X-+WBO#L'!_L7 ^]L5:_R
M3G^O9=Q?#/JIT,"B[[&CIV?PIIT9F4"]TW[K\LG\6;@M]E\\5+]LKMK,9]#6
M+*M/%R3O>_*K:A==_^<:A-(!TA0MDZ_2^8>M79;^N0$8>H+?_R_.#IUM"42H
M8(;:R6'670\JM>T<&*:GM,J$2@@&0*!?'E,WC=@*Z+81JCA<K>]0TH$Q\\QS
M::W* Y@EJ5^EHM'##*W0 ::]B?:3R\:]3KSBVS$>S6]YW<VL2_9WE3DTPI$<
M'B^FUM-ZFLA]^08'7W-KKS=1?@5[K1O$:S&?GE5&KP:P ]W&LU((&L"N5]OQ
MO#YB(XYS9^19OQM[4(I3<;Z5NP(>F7FA1G(-"N,IIP>OIRXFR5/)*E7=)YR^
MCQ"]RF5&=#-T\N#YO;XI[>:694/&YWH"V2^EBO1\/*%0Z61W9[6"(OYLT9WG
M-A%WM0AE-@DYM@AGRZDTID\:38T#J;=IMD]/TUX(Q?2[_LPL]V375+XH..<,
M3%^%R^:9 '28B7&XY'ODA*<"!8+WAWA-7W)%GG<5VE43W_8[IBN#,Q,M;QG5
MY(5TK/>*0\LN]@PK/RJ)I2+B)"4)4N#I:N.MP06&[2'WQ64QR-8GN,*N,%="
MAK5;&OI^&7/_3=>N5O*OH QS$%MU;B:PZ&N07@9=">VPNWD0GU8?P6L%>4.E
MX(_[A-V*/!.5<+L"J!Q5['S@(\=)LX%'K+7%/"X9S.7.>!0A"XA]'-QJQ+#:
M3N-H<1_G$ET5,*GTXWBWL\A8N;IDZ1$TO4 H-JL&)-L'KO1";G#53(=C5J\*
M%W-VJZH.;-/;6S8,!ZZ(0<98<.^%'ALL_^6XLV3?)$*(#%GW[[+3FU56W4;>
MB(AF*OL2"\V/Z&WS[AE"D%[%<-E-T>E?6&:>U6N^M!WVLY.]%.RK15!9FEV*
M*0IBYZ]!/=>@;I.3DZ4&?0\WI@SX;UW9NVGU=?)SQJOMU']@"$QLTT;J124"
M+D 4+3'(54L]Z#\=0M602^&!>_QF!LFA!J%;;8[S[7[>"#6-F6V/_PTI/9OE
ML]+&*,!(*H##GO/9=.SR7&\&Y#&CB-TC)N]Y_V'!#85&;FTZPF\%)*,JX/7=
M-VEMY+B$($^=EV\ !V^7$H?ZFM;UL0C$=.PO'VORT#R%X([MK%7#EC;^'T 4
MENWUK!,*)G18FXF$985,R.67DQ_+\(0>R^PK<ZPC>XR\JLT6&F!%*O=$\7P\
MW/C7?.Y*=X3YF@ -5)3 Z#5H[_?+[(*'^^"_MQK_**$_7WTW5/WK@!?_,=^?
MR^35G?#VZQA:!^0;QH#)9JB9@=L4 ->@WG.&N<1 A!9??(SK2-!G97+[08VE
MQ87&/77']FY3ESM; 0\G]T0D=:R[;@HR+^-WS=D:,:_N*GI1-28]9[^!+V<H
M/<'^1T.1V&O0FNK<S2>P>5R#OF>TI#T%+/.AED0?I$:>[9P[N7U\GSUF *TW
MK/[#:*TY35U61D_8I\>;=:3,<=;33KT3P'4-^J1]<6]S[QHTK\A?\Z/I:KX^
MG2CSK'B84B+X5R>FTFL&Y5N$]$%SA5V#;DOIZ&1H-UX:%/W[*;.A_O+A@9*9
M':[R&A0YLFK:SEA9'+6/;*=UO/VA\*."K.VWNV8YRU\Q'>0>,PG*HO<)9^P1
M=[!,D0<?J2(L:2R?Z3PA,Z=T*)C<EWK]5BI7]("T\Z<R.(MKUQ1/#NB@6E6[
MYKDBI51]?!!+*A2730UM:2,.'*I9'+\%1\5B:0Z5.2OUES4GWIAIL707/!]T
M&P^VH$-K28FPP<UQ_.D^*,$<QFW?.PMJ+F\YRU)=.R;O6O.4B_^+[:&FLE),
MF89+3K3HY*F@,\TMU1LG:IE>I6G];)Q^@:O\&\NGO-.S_XN(,-8O*P.T'<
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MRC+,H[((Z^]!D.;^=N*[.+L8IIYSID@7N%3EE]M",V6I1Z+2H=V"A/5DGY=
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MR.K5X3L?.1?F\S?<CM*;_+;-Z1I  O#T-/PZBFZ!C0O,NCJ8G&W%X45*>[6
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M/U%I.@2YL'K#Y$#0X %.TO![.GBZ!'K_E1SCMM 1=URN( @.ZAZ#.<^8Y.3
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M883Q3Y]#G,UF^$66(7(K$^[/]A "1]:$;:P'@K)AWOFXF'<HL1B1P!@CEKY
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M;DJ:1CLPO0W-:#.)2=:9B[_F??.C$)!.L>AST>5T?3I[IF#N\!6%LA[QD0&
M(SI4MROT,@B9GD5RU.\E1N^Y/.;X_5N"$J&+H7N(LH6O=KE#:UA@_;O(DB$_
MET;R/7<U]O(?KS3@P\3Z!2#/BDXIY/U:H:'R*/ZP&L>CBWBJ$MT8C$ (0D*7
MFYMJ%'L(A_2VM\XC$!O:<,ME@!X=H/^2Y3*U..IPV:BRE_1 7B_1932Q74T
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M7(/I0+7C*@#2+Q7HHMZEXK7G4R!5>. W_S:U"/"[A@Z;A.<?DD@38@9>I^'
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M)S_N .$LOWP#,>CEP/6T.P AH.H.0" :>@>0[Y"Z SRX#SIZ6?BSR< ]L=+
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M2X*;QPG:(&11(>!0@6U\W35=Y%Z8U,O]0D8@#OCX'$\@7YI<Y]C( ?A7??2
M0XSE9A5>=ZOY,DS>>SL=;Z0QRCG33>JI]S42SXU;N>]ZKBL:)/6A<K&X=MF\
M.[6_#L#(31PDQV:[IVZ%7E:>*48>MU2,6&,?".Q=O6 ??<P7O5V[!/R0NE2
MUKL#L"7VW@$NB>XUE!PE5FH9QG9*>,OORQ1,62:5X7>J?NP;Y^\UXJLM418M
MQY0Q\ZB\V&J/O$A!:$T? >2K/*&BU\L'K^;[0[956/$^L%%T#SVMD^%'!_-@
MF&0C>9[<>+4@Q'-[!P=(3:^^ZB==<WUEJ]UP-6JU#:=00JNRA%>S4>![I-=_
M1O6ETI'*G8^ ?+7PU*Q]< L^./O9/DY9VV%/YV"B,[!B&9Z=ZX$!N_S5-DHC
M=I-2=%8WZ,X3E.,"HKBY$=R'"^N4&(Y\.]^C^43<$K 77W'PN!??(+O^\4DW
M%VUHDRMK)N""BWOX]JG#4F3?'8 4[==G)%I:O:9680[2,;\##!U=]\K8&IQ=
MY>T *+*)YY4C14R]U5''T=3!P'[N,;YC2])2ENC?6]!-G2Z>"E9@4NBLQ],@
MZ?'F$SQTYTV_C  J(-6;I-W%SCM9WFF*&]?3BBV#+4E#^3UW>EVD'CIC\X1R
M0#;:TY]&=9(O?7!Z6:7E1@H4K.K#YLC4)XVG.9I]$I%T0&]6@=+A/E*L<:[Z
M(N>L@+^D\ 0F@X?5ZG$BQ[R@Z),1?.&O='@)B=5K[6K)T[H=:4T]<OLQ]MSS
M[,5R]+@2GLQ<Y+T4-H]ZNY$7##E?5?I0B4[96=>$O+8YLXHV=_41_#7ZP>\.
M -+"JY]WBD>0"/6S.-\.M]XH7_K_3J<Q;[,^W4UDF-G!%A_>LF(>;.D0@O^\
MMIJA0M7$\,%;&E+6H"?\F)ET$Y_:1JSX03="U$P,HI,8+4VCCU*\=Y_C=HTL
M1,6AJY,G]:F35SC#CD:*Q.HH<S/S1ZP#(](.F0;/\CZ9^, OU7G0RZD1;^:!
MUGO/2Z^]+O@-MFE/544E%!5" Q$1M:Z@A:.B@ZNGT]S1AO,OR+SR1_YH44Q:
M=BCE$J! MUC,[%E#UY@ 5C!_TT.U))[D2V>R/[1+^HV!+ Z BVON 8SJIJFW
M"9I_8S50M1TBI#?;8"R^IC*BRV>:%LHI*VR=P:Z)X_H.)%\*[@*"5.&\.D":
M0\E6AZ6?].^*P&7C]'2@HW60:W 4*L2E<^T/X))P$#G?(1O%R_^L>:KF/-79
MA_W[D#_SX&=]VC1E#XF-&_I?-?0SGJM&FB%=CTZ*Y_CICR>T9J>7-E8D4AYJ
M-I/5I6$W2GKE ZT+V\6,IT'ZI3"VQ*% 9/8AL-K8< #VV%#A%^43S?0/0V.G
M>>W]*3XU]C-.\9=I]EX_'JW(I:3AB:_D;U[D$PGKISB\\SV)OA4'2^+(/)NM
MKZ)F$EU"0'\[T;'SIF-9.KUZGYK^V.H(>[ZAW9/Y<]%^JUY75.?3 TG2'&?G
MK62J'T/>L / &;T646KP^*2@\;X<<ZSA$G^4\,2CY96QHI6_7Z2,/_,^DS'F
M^Z4%S[AW >DAJNT\8I$:M&J#,RW4;&@@,[VAH(>2Y$,YZ#<?@KP"3_LYUG?\
MC<TXW4 <V-/DQHKR.X 3N'+>Z.+W@[D&7-&SC:-U-G^F<3>#B\?,LUA'E/KC
MC9W\G:B&P:+R@[>P5]$/M[XM#L#]E*F_#482M7QD$4"/VB:XQNE78+CF8/(5
M4'("D"G$![>(>%K![')V>53R^1\V*VD"'-L5>L#OO?^/+]W]GR[A_0P@@(G,
M==+;^9;D-GE:N[.O_ABEJ_-^3\DGL5(QL6N6HPAP9WF$(8.@\'J\C4A6=GX5
M<[.)88GYZ#P?=O1FDJ=CI#!3Y^])C*'?28/ \RBA.R,8$2?M5RY/[ TI&.1_
M.FB\$&@9?P$4.7](B;4=^$B&1+3#'GZ8B.N@5GC0R1C]H3:YA\O2!$*L_#A$
M*)MQ:\O=T(BEEX7VX%9L!J2(,NZ_;&V99E2U!]OD/7DOCX.)PON)):ZC@:ON
MITZ)M;,4V.>OL;!Y6[L9?<Q3/-U 1-5D@"WPZ44"FX1.F^M-'<9TB&K8",.$
MCM_(.AQUCI 1_/Y]RFE'B,%O\71J%SMNZ#$; '=#-YOP*H83>Q0DCTQ]BS+O
MY02)(&0?9?UU(TJ%9F:7O?X3UC0:MVNSP'W4,T1;S6&.?H*2&NAD:*I#B<7S
M\)?4>E*G_S1Y14/+=\Q*/)& *P_*R^R,+@PB1/D'PEGBZKN8'0(XT(8(/]-G
MZJ8_,](7DK>]4]-9MUQ^66ARX8_L=-SOPQF#.3Y,I0GM4VVPBJY>T$$QE_58
MM'S.%8>PLH(=E]H9;6FU0T.76L!YOZ[O $K3& Z_#? A@R;Y7DWG\<%VCF4K
MV[$$5W$2 1<68T'/OMF)(@!Z$G]+#?UQ!T"  D20HAVE^ZT?TT=P]GV8+V*)
M0K0^+3YRD2R3UO IA4FCI2NA@:8H]:'8"V-3"^"C)1^*$>;M%"47V.H/?8!U
M%"U'0E^)W_T&;OC:]DS$R-"%0/!Z.V4:ZI"_OPL]T(H-(UFP6_3*NS+UV8W9
M [DB,_KU \03!P.!,$72U&J1UA[WR^(?ZO4/5S3F#\KSO^K(:)NU* )\KH+;
MN3='Z42D[I5.-:\9N,V56/1RI)%64\+QH7QNZ/&M\$1(%_!",^*6J&U:I"U6
M+7IGEGG?:.K7Q^<)(H!T/8D?S&MI>Q^U\")68,RH[<@$C!JBA@!:/?&Z?=8I
M+KTVC2]%J3_=,/0)(+0)!_=DNAY#@WQ]J(H\B5&.$2GPJT9GKJGP.<%Q*I_T
MC#S\9I#NF!T\24QX<<V)O?L,38;B,L=3@TO 3(OC":D%C8W87OG4M+F<T2K1
M$I_-W:;]1S?RGL3*$.W)4*@MVXFH,S.\KQ/=I&AW^>,H%-^CH3HNU(WHT(D!
MH/+(8 *HJ]B 1V*1[6H()C&MA<#ZE&T^!K=7W\HA!&EQY.ZI.>V[-;Y=FW>
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MFO[-EV B(N&0)75)PTQ][N",M7Q+YIS#IOO49:N 5!Y@8NB_3HPZ3@P3,;5
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M!"V7BAB%L+*3>R8HL<[9J4['VY 1+*28)XD(]HP8$6T$%MC9]RRZ6UGP(]P
M\.?/(.EFML=.9PC:N\H4&@L?#*UP8&-HJ^!<L\%F6*;E12?G#0:![D7Q4#S&
MTAG%*H?D#W(ZJK\Y>@VLEU[M=]C$:<;>>0? 8J X31T>\#32.^F/:C<LVK\>
MS"B9*/P;K%'RM>\9HTF8Q&);<(]+5T\<Q?"^&>OF282DR,214*D=OWL +TR9
MX8#&B4U]G[5]*XS=A48@[@'!X9AGDN&7SS<F>TL>0-8^VX*J=ANE42H#6N(;
M5%X5P&^;ZG0A'/- AAUF@(XL.6B=^YN;!JZ8$$Z_3,#*?"D<$Y:.\T$A=ZB&
M]FL 'U1?IPD=RGX5#VE7+(-*$ME-_]A52:-=<E1\F&.HPAC)(>6>Y.V5#X2A
MUA,\)B([&6Z7YA&MF>OC!@^,GM:E.VY&6--N7%4=2A5WU(8</.J5V#2D?+%+
M+"CT9V'T#D!USDM]!]B0#<>H?CG,:.VI#?RVO#)V^B>Y3N+)Y%:D:;#OY;5^
M(X83B9NQ(4L8-G7,_XP^9<A3;"G'&/R1D6_.!%@=4(]5M'D212_6UP6,?VMB
MS_ SD&]M[1%QJHQ0$!! NH64*<;NMKL#L(A(';WN=C G]<R15>MJ3J#UI+:Q
M&[\DK/KIT+SE86ER,K0;A[%%/@ SR-;V3]'!UEOJ5_BS\B %[D?FKX*#@[OS
M@1+H<%2&*E*TAC0:4KH*SMPZH'/DN2Z3QF8D)S@ X&SF"@I-V ?6O](&SR_9
M)F">?$6_615=W&GCT?7[9J5 PU&&QVB;\"D/"/LJ"]:D:ZP*]:U5N]04*C.=
M"FY:'QV"Y_G._BVG'X8)?Z-AD)GW9+N1";@$-:TG.EI*M_IIX:FAWB*6,6*=
M4Y5',-EG33(57:,JQ[!"PC0 @"R6W+CT;,P:;;XYZYL7>P030:P3.LA0S_(;
M\'Y?)7]9YY(?\>I#:K<XJ\CN'8"!]"O$#UE554#A@%H>M(RP[!LGIGVWY>D$
M9#TTY<O:X(_JE$)G%4*+$'K5>47+=@G?^\ V\-CO,A?8I'\-'J@ZA0*T<$NC
M;Z4.C,3Z>=5Z?5F"^45N8DF*&TI&:5ST#)K2:P4 3M@25;+8&/=IC!Y"$;E3
M5VR&]C9V;@'[_&BSE'KYJ%A4 E VX02M5NLU/_61>7X'J+GWA,G'9;<R^,"!
M]4A+M=,[0&/ ?-NE_]]<F-D[UW$QGT\8.^P]+J[&(L]+)KZ#WWQGSD2C3=)>
M7\7_<F_Z\RV91TD&%"'X'RU!S_07S&RI,XQ$@G*G<0%4.JK#/;*>KL%Q6GA+
MPOKCUX/AE="B2_.$FR$2SU+P&HL/'^^Q" [TR_OXH*HD!IYB3FE50H?27B:S
M0\35@+C("=7**VOD>,ZC^CJ\OXZE$7DL)["AR?J CUCG.53WJTRL#\1'IPZ9
M/?:+?SFXQCG+N^,_N?=.C8?>%1N+MA&J@_]CL[1,>)T8>M-/[_R[I-)LH.SG
MPC>'KE_S"WS;N;2?+2Q#?(;7-GRM+//S@65E-61H=Z3"C*8Y*?3'>G]KP9QU
M L/R-U,C[J ]VJ%)48E!58GS\]/#ECL W 9ZV)]AQE>/^E)!DK;\TM(9WJ:8
M*Z5(W(V[VHLLRG^8L)D)N+XM:$\NJ,W5O1EA>#%11G46'[;&%7MI@4I+C-F8
M>W_#%LL4>Y $>BO\<'.39 0[=Y>.59QJ$O8$#:&'@M50.T55!S29Q9G& XP\
MFR,)0)Y"Y3C;;2VI3>FV23QE)/:@T4D\!MOO*S3WZJC)U<%-+@5?!_0XYADV
M/N!@;,(,/ O>R@N3):CJ? H3F>.[X W4JHN8O]1MK ^?54B)*K+D#B%U(TQX
MX=(!+D!RQ# 8_,WTC (9(OS&GJV-_X58SEJL\NP(;7=]!$BP;6?4$/H_!/AS
MFU0WH8 JDS#O(K3&*</0K$CX*O8 _:<DJ\1/Z3C^,Y/T?WS_#_;>*JH-KFL7
M#=X6=W<H4*S%)5@I5EZDM+B5 J6X0X)+@>(%7J#%6[Q(B@8)#L&*NT.":X*F
M!<+FW?\XY_QCG#WV_B_V=['W^"[61<;,2-98\CSS66O.N3X(!3$CR4F<0A[&
MPP.\+:TYLG8LH2;O6BT/L)75TI%IG[V[:&=N##'^16O8B2R1?,F^W?C>IJRC
M#+459OO,*SL(W@.YG39 ("1>DIQIT7F1Q8IBXM#]?*%DZ8>.-X=QA,+P$.E!
M6D1_H0^+L;&U_,W+\:-_PI+6+Z-*AX$9C=(3?<RZG<VX"#8M ,DMH,292:<?
MKI2\>!+5</3N=$QU@F.%MK@H7#OE)UT7@9?IH) *$C=,,?Y[>RC&AN"DYWY-
M+4)ZKG7,#O0G"#YGR1Q;/Z9;3"(C FQ\DL'CB)PWYD35;60'Z4X!-<@J$*SJ
M4WH-TRQ]#FX]MKK(KQ8LD=UE</%C?KS]/X+PCO<*7G< 8XR#KWNYQ:"7D.@B
M Y.ZD)'8IRZO0%Q=Q:8CJ^%_D8]MS(K6@W>@(D!4R->?"EKSU.KK';UK>(,V
MLMF["\39+9M.E!E;DON^N+;SF6)T>[0"YWF;S>5S-?5J.)KXK8>)ZT\XE?E2
M$M;/+,GC;QQ+,8J+RQ9]GH&A02.L2;D.C*F!I0 [_G-&1K[P_&*0;W\\#.>[
M]CJS)7>OI[5(]H^V[7+0Q&"+%IMXNP.OEU?_<GCX8GM<7=Z806/#=!6)MX8$
MES:X^]36@SD"# @K1='@Q**N^]90N1AZ/31#[36@[2QTXF9-_/V@E5);>,[A
MF.[%P&*0]MS[ABF@EG!>_AW@P6AIY1W OH]*\/8'KUB]H+SB49&[E;Z(,G>:
M4:C#V&].1;8[ #3_5B"C)DAG0W6]BFEH5<%(1T\WWOC:*'9CJX%8:"[A$-T[
MY;;-Z^>@Q,]!IM4'\&>"QKFS]].QT:,V]?6\"BR=ZGY5#CJXSGMHG+"@"H$
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MQSB4[,:\PGRPY,":2M3-!QRN51"I$TT<:ZN@_ZOMT_J&NIH+IO:XIU/ID:^
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M/R?-$*,(YWCW(T\/7#!*=7N8J62JU<U0:V"KK4*[3U$Q6P,M"8D.4OBF SF
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M)O8D)\K%2_P"HEB#\4=<,_/7-V%YUQ*Y:"G[F?9^QJ<G>-"/R2K('XT$2 )
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M_F@R++ 6\3#D-Y)EMF&U'.D>TU%W\JEHQJ9I"F+3_G3O,0(M\A[:D#+.+R;
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M6'B"G.Z@.:+<<S8Z!]2[^IR)L1Z0Y=[J3QM7>BX)3?'#6I+"=+LFJ8NIP#1
MR\<+/(Z95YP%F.S,.MGK<_NNHBI+6_X$L$LYUB<X2 RZ+1EP#O],MW5N!(2P
MEQ?V$0F-575@LNY(;R=_QZ0]Z>#;A;SYAT*IQ3I>RE]@]*E]:_8[X.KZZN?Y
M58 O$5IU&@4KP_$!N"LU#KTL"!I3\;%'DP8-PCSQ\ZGSR%.U>OO8=VRW*P#
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M>ID@H1TS;YID99E\.=Q/D.C3R_T-9&B9=;7%6B]:+/=N?$SZW0CSSN'"@+L
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M+NV3-;*7J(79Q^Z>-B^Y+R&Z&+EW\XKKMNMER3O]6343,5.8QQ! +AA  A+
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MP5.F]F05//GX,$KX6M;A=,_;;(6W_#^?YF7CA?@WN?ZV$K,LUMLF@0K XZP
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M@&^4BXQV=J/Z&*[^D7P5".&/_VWLMQZR9VT],4PKR?]\O_K^BWZG&:'ZA^W
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MW>'T\H!L+Q_K?<,7D[+]&YU_TC3W0%^O/JS%W^0#D^4L)86@/$8 QX:"<IF
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M!!Z.;I ,N*4\:?@5UY+[[8U\#WG2F..+Q]./N0_9UZ863OG\6=[7QZ(\3H3
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MLJHVR'C+3M$C:N3T%)>-/LY/8?'. ,^0NQ]*/_M5E@\?5G39>N\SF*=Z(8!
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M#E9C5!*]%JQ#/KVZO:NS)&@:W\U8__8_G_2^;9;'6,14(2!5# %*1&(R. O
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MX+7G[V\?'A>K9]E5\#ZS1EG47:5_NE-M=>__TDN4>K5ABM%7V_-B+ I"$IH
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M\#E(@?NI?$<1\#X\]VZ.BQ3&6IG!@"QC*4#$4 .G/ 5F(59 9K/JF5=L_=C
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MU7^VO^VTC6:/!G/24?;X]T/3[1#?#^:GO_VE_Q?S'RNO\+>__ =02P,$%
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M_O[VM_0)SP+,EYMM6*:ZP&;^KYOABV]7*6P'J7^7KA\>_8GZ-[C\,:A? BY
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MB(LKII)6Z+/CP'*LB8XV@W?.@>!<Y%"8489]ST-^UHK3=#EICY7QQ'PP=BC
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M-BSPXIYC""^0CEZ38@&%%?XQ!G"UPY4B,EQ27/K0&CB/$M-)/Y4&H7L3<?>
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MB]%0"KMTKIFW7IL4&22F[:YC;> ^ %=99>Z3<Z%UW\_F3$Q\*]L!,L?;+ ?
MY.!]\GGPXR@@7V^[V"U_HQ_<;GY9[OS+OZU7FSJH)5CFR9G$;&N5.WE_7M5W
M=&XLV3+-BFH^O[@]&Q-'KG^^'7,L5/X$9PM%1?/U\&^NY##SS#C)@@-,M00_
ME=KJ229PREGKT;!46H\>&X&-:?-Q_X2[Y5BH_ EV"ZFAX'Q+KO0-$?"8+;I
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MD!L=G0%'&P<LVJ1YXO2_;ER_9_+V!TUI^Y-LPR-P=NQC;N<[\*Z!"L%;BS&
M- Y!<7)CHDH2&%KAF?52YQ>_W7K1H["_1+D_R1X\!FD]/Q&_"I_GV["8__?P
M2:2-)6X7J\V&EMY4254YGN^6.>*Q^(!5FCP;'\M=HP?D-V&]))1OR( /\+MZ
M9A,V>/3<@.5H02DO*0H3!KC%[)3*A/76KOMCM!QJY#/.9V^6VZ'5WF9+G_P:
M/Z\V<_KA;Q\PX?QS;9,W7\V<9A1ETJFE G<US+00? B@F @*?0PV/M4F88/I
MKZ>K+S_2<CLNZ0_7S.U)Q,1%N"U0<&GQQA![!W=2O^)VUSGB+>W2DR^T(^O%
MWL<5;=2SU7*X8OZT6I">-J_GBW,RQU="]%[9R*6&R#,'Y5R-4C0)T9@LO2O<
MZ-;=7@XF=EIWNBD.7U9QO2%TAJ)D9<A9B3BT^1<98F %N$;RR4,L,;1.*+Q%
MP+06[864_A34GJ6!#N#S3YR??JJ2((<EG.)EW_]=\NX-C_A"8-=I/,-E[97\
M#%EN)UFB7:I93>@5$ 4OX+E3(O&4=6Q]U]"&\FFCF%%,WP0J_0,!F4*M>9H9
M79!AL. RIW )T4-POH!SW*><,NW[ULE0SR)P6CLZ!8(.!/'SU=DO5B_$>8_'
MF4,;..,*G+8DS1P=.),#&(/!^V("DZU;NCV3Q&D]R'[QVD2E'2#V[D&UVW8Y
M1:YTRB!%CJ *<>*P#O?&P%$JKR-KWM7M(4*F/<0[0-_QZNGBC?HN&Q<2FZ4B
M=7&*@6:HB)&(X+W04,<)2ZTD,CTVSBY(F;;>M4.D':*B+K!VLMS.<R5^_@5_
MPW2^GF_GN'GS-2W.,^8ZM>K&9>R[<L]3/UN=+[>S9%7*QG)PLM 6DU%"2%:3
M*),U66FE;.N.Y4T(GQ;'HX0]+Z_07MO\U>N.^;8^&Y$Y2*MEO8[%92)I'/-D
M\MT/;?-"\CS:&SV(7*^Z.5GF5[>6O3*BUZW-D =4!BG:2(*B#<8)([Y:/2E=
M3$JA:#V(XUD$'CW\=;797"_Q[22E]7E8G&Q?A?7Z&WWQ/\/B'&?66Y,$MZ#K
M(#65DP(?K =E?&%%A*1LZ[?MO0B;-G0>#TGWQK\VUU('<09Q4<WPYGWX5J]N
M7YVOJ]!)DK^NEFGWEYF0DM,IH2!H4YL'!$?!/GD>QLBL34Z(I74TO =9TT;
M+P>[UAKJ '1W=E+]ZU5R4U198PH!2O:UC24G5B*C[12-=DY8Y;&U@_<$.=,&
MNI/9MH,U,ODDZP=M] <DWV<3%K6M]4-#*H9BZ!E&1GZH\>!9)CZ%M^ 88Q2]
M.ZX]*[FX\#VG[5@BI@T3QL?;BRII_'#AXAOUEUI&_Q__\O\#4$L! A0#%
M  @ 5T0#5X'I_:6L!P  *2(  !(              ( !     &5X:&EB:70S
M,3%Q,C(S+FAT;5!+ 0(4 Q0    ( %=$ U>XR=C'J@<  (@B   2
M      "  =P'  !E>&AI8FET,S$R<3(R,RYH=&U02P$"% ,4    " !71 -7
M8L@(X<L$  "?$P  $@              @ &V#P  97AH:6)I=#,R,7$R,C,N
M:'1M4$L! A0#%     @ 5T0#5^C!*P++!   /!0  !(              ( !
ML10  &5X:&EB:70S,C)Q,C(S+FAT;5!+ 0(4 Q0    ( %=$ U=^[5%)8[
M /@3"@ 1              "  :P9  !V<FYA+3(P,C,P-C,P+FAT;5!+ 0(4
M Q0    ( %=$ U?!1JB.N@D  !E5   1              "  3[*  !V<FYA
M+3(P,C,P-C,P+GAS9%!+ 0(4 Q0    ( %=$ U?5,Q-TBQ(   RD   5
M          "  2?4  !V<FYA+3(P,C,P-C,P7V-A;"YX;6Q02P$"% ,4
M" !71 -7@$7,UC<8   RZ   %0              @ 'EY@  =G)N82TR,#(S
M,#8S,%]D968N>&UL4$L! A0#%     @ 5T0#5WHW,VRI( ( ZLD" !0
M         ( !3_\  '9R;F$M,C R,S V,S!?9S$N:G!G4$L! A0#%     @
M5T0#5UI4SRO<;@  @I $ !4              ( !*B # '9R;F$M,C R,S V
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( %=$ U>1U^7,$S\  -RJ @ 5
M      "  3F/ P!V<FYA+3(P,C,P-C,P7W!R92YX;6Q02P4&      L "P#,
) @  ?\X#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
